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                                                                     ABSTRACT 
The facile labeling of biomolecules with a radionuclide is a key goal in 
radiopharmaceutical development. This study explores two different ligand systems for fac-
[Re(CO)3L]+ complexes, that could be used in bioconjugation. 
The first approach uses a tridentate ligand having a sulfonamide linkage and modeled on 
previously evaluated fac-[Re(CO)3(N(SO2R)dpa)]PF6 complexes. The present goal was to 
develop new related sulfonamide complexes with more hydrophilic ligands designed to avoid the 
bioavailability problems that would plague the N(SO2R)dpa ligand system. A series of fac-
[Re(CO)3(N(SO2R)dien)]PF6 complexes with different R groups linked to the central nitrogen of 
a symmetric tridentate sulfonamides were synthesized with the aim of improving the favorable in 
vivo bioavailability. These compounds are characterized by NMR spectroscopy and by X-ray 
crystallography. 
The second approach using monodentate ligands led to the synthesis of several amidine 
complexes. The challenge of avoiding isomers of amidine complexes was overcome by using C2-
symmetrical heterocyclic secondary amines with 6-membered and larger rings to create an 
amidine substituent bulkier than the amidine CCH3 group. Treatment of fac-
[Re(CO)3(Me2bipy)(CH3CN)] BF4 with these amines in organic solvents yielded novel fac-
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)2Y)]BF4 complexes having only one isomer with the E 
configuration as established by solid-state and 1H NMR spectroscopic data. The combination of 
the high steric bulk and the C2-symmetry of the amidine substituents favors the E configuration 
exclusively. 
I extended the chemistry to smaller heterocyclic amines with 4- and 5-membered rings 
and found amidine formation reactions were faster. Moreover, I also showed that the amidine 
formation reactions were faster when the methyl group of fac-[Re(CO)3(Me2bipy)(CH3CN)]BF4 
 xvi 
was replaced by a phenyl group. A series of fac-[Re(CO)3(Me2bipy)(HNC(C6H5)N(CH2)x)]+ 
complexes were synthesized, characterized and used in the comparison with the analogous fac-
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)x)]+ complexes in order to understand the properties of 
amidine complexes and to correlate the structural features with their behavior in solution. 
Furthermore, a new method employing the fac-[Re(CO)3(H2O)3]+ precursor successfully 
demonstrated the synthesis of fac-[Re(CO)3(Me2bipy)(amidine)]+  complexes in more aqueous 
conditions. This new method holds promise for use in biomedical studies. 
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CHAPTER 1 
INTRODUCTION 
The non-invasive nature and the ability to function as a technique for dynamic imaging 
make nuclear medicine a powerful diagnostic and therapeutic tool. Procedures in nuclear 
medicine provide the ability to view metabolic activity and physiological function, thus playing 
an important role in obtaining useful information about the function of certain organs and 
tissues.1 Radiopharmaceuticals are pharmaceutical preparations of radioisotopes which are safe 
for human administration for the purpose of diagnosing or treating diseases. The widespread 
utilization of radiopharmaceuticals and the challenges in diagnostic and therapeutic procedures 
create a growing demand for the development of specific radiopharmaceuticals. Thus, much 
research is employed in order to identify better agents with the ability to specifically target 
different locations in the body to produce images with better resolution as well as to treat specific 
cells, organs, or tissues.2-4 
1.1 The Role of Technetium and Rhenium in Imaging and Therapy 
Technetium-99m (99mTc) is the most widely used radioisotope in diagnostic nuclear 
medicine, with over 80% of the nuclear medicine studies performed every year utilizing it.3-8 The 
availability of the short-lived 99mTc (t1/2 = 6 h) is one of the major factors that has promoted the 
universal use of 99mTc. The parent nucleus, molybdenum-99 (99Mo) decays to 99mTc through beta 
decay with a half-life of 66 h.  Moreover, 99mTc emits 140 keV gamma rays with sufficiently high 
energy to be useful for clinical imaging and sufficiently low energy to prevent a high radiation 
risk to the patient. 99mTc also has an ideal half-life that is long enough for pharmaceutical 
preparation, accumulation in the target tissues, and clinical investigations, yet short enough to 
reduce excessive radiation exposure to the patient.2,3,7 Early studies in the development of 
various 99mTc complexes takes advantage of physiological processes in the body (e.g., absorption, 
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distribution, metabolism, and excretion) for imaging different organs. However, over the years 
research has led to the discovery of careful design of novel 99mTc complexes with the ability to 
efficiently and accurately diagnose many diseases at earlier stages and follow up with the 
response to treatment.4,7  
Radionuclide therapy employing radiopharmaceuticals labeled with beta-emitting 
radionuclides is emerging as an important part of nuclear medicine. 186/188Re isotopes are being 
used as beta emitters in therapeutic applications.7 Both 186Re (E = 1.1 MeV, t1/2 = 89.2 h) and 
188Re (E = 2.1 MeV, t1/2 = 16.9 h) possess favorable nuclear properties that make them capable of 
delivering therapeutic doses of radiation to cancerous tissue.7 Furthermore, complexes containing 
the 186/188Re  isotopes have been developed to target specific tissues without causing adverse 
effects on normal tissue.9,10 Radionuclide therapy, in addition to the management of thyroid 
cancer, is utilized for bone pain palliation and for the treatment of joint pain, as in rheumatoid 
arthritis. Some other recent research areas include treatment of non-resectable liver cancer, non-
melanoma skin cancer, and inhibition of arterial restenosis following balloon angioplasty.11,12  
Rhenium and technetium, which are members of the same group of the periodic table, 
share similar chemical properties. Non-radioactive Re is frequently used as a model for studying 
the initial properties and behavior of clinically useful agents with radioactive 99mTc. A ligand 
suitable for technetium chelation is usually also suitable for rhenium chelation. This possibility 
of radiolabeling molecules of medicinal interest with diagnostic or therapeutic radionuclides by 
the same chemical approach has recently received considerable interest. The diverse chemistry of 
technetium and rhenium has led the way to the discovery of many complexes with different 
coordination numbers and geometries. This study is mainly aimed at exploiting the chemistry of 
new complexes with the versatile tricarbonyl core : fac-[M(CO)3]+ (M = 99mTcI, 186/188ReI).  
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1.2 Conjugation of the fac-[MI(CO)3]+ (M = 99mTc, Re) Core with Biomolecules 
Among several other 99mTc or Re-incorporated cores used in current studies and 
applications, the fac-[M(CO)3]+ core possesses promise for developing useful clinical agents 
owing to its many attractive properties. This core contains three facile CO ligands which are 
tightly coordinated to the metal center, thus stabilizing the low +1 oxidation state (Figure 1.1). 
Complexes of the fac-[M(CO)3]+ core have a low-spin d6 configuration, hence, exhibit a high in 
vivo robustness, an essential for medical applications.13  
 
 
 
 
 
Figure 1.1. Representation of the fac-[M(CO)3]+ core with three ligands depicted by L 
Octahedral complexes of [M(CO)3]+ are generally smaller than complexes of the 
corresponding metals in higher oxidation states with other cores and are therefore considered less 
likely to impact important characteristics of molecules to which they are conjugated.4,7,13 The low 
molecular weight of the fac-[MI(CO)3]+ core therefore permits the labeling of low molecular 
weight biomolecules while retaining their high specificity.6 The precursor complex, fac-
[MI(CO)3(H2O)]+, is soluble in aqueous media and is readily accessible in aqueous-based kit 
formulations.6 The three water molecules in this precursor can be readily replaced by mono-, bi-, 
and tridentate ligand systems, or a combination of them. Numerous ligand systems and their 
coordination with the fac-[M(CO)3]+ core  have been investigated. In particular, tridentate 
M = 99mTc, 186/188Re 
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chelators containing N-, S-, or O-donors have been shown to provide well-defined, kinetically 
inert and stable organometallic complexes which are suitable for application in vivo9,14-17. Many 
studies of fac-Re(CO)3L complexes (L = a facially coordinated tridentate ligand), including those 
from our laboratory, have aided in developing a better understanding of NMR spectral features of 
fac-Re(CO)3L complexes having simple donor ligands.18-21  
Owing to the broad applicability of the fac-[MI(CO)3]+ core, many molecules such as 
peptides, antibodies, glucose and certain receptor ligands have been labeled.4 At present, great 
interest surrounds the concept of combining 99mTc and 188/186Re with biomolecules in order to 
selectively target specific locations and biological processes.4,6,7,22-27  Introduction of a suitable 
chain of bridging atoms (linker) into a basic ligand framework or into a functional group allows 
coupling of the fac-[MI(CO)3] core to the biomolecule (Figure 1.2).28 
 
 
 
 
 
 
Figure 1.2. Schematic representation of the bifunctional chelate strategy 
  
When medicinally interesting molecules are been radiolabeled with the fac-[M(CO)3]+ 
core, usually a post-labeling approach with bifunctional chelating agents is employed.6,29 These 
agents enable the covalent linkage to a biomolecule as well as the coordination of the radiometal. 
Different functional groups such as amines, thiols, and carboxylates have been used to 
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functionalize many of the ligand systems that are used to chelate the fac-[M(CO)3]+ core.8 
However, despite the success of these complexes with the metal tricarbonyl core, there is still a 
need for novel and innovative strategies for bioconjugation techniques and radiolabeling 
procedures in order to expedite the development of radiotracers with the fac-[M(CO)3]+ core. The 
specific theme of the present study is to explore two new possible approaches of bioconjugation: 
fac-[ReI(CO)3L]n complexes with a tridentate sulfonamide linker and with a monodentate 
amidine linker.  
The first part of this work describes the synthesis of new fac-[Re(CO)3(N(SO2R) 
)(CH2Z)2]PF6 complexes (Z = CH2NH2; R = Me, dmb, or tol) in aqueous medium and detailed 
analysis of the structure and solution behavior of these complexes. Our recent discovery of the 
rare sulfonamide nitrogen-to-metal bonds of normal length, in fac-[Re(CO)3(N(SO2R)(CH2Z)2)]n 
complexes with  N(SO2R)dpa ligands derived from di-(2-picolyl)amine (N(H)dpa) (Z = 2-
pyridyl) showed the potential of the sulfonamide bond as a linking method of targeting moieties 
to the fac-[M(CO)3]+ core.30 However, the planar, electron-withdrawing 2-pyridyl groups of 
N(SO2R)dpa destabilize the ligand to base and create relatively rigid chelate rings. Moreover, the 
hydrophobic 2-pyridyl groups could cause undesirable accumulation in the liver, limiting future 
use in radiopharmaceuticals. To overcome these problems, a robust, hydrophilic, and flexible 
N(CH2Z)2 chelate framework was synthesized by using new C2-symmetric ligands, 
N(SO2R)(CH2Z)2 with.  
The second part discusses how treatment of the organic precursors,  fac-
[Re(CO)3(L)(CH3CN)]BF4 [L = 5,5-dimethyl-2,2-bipyridine (5,5-Me2bipy) and 6,6-dimethyl-
2,2-bipyridine (6,6-Me2bipy)], with five C2-symmetrical saturated heterocyclic amines yielded 
new amidine complexes, fac-[Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4 [Y = CH2, (CH2)2, 
(CH2)3, NH or O] possessing the novel feature of having only one isomer.31 In contrast to the 
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closely related amidine complexes with primary amines, which had isomers owing to the double-
bond character of the amidine (Cam–N3) bond,32 the presence of only the E isomer of the fac-
[Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4 was established by crystallographic and 1H NMR 
spectroscopic methods.31 The absence of other isomers is undoubtedly attributable to the 
unfavorable clashes between the equatorial ligands and the bulky N(CH2CH2)2Y ring moiety of 
the axial amidine ligand. Moreover, the rate of amidine formation was found to be faster when 
the size of the saturated heterocyclic amine ring was getting smaller. Thus, further studies were 
employed using smaller heterocyclic rings and important NMR spectral features have been 
investigated. Because this new linking chemistry offers promise as a suitable method for 
preparing isomerically pure conjugated fac-[99mTc(CO)3L]n+/- imaging agents, a new method in 
more aqueous media was utilized as the next step. The new method evaluates the ability to utilize 
the fac-[Re(CO)3(H2O)3]+  precursor in the amidine synthesis. The promising results of this study 
starting with the fac-[M(CO)3(H2O)3]+ precursor encouraged us to demonstrate further the 
applicability of the Re amidine chemistry. Thus, amidine complexes with different drug 
analogues were synthesized and characterized as a preliminary step before 99mTc labeling and 
biological studies of these complexes. 
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CHAPTER 2 
COMPLEXES POSSESSING RARE “TERTIARY” SULFONAMIDE NITROGEN-TO-
METAL BONDS OF NORMAL LENGTH: fac-[Re(CO)3(N(SO2R)DIEN)]PF6 
COMPLEXES WITH HYDROPHILIC SULFONAMIDE LIGANDS 
2.1 Introduction 
Many fac-[99mTc(CO)3L]n imaging agents with facially coordinated tridentate ligands (L) 
have been studied1-8 because of the convenient generation of the fac-[99mTc(CO)3(H2O)3]+ 
precursor.9,10 Some of these imaging agents have exhibited satisfactory results in human 
volunteers and in early patient studies.4,7,8 Such fac-[99mTc(CO)3L]n agents are more robust and 
have better pharmacokinetic properties than agents with bidentate ligands.11 The -emitting 99mTc 
radionuclide has ideal nuclear properties12,13 for diagnostic applications in nuclear medicine.1,14-
17 
The development of 99mTc radiopharmaceutical agents benefits from an understanding of 
the chemistry of their Re analogues. The discovery of a straightforward preparation of the fac-
[Re(CO)3(H2O)3]+ precursor18 has led to significantly improved aqueous synthetic methods for 
fac-[M(CO)3L]n agents (M = various isotopes of Tc and Re).3,16,17,19-21 fac-[Re(CO)3L]n 
complexes serve as excellent structural models for fac-[99mTc(CO)3L]n imaging agents.4,22-27 
Moreover, fac-[186/188Re(CO)3L]n agents themselves are emerging as promising 
radiopharmaceuticals, owing to their potential usefulness in radiotherapy.1,12,20,28 
New types of tridentate ligands and ligand conjugation methods will expand the 
likelihood of developing useful new agents with the fac-[MI(CO)3]+ core (M = 99mTc, 
186/188Re).10,29,30 Meeting such goals requires the identification of suitable linker systems with hi- 
 
 *Reproduced with permission from American Chemical Society: Abhayawardhana, P. L.; 
Marzilli, P. A.; Perera, T.; Fronczek, F. R.; Marzilli, L. G. “Complexes Possessing Rare 
“Tertiary” Sulfonamide Nitrogen-to-Metal Bonds of Normal Length: fac-
[Re(CO)3(N(SO2R)dien)]PF6 Complexes with Hydrophilic Sulfonamide Ligands”. Inorg. 
Chem. 2013, 53, 1144−1155. Copyright 2015 American Chemical Society. 
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-gh stability, small size, and core ligands having a tridentate donor framework that does not 
increase the number of isomers.31-34 Symmetrical linear tridentate ligands with linkage at the 
center donor are thus suitable candidates because the generation of racemic or diastereoisomeric 
mixtures of radiopharmaceuticals can be avoided.35 Recent studies have reported promising 
biomedical properties for fac-[Re(CO)3L]n complexes bearing a tridentate L with three N donors 
having a substituent replacing the proton at the central sp3 N.16,29,36,37 However, the conjugation 
of biologically important groups in these complexes was limited to groups attached via an N–C 
bond to the central N of ligands with the N(CH2Z)2 tridentate ligand framework. Z is commonly 
an N donor (e.g., 2-pyridyl)16,36 or a carboxyl group.3 The use of a biologically compatible 
linking group that did not create an N–C bond would greatly increase the chances of discovering 
useful agents. 
Molecules containing a sulfonamide represent a very important class of biologically 
active molecules with a wide variety of applications.39-45 Therefore, we previously set out to 
explore conjugation that utilizes an N–S bond with the central N being the sulfonamide N.35 The 
reaction of various sulfonyl chlorides (RSO2Cl) with di-(2-picolyl)amine (N(H)dpa) afforded 
N(SO2R)dpa ligands.35 [Note that we use the normal convention: an N (italic N) designates a 
substituent location on nitrogen in the name of a compound. In this article, N designates a 
substituent located on the central or anchoring nitrogen atom of a tridentate ligand.] These 
N(SO2R)dpa ligands readily added to fac-[Re(CO)3(H2O)3]+ to form fac-
[Re(CO)3(N(SO2R)dpa)]PF6 (or BF4) complexes. We learned that these were the only examples 
of structurally characterized bearing an N-bound, open-chain tertiary sulfonamide linkage with a 
normal M–N bond length. These fac-[Re(CO)3(N(SO2R)dpa)]PF6 complexes were the first 
examples of such structurally characterized complexes with a neutral tertiary sulfonamide donor 
bound not only to the fac-[ReI(CO)3]+ core but to any metal center.35 Although the results in that 
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report appeared to serve as proof of principle, the tridentate framework, N(CH2Z)2 with Z = 2-
pyridyl, is relatively rigid and the resulting geometric constraints could possibly account for the 
observation of the M–N(sulfonamide) bond of normal length, as found in cases when 
complicated ligand ring structures fix the bond lengths.35  Thus, the study of fac-
[Re(CO)3(N(SO2R)(CH2Z)2)]n complexes with more flexible chelate rings is of fundamental 
importance to coordination chemistry. 
The new fac-[Re(CO)3(N(SO2R)dpa)]X complexes revealed the feasibility of having a 
tridentate ligand anchored by a central tertiary sulfonamide N. However, the two 2-pyridyl rings 
in a potential fac-[M(CO)3(N(SO2R)dpa)]n imaging agent are hydrophobic, an undesirable 
property in an imaging agent because it is expected to promote liver uptake.12 Also, the 2-pyridyl 
groups are electron withdrawing, facilitating decomposition of coordinated N(SO2R)dpa ligands 
by strong base.35  
With the goals of exploring fundamental coordination chemistry of sulfonamides and of 
identifying ligands for use in imaging agents, we have now explored a more hydrophilic and 
more flexible ligand system that is suitable for our new conjugation method. Here we employ a 
prototypical triamine ligand framework based on diethylenetriamine (N(H)dien).46 In the new 
N(SO2R)dien ligands, the aromatic 2-pyridyl groups of the dpa moiety are replaced with 
hydrophilic –CH2NH2 groups. The new ligands are stable to base and have the advantage of 
being small in size, a feature considered to be desirable for bioconjugates.32,34 All of the new 
complexes discussed below have the facial geometry, and thus from this point onward we omit 
the fac- designation when discussing specific compounds. 
2.2 Experimental Section 
Starting Materials. Methanesulfonyl chloride (MeSO2Cl), 3,5-dimethylbenzenesulfonyl 
chloride (dmbSO2Cl), 4-methylbenzenesulfonyl chloride (tolSO2Cl), N,N,N-triethylamine, 
 12 
trifluoroacetic acid (TFA), N(H)dien, 2-(tert-butoxycarbonyloxyimino)-2-(phenylacetonitrile), 4-
dimethylaminopyridine, and Re2(CO)10 were used as received from Aldrich. Aqueous 
[Re(CO)3(H2O)3]OTf (OTf = trifluoromethanesulfonate) was prepared by a known method.18 
NMR Measurements. 1H NMR and 13C NMR spectra were recorded on a 400 MHz 
Bruker spectrometer. Peak positions are relative to TMS or to solvent residual peak, with TMS as 
reference. All NMR data were processed with TopSpin and MestReNova software. NMR data 
not presented in the Experimental Section can be found in the Results Section or in Supporting 
Information. 
Mass Spectrometric Measurements. High resolution mass spectra were recorded on a 
Bruker Ultraflex MALDI TOF TOF mass spectrometer and an Agilent 6210 ESI TOF LCMS 
mass spectrometer. 
X-ray Data Collection and Structure Determination. Intensity data were collected at 
low temperature on a Bruker Kappa Apex-II DUO CCD diffractometer fitted with an Oxford 
Cryostream cooler with graphite-monochromated Mo K ( = 0.71073 Å) radiation. Data 
reduction included absorption corrections by the multiscan method, with SADABS.47 The 
structures were determined by direct methods and difference Fourier techniques and refined by 
full-matrix least squares using SHELXL-97.48 All non-hydrogen atoms were refined 
anisotropically. All H atoms were visible in difference maps, but were placed in idealized 
positions, except for N–H hydrogen atoms, for which coordinates were refined. A torsional 
parameter was refined for each methyl group. Compound 6 has two independent formula units in 
the asymmetric unit. 
Synthesis of N,N-Bis(tert-butoxycarbonyl)diethylenetriamine (N(H)dien(Boc)2). The 
N(H)dien(Boc)2 ligand was prepared in 96% yield by a known method.49 1H NMR signals (ppm) 
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in CDCl3: 4.89 (br s, 1H, NH), 3.20 (m, 4H, 2CH2), 2.72 (t, 4H, 2CH2), 1.44 (s, 18H, 6CH3). 
These 1H NMR chemical shifts matched the previously reported values.49  
General Synthesis of N(SO2R)dien. The following general procedure was employed to 
obtain the [N(SO2Me)dienH2](CF3CO2)2 (1) and N(SO2R)dien (R = dmb (2), R = tol (3)) ligands: 
a solution of the sulfonyl chloride (2 mmol) in 30 mL of dioxane was added dropwise over 2 h to 
a solution of N(H)dien(Boc)2 (0.61 g, 2 mmol) and triethylamine (0.28 mL, 2 mmol) in dioxane 
(100 mL) at room temperature. The reaction mixture was stirred at room temperature for 20 h 
and filtered to remove any precipitate. The solvent was completely removed by rotary 
evaporation, water (50 mL) was added to the resulting oil, and the product was extracted into 
CH2Cl2 (2  25 mL). The CH2Cl2 extracts were combined and washed again with water (2  25 
mL) at pH 6. The organic layer was dried with anhydrous Na2SO4, and the CH2Cl2 was 
removed by rotary evaporation to yield an off-white solid. The Boc-protected diensulfonamide, 
N(SO2R)dien(Boc)2, was purified if necessary by column chromatography (silica gel column and 
a mixture of ethyl acetate/hexane). After characterization by 1H NMR spectroscopy, this 
N(SO2R)dien(Boc)2 product was then deprotected by dropwise addition of trifluoroacetic acid 
(0.16–0.24 mL, 2–3 mmol) to a CH2Cl2 solution (at 0 oC) of the compound (5 mL, 1 mmol). 
The reaction mixture was allowed to warm to room temperature, stirred for 16 h at room 
temperature, and then filtered; the filtrate was taken to dryness by rotary evaporation. Water at 
pH 8–9 (50 mL) was added to the residue, and the product was extracted into CHCl3 (2  25 
mL). The combined CHCl3 extracts were dried over anhydrous Na2SO4, and the solvent was 
removed by rotary evaporation, leaving a white/off-white powder or, when R = Me, a yellow oil.  
General Synthesis of [Re(CO)3(N(SO2R)dien)]PF6. A solution of the N(SO2R)dien 
ligand (0.1 mmol) in methanol (2 mL) was added to an aqueous solution of [Re(CO)3(H2O)3]OTf 
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(5 mL, 0.1 mmol). Methanol (1–2 mL) was added to dissolve any precipitate that formed. The pH 
of the reaction mixture was adjusted to 6–7 with 0.5 M NaOH if necessary, and the clear 
reaction mixture was heated at reflux for 24 h. An excess (0.16 g, 1 mmol) of NaPF6 was added 
to the clear solution, and the precipitate that formed within 30 min was collected on a filter, 
washed with water, and air dried. 
 Synthesis of [N(SO2Me)dienH2](CF3CO2)2 ([1H2](CF3CO2)2). The use of MeSO2Cl 
(0.16 mL, 2 mmol) in the general method described above yielded crude N(SO2Me)dien(Boc)2 as 
a brown oil (0.65 g, 85% yield). 1H NMR signals (ppm) in DMSO-d6: 6.92 (br s, 2H, 2NH), 3.14 
(m, 4H, 2CH2), 3.06 (m, 4H, 2CH2), 2.89 (s, 3H, CH3), 1.37 (s, 18H, 6CH3).  
The deprotection process described in the general method above afforded N(SO2Me)dien 
(1) as a pale-yellow, oily substance (yield: 0.004 g, 18%). 1H NMR signals (ppm) in CDCl3: 3.25 
(t, J =  6.3 Hz, 4H, 2CH2), 2.93 (s, 3H, CH3), 2.90 (t, J =  6.4 Hz, 4H, 2CH2); in acetonitrile-d3: 
3.14 (t, J = 6.5 Hz, 4H, 2CH2), 2.86 (s, 3H, CH3), 2.76 (t, J = 6.5 Hz, 4H, 2CH2); in DMSO-d6: 
3.08 (broad t, 4H, 2CH2), 2.91 (s, 3H, CH3), 2.67 (broad t, 4H, 2CH2). 13C NMR signals (ppm) in 
CDCl3: 51.59 (C5/6), 40.70 (C4/7), 37.60 (CH3).  
Compared to ligands with other R groups, isolation for R = Me produced a low yield, 
owing to the more hydrophilic nature of N(SO2Me)dien. To increase the amount of material 
available for synthesis of the complex, the general deprotection process was modified by adding 
a slight excess of trifluoroacetic acid to obtain the protonated ligand 
[N(SO2Me)dienH2](CF3CO2)2 ([1H2](CF3CO2)2). A mixture of N(SO2Me)dien(Boc)2 (0.38 g, 1 
mmol) and trifluoroacetic acid (0.24 mL, 3 mmol) was stirred at room temperature for 16 h, and 
the resulting mixture was filtered; the white precipitate that was collected on a filter paper was 
washed several times with CH2Cl2 and air dried. The precipitate was then dissolved in methanol 
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(3 mL), and the solution was filtered. CH2Cl2 (10 mL) was added to the filtrate until cloudiness 
was observed. After 24 h the undisturbed solution yielded thin, colorless, needle-like crystals of 
the trifluoroacetate salt of the protonated ligand [N(SO2Me)dienH2](CF3CO2)2 ([1H2](CF3CO2)2) 
(0.29 g, 72% yield). 1H NMR signals (ppm) in DMSO-d6: 7.81 (br s, 6H, 2+NH3), 3.37 (t, J = 6.2 
Hz, 4H, 2CH2), 3.04 (s, 3H, CH3), 3.00 (t, J = 6.3 Hz, 4H, 2CH2). ESI-MS: m/z calcd for 
C5H15O2N3S [M + H]+: 182.0958; found 182.0957. 
Synthesis of N(SO2dmb)dien (2). The use of dmbSO2Cl (0.40 g, 2 mmol) according to 
the general synthetic procedure above yielded a pale yellow oil, which was purified by dissolving 
the oil in a minimum (1 mL) of ethyl acetate and loading the solution onto a silica gel column. 
A 1:5 mixture of ethyl acetate:hexane was used to elute the remaining dmbSO2Cl starting 
material (UV-vis). The product (UV-vis) was then eluted with a 2:3 (v:v) mixture of ethyl 
acetate/hexane. Thin-layer chromatography was used to determine the progress of separation. 
Removal of solvent by rotary evaporation yielded N(SO2dmb)dien(Boc)2 as a pale yellow powder 
(0.87 g, 92% yield). 1H NMR signals (ppm) in CDCl3: 7.65 (s, 2H, H2/6), 7.21 (s, H, H4), 5.19 
(br s, 2H, NH), 3.32 (m, 4H, 2CH2), 3.18 (m, 4H, 2CH2), 2.38 (s, 6H, 2CH3), 1.45 (s, 18H, 
6CH3).  
Deprotection of N(SO2dmb)dien(Boc)2 (0.47 g, 1 mmol) with trifluoroacetic acid (0.16 
mL, 2 mmol), by the procedure described above, afforded N(SO2dmb)dien (2) as a white powder 
(0.26 g, 98% yield). 1H NMR signals (ppm) in CDCl3: 7.42 (s, 2H, H2/6), 7.20 (s, H, H4), 3.15 
(t, J = 6.4 Hz 4H, 2CH2), 2.91 (t, J = 6.4 Hz, 4H, 2CH2), 2.38 (s, 6H, 2CH3). ESI-MS: m/z calcd 
for C12H21O2N3S [M + H]+: 272.1427; found 272.1431. 
Synthesis of N(SO2tol)dien (3). The general procedure using tolSO2Cl (0.44 g, 2 mmol) 
yielded N(SO2tol)dien(Boc)2 as a pale yellow oil (0.78 g, 86% yield). 1H NMR signals (ppm) in 
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CDCl3: 7.67 (d, J = 8.3 Hz, 2H, H2/6), 7.31 (d, J = 8.1 Hz, 2H, H3/5), 5.18 (br s, 2H, NH), 3.32 
(m, 4H, 2CH2), 3.17 (m, 4H, 2CH2), 2.43 (s, 3H, CH3), 1.45 (s, 18H, 6CH3).  
Deprotection of N(SO2tol)dien(Boc)2 (0.45 g, 1 mmol) with trifluoroacetic acid (0.16 mL, 
2 mmol) afforded N(SO2tol)dien (3) as a white powder (0.23 g, 92% yield). 1H NMR signals 
(ppm) in CDCl3: 7.70 (d, J = 8.2 Hz, 2H, H2/6), 7.31 (d, J = 8.0 Hz, 2H, H3/5), 3.15 (t, J = 6.4 
Hz, 4H, 2CH2), 2.91 (t, J = 6.4 Hz, 4H, 2CH2), 2.43 (s, 3H, CH3); in acetonitrile-d3: 7.69 (d, J = 
8.4 Hz, 2H, H2/6), 7.39 (d, J = 7.9 Hz, 2H, H3/5), 3.07 (t, J = 6.4 Hz, 4H, 2CH2), 2.79 (t, J = 6.5 
Hz, 4H, 2CH2), 2.41 (s, 3H, CH3). ESI-MS: m/z calcd for C11H19O2N3S [M + H]+: 258.1271; 
found 258.1277. 
 Synthesis of [Re(CO)3(N(SO2Me)dien)]PF6 (4). The general method above, with the 
[1H2](CF3CO2)2 ligand (0.04 g, 0.1 mmol) and [Re(CO)3(H2O)3]OTf (5 mL, 0.1 mmol), afforded 
[Re(CO)3(N(SO2Me)dien)]PF6 (4) as a white crystalline precipitate (0.036 g, 60% yield) after the 
addition of NaPF6 (16 mg). (The pH of the acidic reaction mixture was adjusted to 7 with 0.5 
M NaOH before the solution was heated at reflux.) 1H NMR signals (ppm) in DMSO-d6: 5.65 
(m, 2H, NH), 4.27 (m, 2H, NH), 3.57 (s, 3H, CH3), 3.45 (m, 2H, CH2), 3.22 (m, 2H, CH2), 3.10 
(m, 2H, CH2), 2.97 (m, 4H, 2CH2). 1H NMR signals (ppm) of the R group in acetone-d6: 3.62 (s, 
3H, CH3); in acetonitrile-d3: 3.33 (s, 3H, CH3). Chelate ring 1H NMR signals for 4-6 in these 
solvents are reported in the Results Section. 13C NMR signals (ppm) in DMSO-d6: 55.91 (C5/6), 
44.86 (C4/7), 32.50 (CH3). 13C NMR signals (ppm) in acetone-d6: 55.11 (C5/6), 44.46 (C4/7), 
30.97(CH3). MALDI-TOF: m/z calcd for C8H15O5N3SRe [M +]: 452.029; found: 452.158.  
Synthesis of [Re(CO)3(N(SO2dmb)dien)]PF6 (5). The use of the general procedure with 
N(SO2dmb)dien (2) (0.03 g, 0.1 mmol) afforded [Re(CO)3(N(SO2dmb)dien)]PF6 (5) as a white 
precipitate (0.047 g, 69% yield) after the addition of NaPF6 (16 mg). 1H NMR signals (ppm) in 
DMSO-d6: 7.72 (s, 2H, H2/6), 7.57 (s, H, H4), 5.72 (m, 2H, NH), 4.28 (m, 2H, NH), 3.41 (m, 
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2H, CH2), 3.14 (m, 2H, CH2), 3.00 (m, 2H, CH2), 2.65 (m, 2H, CH2), 2.42 (s, 6H, 2CH3). 1H 
NMR signals (ppm) of the R group in acetone-d6: 7.77 (s, 2H, H2/6), 7.60 (s, H, H4), 2.46 (s, 6H, 
2CH3); in acetonitrile-d3: 7.65 (s, 2H, H2/6), 7.55 (s, H, H4), 2.44 (s, 6H, 2CH3). 13C NMR 
signals (ppm) in acetone-d6: 142.30 (dmb ring C1), 139.54 (dmb ring C4), 130.93 (dmb ring 
C2/6), 126.71(dmb ring C3/5), 57.83 (C5/6), 46.93 (C4/7), 22.09 (2CH3). MALDI-TOF: m/z 
calcd for C15H21O5N3SRe [M+]: 542.076; found: 542.155.  
Synthesis of [Re(CO)3(N(SO2tol)dien)]PF6 (6). The use of N(SO2tol)dien (3) (0.02 g, 
0.1 mmol) as described in the general synthesis afforded [Re(CO)3(N(SO2tol)dien)]PF6 (6) as a 
white precipitate (0.056 g, 84% yield) after the addition of NaPF6 (16 mg). Slow evaporation of 
a solution of the compound in acetone produced colorless, X-ray quality, needle-shaped crystals. 
1H NMR signals (ppm) in DMSO-d6: 7.99 (d, J = 8.5 Hz, 2H, H2/6), 7.61 (d, J = 8.1 Hz, 2H, 
H3/5), 5.70 (m, 2H, NH), 4.28 (m, 2H, NH), 3.40 (m, 2H, CH2), 3.14 (m, 2H, CH2), 3.01 (m, 2H, 
CH2), 2.66 (m, 2H, CH2), 2.5, overlapped (s, 3H, CH3). 1H NMR signals (ppm) of the R group 
in acetone-d6: 8.05 (d, 2H, H2/6), 7.65 (d, 2H, H3/5), 2.53 (s, 3H, CH3); in acetonitrile-d3: 
7.91(d, 2H, H2/6), 7.58 (d, 2H, H3/5), 2.51 (s, 3H, CH3). 13C NMR signals (ppm) in DMSO-d6: 
147.80 (tol ring C4), 132.07 (tol ring C2/6), 131.00 (tol ring C3/5), 125.98 (tol ring C1), 56.20 
(C5/6), 44.80 (C4/7), 21.69 (CH3). 13C NMR signals (ppm) in acetone-d6: 148.88 (tol ring C4), 
132.70 (tol ring C2/6), 131.58 (tol ring C3/5), 127.05 (tol ring C1), 56.94 (C5/6), 46.00 (C4/7), 
21.74 (CH3). MALDI-TOF: m/z calcd for C14H19O5N3SRe [M +]: 528.060; found: 528.001. 
Challenge Reactions of [Re(CO)3(N(SO2tol)dien)]PF6 (6). Two 5 mM solutions of 6 in 
DMSO-d6 (500 L) were treated separately with 10 molar equiv (0.6 µL, 50 mM) or 2 molar 
equiv (0.12 µL, 10 mM) of diethylenetriamine and monitored over time by 1H NMR 
spectroscopy. Another challenge experiment was carried out with a 5 mM solution of 6 in 
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DMSO-d6 by first adding 1 molar equiv of 4-dimethylaminopyridine (4-Me2Npy) and then 
increasing the 4-Me2Npy to 10 molar equiv. 
2.3 Results and Discussion 
Synthesis of N(SO2R)dien and [Re(CO)3(N(SO2R)dien)]PF6. N(SO2Me)dien (1), 
N(SO2dmb)dien (2), and N(SO2tol)dien (3) were synthesized by coupling N(H)dien with the 
respective sulfonyl chloride (Figure 2.1). In this case, unlike in the synthesis of N(SO2R)dpa 
ligands,35 additional steps are required to synthesize the N(SO2R)dien ligands (1–3), owing to the 
possibility of attack by the terminal N(H)dien amino groups on the sulfur atom of the sulfonyl 
chloride. Thus, the N(H)dien terminal amine groups were protected with Boc groups. The 
products were obtained in good yield and purity, as indicated by 1H NMR spectral data. Reaction 
of the deprotected ligands with an aqueous solution of [Re(CO)3(H2O)3]OTf afforded 
[Re(CO)3(N(SO2Me)dien)]PF6 (4), [Re(CO)3(N(SO2dmb)dien)]PF6 (5), and 
[Re(CO)3(N(SO2tol)dien)]PF6 (6) in 60–84% yields. All three complexes were characterized by 
1H and 13C NMR spectroscopy and by mass spectrometry (Experimental Section).  
 
 
 
 
 
 
 
 
Figure 2.1. General reaction scheme for the synthesis of N(SO2R)dien ligands (top) and 
[Re(CO)3(N(SO2R)dien)]+ complexes (bottom). 
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X-ray quality crystals of 4 and 6 were grown by slowly cooling a 5 mM solution of the 
compound in warm water. Crystals of 5 (grown by slow evaporation of a 5 mM acetone solution) 
suffered from twinning, space-group ambiguity, and disorder problems in the molecule, which 
prevented refinement within acceptable values. However, the structural characterization of 5 
(using the same procedures as for 4 and 6) confirmed that all three N atoms of N(SO2dmb)dien 
are coordinated to Re. 
Structural Results. Crystal data and structural refinement details for 
[Re(CO)3(N(SO2Me)dien)]PF6 (4) and [Re(CO)3(N(SO2tol)dien)]PF6 (6) are summarized in Table 
2.1, and the ORTEP plots appear in Figure 2.2 (see Figure 2.1 for the numbering scheme used to 
describe the solid-state data). Both 4 and 6 exhibit a pseudo octahedral structure, with the three 
carbonyl ligands occupying one face; the remaining three coordination sites are occupied by the 
three nitrogen atoms of the tridentate ligand. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. ORTEP plots of the cations in [Re(CO)3(N(SO2Me)dien)]PF6 (4) (left) and 
Re(CO)3(N(SO2tol)dien)]PF6 (6) (right). Thermal ellipsoids are drawn with 50% probability. 
Re 
 
Re 
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Table 2.1. Crystal Data and Structure Refinement for [Re(CO)3(N(SO2Me)dien)]PF6 (4) and 
[Re(CO)3(N(SO2tol)dien)]PF6 (6) 
 4 6 
empirical formula C8H15N3O5ReS·PF6 C14H19N3O5ReS·PF6 
fw 596.46 672.55 
crystal system monoclinic monoclinic 
space group P21/c P21/c 
unit cell dimensions   
a (Å) 12.822(3) 26.0233(14) 
b (Å) 8.8089(19) 13.0607(7) 
c (Å) 14.026(3) 12.2147(7) 
 (deg) 94.373(10) 95.831(3) 
V (Å3) 1579.6(6) 4130.1(4) 
T (K) 100 100 
Z 4 8 
calc (Mg/m3) 2.508 2.163 
abs coeff (mm-1) 8.02 6.15 
2max () 70 71.2 
R indicesa 0.018  0.029  
wR2 = [I> 2(I)]b 0.044  0.055  
data collected, Rint 28379, 0.034 51479, 0.033 
data/param 6953/239 18802/585 
 
aR = (||F| - |Fc||)/|F|; bwR2 = [[w(F2 - Fc2)2]/[w(F2)2]]1/2, in which w = 1/[2(F2) + 
(dP)2 + (eP)] and P = (F2 + 2Fc2)/3. 
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Selected bond distances and angles of complexes 4 and 6 are presented in Table 2.2. The 
Re–C bond distance of the CO group trans to the sulfonamide group is not significantly different 
from those of the two cis Re–CO bonds, indicating the absence of any trans influence. All Re–N 
Table 2.2. Selected Bond Distances (Å) and Angles (deg) for [Re(CO)3(N(SO2Me)dien)]PF6 (4) 
and [Re(CO)3(N(SO2tol)dien)]PF6 (6)  
 4 6   4 6 
bond distance    bond angle   
Re–N1 2.2377(14) 2.221(2)  N1–Re–N2 77.07(5) 77.54(7) 
Re–N2 2.2763(14) 2.2686(19)  N1–Re–N3 86.53(6) 85.83(8) 
Re–N3 2.2072(15) 2.216(2)  N2–Re–N3 77.80(5) 77.86(7) 
Re–C1 1.9128(16) 1.913(2)  C2–Re–N1 95.72(6) 92.70(9) 
Re–C2 1.9109(18) 1.911(2)  C3–Re–N1 92.31(6) 94.99(9) 
Re–C3 1.9136(19) 1.917(3)  C2–Re–N3 96.60(7) 98.29(9) 
S1–O5 1.4273(13) 1.4280(18)  C1–Re–N3 93.12(6) 91.92(9) 
S1–O4 1.4324(13) 1.4339(17)  Re–N2–S1 111.07(7) 111.35(9) 
S1–N2 1.7434(13) 1.759(2)  Re–N2–C5 105.93(9) 106.14(13) 
    Re–N2–C6 110.01(10) 109.86(13) 
non-bonded distance    S1–N2–C5 109.13(10) 108.82(14) 
N1–N3 3.046(2) 3.021(3)  S1–N2–C6 108.52(10) 108.18(13) 
N1–N2 2.812(2) 2.812(3)  C5–N2–C6 112.19(13) 112.52(18) 
N2–N3 2.816(2) 2.818(3)  C1–Re–N2 99.98(6) 100.55(8) 
    C3–Re–N2 97.91(6) 96.81(8) 
deviation of N2a 0.513(1) 0.514(2)  C1–Re–C2 87.25(7) 89.08(10) 
    C3–Re–C2 87.62(7) 87.29(10) 
    C1–Re–C3 87.83(7) 87.10(10) 
a Distance to the sulfonamide N from the plane defined by the S and the two C atoms attached to 
N2 (average of two independent molecules for 6). 
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bond distances in 6 are generally similar to the Re–N(sp3) distances observed in [Re(CO)3L]+ 
complexes with prototypical NNN donor ligands, which range from 2.21 to 2.29 Å as the bulk 
of substituents on the N atoms increases.46,50 However, the distances from Re to the central N2 
(2.2763(14) Å in 4 and 2.2686(19) Å in 6) are significantly longer than the Re–N1 distances 
(2.2377(14) Å for 4 and 2.221(2) Å for 6) and Re–N3 distances (2.2072(15) Å for 4 and 2.216(2) 
Å for 6) (Table 2.2). These Re–N2 distances in 4 and 6 are significantly longer than the Re–N2 
distance in [Re(CO)3(N(H)dien)]PF646 (2.201(3) Å), but they are comparable to the Re–N2 
distance of [Re(CO)3(N(Me)dien)]PF6.46 The Re–N2 distance in the latter complex (2.250(4) Å) 
is not statistically different from the Re–N2 distance in [Re(CO)3(N(SO2tol)dien)]PF6 (6, Table 
2.2), suggesting that the bond lengthening in 6 is caused chiefly by steric effects, not electronic 
effects. Furthermore, the good overlap of the three donor N atoms observed when the three 
carbonyl carbon (C1, C2 and C3) and Re atoms in the structure of 6 are superimposed with the 
corresponding atoms in [Re(CO)3(N(Me)dien)]PF646 (Supporting Information) demonstrates the 
lack of any large effect of having a tertiary sulfonamide nitrogen instead of a typical sp3 nitrogen 
serve as the central anchor of the tridentate ligand.  
The lengthening of the Re–N2 bond in 4 and 6 versus [Re(CO)3(N(H)dien)]PF6 is similar 
to that observed in [Re(CO)3(N(SO2R)dpa)]PF6 complexes (e.g., R = Me and tol) versus the 
parent [Re(CO)3(N(H)dpa)]Br complex.30,35 The similarity of the central Re–N bond distances of 
the analogous [Re(CO)3(N(SO2R)dpa)]PF6 complexes (average = 2.277 Å) and in 4 and 6 
(average = 2.272 Å) indicates that the donating ability of the sulfonamide N is similar for both 
ligands.35 Furthermore, all three donor N atoms show good overlap when the C1, C2, C3, and Re 
atoms in [Re(CO)3(N(SO2tol)dien)]PF6 and [Re(CO)3(N(SO2tol)dpa)]PF6 are superimposed 
(Figure 2.3). The central Re–N bond distance of the [Re(CO)3(N(SO2Me)dpa)]PF6 complex 
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(2.2826(16) Å) is not significantly different from this distance in 4. Thus, the normal length of 
the Re–N(sulfonamide) bonds in [Re(CO)3(N(SO2R)dpa)]PF6 complexes is not a consequence of 
the rigidity of the 5-membered dpa chelate rings. 
 
 
 
 
 
 
 
 
 
Figure 2.3. Overlay of Re, C1, C2, and C3 atoms of [Re(CO)3(N(SO2tol)dien)]PF6 (6) (blue) and 
[Re(CO)3(N(SO2tol)dpa)]PF6 35 (magenta) complexes. (The SO2R groups have been omitted for 
clarity). 
The sulfonamide nitrogen of the N(SO2tol)dpa ligand in a PdII complex is not bound to 
PdII and all bond angles around the sulfonamide nitrogen of the N(SO2tol)dpa ligand in the 
bidentate binding mode are close to 120, indicating sp2 hybridization for this N atom.52 In 
contrast, in 4 and 6, all bond angles around the sulfonamide N (N2) are ~109 (Table 2.2). This 
observation, which is consistent with data for [Re(CO)3(N(SO2R)dpa)]PF6 complexes,35 indicates 
that the sulfonamide nitrogen changes from sp2 to sp3 hybridization upon tridentate binding to 
ReI.35 This conclusion is confirmed by the fact that the C5–N2 (average = 1.511 Å) and C6–N2 
(average = 1.512 Å) bond distances are longer than an average C–N(sp2) distance (~1.28 Å).53 
Data for all of the bond angles and distances involving the sulfonamide N indicate that it is sp3 
hybridized. 
N2 
N1 N3 
Re 
C3 
C2 
 C1 
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In [Re(CO)3(N(SO2R)dpa)]PF6 and other complexes that have metal-bound tertiary 
sulfonamide groups, the distance to the sulfonamide N from the plane defined by the S and the 
two C atoms attached to N typically ranges from 0.47–0.52 Å.35 Such values are larger than those 
for the corresponding distance in complexes with an unbound sulfonamide N atom (0.06–0.26 
Å).35 In the new complexes, [Re(CO)3(N(SO2Me)dien)]PF6 (4) and 
[Re(CO)3(N(SO2tol)dien)]PF6 (6), this distance (Table 2.2) is in the range characteristic of a M–
N bond. 
Most of the known complexes with tertiary sulfonamide ligands exhibit relatively long 
M–N(sulfonamide) bond distances and short S–N distances, features attributed to the resonance 
contribution of the lone pair on the sulfonamide N and to the poor electron donation of the 
sulfonamide N to the metal.54,55 Thus, both the comparatively short Re–N(sulfonamide) bond 
distance [2.2763(14) for 4 and 2.2686(19) Å for 6] and the long S–N bond distance in these 
complexes [1.7434(13) for 4 and 1.759(2) Å) for 6] indicate that the sulfonamide N is a relatively 
strong donor.  
Only one other structurally characterized complex in which a diethylenetriamine 
derivative is bound to a metal (LaIII) via a sulfonamide bond through the N has been reported;56 
the sulfonamide group in that complex, however, is part of a cyclic heptadentate ligand. Thus, the 
sulfonamide complexes reported here are the first structurally characterized metal complexes in 
which the metal is coordinated by the central tertiary sulfonamide N in a linear, highly flexible 
tridentate ligand. 
We have previously discussed at length chelate ring pucker λ or δ chirality and the 
consequences on structure and NMR spectra of [Re(CO)3(polyamine)]X complexes.38,46,50 The 
cation of [Re(CO)3(N(SO2Me)dien)]PF6 (4) and one of the cations of 
[Re(CO)3(N(SO2tol)dien)]PF6 (6) (the one shown in Figure 2.2) have five-membered chelate 
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rings of different chirality (λ or δ). However, the other independent cation in the asymmetric unit 
of 6 (not shown) has chelate rings of the same chirality. The relative frequency of observing the 
same or different chiralities in the two chelate rings with a central tertiary sulfonamide N donor 
(4 and 6) suggests that structures in which the chirality of the rings differs may be slightly more 
stable than structures having rings of the same chirality. Thus, our finding agrees with cases in 
which the central N is a classical sp3 N donor, namely that examples in which the chirality of the 
rings in a given structure differs (λδ or δλ) occur more frequently than those in which the 
chirality is the same (λλ or δδ).46 
NMR Spectroscopy. The N(SO2R)dien ligands and the [Re(CO)3(N(SO2R)dien)]PF6 
complexes reported here were characterized by 1H NMR (1–6) and 13C NMR (1, 3–6) 
spectroscopy, usually in one or more of several solvents (CDCl3, acetone-d6, acetonitrile-d3 and 
DMSO-d6). NMR signals were assigned by analyzing the splitting pattern, integration, and data 
from 2D NMR experiments.  
The two methylene 1H NMR signals in N(SO2R)dien ligands (1–3) are triplets integrating 
to four protons in CDCl3 (Experimental Section and Supporting Information). Selected data were 
obtained in acetonitrile-d3 or in DMSO-d6 (Experimental Section and Supporting Information). 
The C(5/6)H2 triplet for 2 (R = dmb) and for 3 (R = tol) is slightly upfield from the C(5/6)H2 
triplet for 1 (R = Me) in CDCl3 (Supporting Information). Shift values for the C(4/7)H2 triplet are 
similar for all three ligands. These observations are attributed to the anisotropic sulfonamide 
aromatic groups, which are close to the C(5/6)H2 groups but far from the C(4/7)H2 groups. 
Similar results were obtained for 1 and 3 in acetonitrile-d3. The two protons in each methylene 
group are not sterically similar because the sulfonamide N lies out of the plane defined by the S 
and the two C atoms attached to N; the apparent magnetic equivalence in the NMR spectra 
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exo-C(5/6)H 
indicates that inversion at the sulfonamide nitrogen leads to time averaging, as discussed 
previously for the N(SO2R)dpa ligands.35  
The spectra of the respective complexes, on the other hand, are consistent with each of 
the four protons in the chelate ring giving rise to a multiplet. For example, the methylene group 
1H NMR signals observed in acetonitrile-d3 changed from two triplets (at 3.07 and 2.79 ppm) for 
the N(SO2tol)dien ligand (3) to four multiplets [at 3.51, 3.16 (two overlapped), and 2.59 ppm; see 
Experimental Section and Supporting Information] for [Re(CO)3(N(SO2tol)dien)]PF6 (6). The 
least amount of overlap of the multiplets for complexes 4–6 was found in acetone-d6 (Figure 
2.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. 1H NMR spectra of [Re(CO)3(N(SO2R)dien)]PF6  complexes (4–6) in acetone-d6 at 25 
ºC. 
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Thus, as expected, the apparent magnetic equivalence of methylene protons in the free ligands is 
lost in 4–6. Similar changes in signals for methylene protons upon coordination of ligands have 
been reported for [Re(CO)3(N(SO2R)dpa)]PF6 complexes35 and for [Re(CO)3(N(H)dien)]PF6.46  
We designate the magnetically distinct protons in –CH2– or –NH2 groups as endo-H or 
exo-H protons, on the basis of the orientation of the proton either toward (endo) or away (exo) 
from the carbonyl ligands (Chart 2.1). Note that the chelate rings in these complexes are 
puckered, and the corresponding protons in the two chelate rings are not equivalent in the solid 
state. However, the chelate rings are fluxional, and time averaging leads to only one signal for 
each type of CH or NH proton, or six 1H NMR signals for the N(C(5/6)H2–C(4/7)H2–NH2)2 
tridentate framework moiety. 
 
 
 
 
 
 
 
 
 
 
 
 
Chart 2.1. Front (left) and side (right) views of [Re(CO)3(N(SO2tol)dien)]PF6  (6), showing the 
designation of endo- and exo-CH and endo- and exo-NH protons. 
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1H NMR Assignments. 1H NMR signals of the protons in the terminal NH2 groups of 
previously reported [Re(CO)3(L)]n compounds (L = simple tridentate ligands similar to 
diethylenetriamine with two terminal –NH2 groups)46,50 are well resolved. The endo-NH signal 
has a more downfield chemical shift than the exo-NH signal; solvent has access to the exposed 
endo-NH protons, but solvent access to the exo-NH protons is impeded by the chelate rings.46,50 
The signal of the exposed endo-NH protons is shifted downfield by NH-solvent H-bonding. Both 
the shifts and the characteristic shift separation between these signals (Δ = 1.5 ppm in DMSO-
d6) are useful for assigning such NH NMR signals.46,50  
In this work, two broad 1H NMR signals of [Re(CO)3(N(SO2tol)dien)]PF6 (6) (5 mM) in 
DMSO-d6 at 4.28 and 5.70 ppm decreased in size when D2O was added, indicating that they are 
NH signals. The signals are connected by a strong COSY cross-peak, as expected for an NH2 
group (Supporting Information). The downfield signal at 5.70 ppm and the relatively upfield 
signal at 4.28 ppm, each integrating to two protons with Δ = 1.5 ppm, can be assigned as endo-
NH and exo-NH signals, respectively.46,50 
Similar Δ values of 1.5 ppm (DMSO-d6), 1.1 ppm (acetone-d6), and 1.0 ppm 
(acetonitrile-d3) were observed between the downfield and upfield NH signals for all three 
complexes studied here (Table 2.3). This consistency aided in assigning the endo-NH and exo-
NH signals in complexes 4–6 (Table 2.3, Figure 2.4). Although X-ray quality crystals for 
compound 5 have not been isolated, the 1H NMR patterns and shifts of its chelate ring signals in 
all solvents used match the corresponding 1H NMR data for the crystallographically 
characterized compound 6 (Table 2.3 and Figure 2.4). These 1H NMR chemical shifts provide 
strong evidence that 5 has a structure very similar to that of 6. The NH signals of 6 in different 
solvents (Figure 2.5) are shifted downfield as the H-bonding ability of the solvent increases.  
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Table 2.3. 1H NMR Shifts (ppm) of exo- and endo-NH and exo- and endo-CH Signals for 
[Re(CO)3(N(SO2R)dien)]PF6 Complexes in Various Solvents at 25 C 
 
 
signal R = Me (4) R = dmb (5) R = tol (6) 
DMSO-d6 
exo-NH 4.27 4.28 4.28 
endo-NH 5.65 5.72 5.70 
endo-C(5/6)H      3.45 3.41 3.42 
exo-C(4/7)H 3.23 3.14 3.14 
endo-C(4/7)H 3.10 3.00 3.01 
exo-C(5/6)H 2.97 2.65 2.66 
acetone-d6 
exo-NH 4.45 4.40 4.40 
endo-NH 5.54 5.52 5.51 
endo-C(5/6)H      3.85 3.81 3.81 
exo-C(4/7)H 3.69 3.58 3.55 
endo-C(4/7)H ~3.50 3.50 3.52 
exo-C(5/6)H ~3.50 3.02 3.02 
acetonitrile-d3 
exo-NH 3.44 3.41 3.37 
endo-NH 4.46 4.52 4.51 
endo-C(5/6)H      3.50 3.52 3.51 
exo-C(4/7)H    ~3.18 ~3.16 ~3.16 
endo-C(4/7)H    ~3.18 ~3.16 ~3.16 
exo-C(5/6)H 3.00 2.60 2.59 
 
Thus, significant downfield chemical shifts are observed in acetone-d6 and DMSO-d6, in contrast 
to the relatively upfield chemical shifts observed in acetonitrile-d3 (Table 2.3 and Figure 2.5), 
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owing to the weak interactions of that solvent with the NH groups. The highest Δ value (1.5 
ppm) occurs in DMSO-d6 because it has the greatest H-bonding ability among the three solvents.  
 
 
  
 
 
 
 
 
 
 
 
 
Figure 2.5.  1H NMR spectra of [Re(CO)3(N(SO2tol)dien)]PF6 (6), illustrating the relative 
position of NH signals observed at 25 ºC in a) acetonitrile-d3, b) acetone-d6, and c) DMSO-d6.  
The endo-NH and exo-NH 1H NMR signals assignments provide a starting point that 
allows us to exploit our structural data to achieve complete and unambiguous assignment of the 
ethylene 1H NMR signals, which are rarely well resolved for coordinated ligands having such 
chelate rings.50 To demonstrate our assignment strategy of assigning the multiplets to a specific 
endo-CH or exo-CH proton (Chart 2.1), we use [Re(CO)3(N(SO2tol)dien)]PF6 (6) in acetone-d6 
because of the low degree of overlap of signals for the ethylene group (Figure 2.4). The atom 
numbering system used in this discussion appears in Figure 2.1. Cross-peaks in COSY spectra 
(Supporting Information) and ROESY spectra (Figure 2.6 and Supporting Information) identify a 
multiplet as a C(4/7)H or C(5/6)H signal. In the solid state, the endo-NH protons have a shorter 
average distance to the endo-C(4/7)H protons (2.20 Å) than to the exo-C(4/7)H protons (2.71 Å), 
a) 
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and the exo-NH protons have a shorter average distance to the exo-C(4/7)H protons (2.22 Å) than 
to the endo-C(4/7)H protons (2.43 Å). Thus, from NH-CH NOE cross-peak intensities, the CH 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. 1H-1H ROESY spectrum of [Re(CO)3(N(SO2tol)dien)]PF6  (6) in acetone-d6 at 25 ºC. 
An expanded version of this figure is in Supporting Information.  
 
multiplets at 3.52 ppm and 3.55 ppm are assigned to the endo- and exo-C(4/7)H protons, 
respectively. The average distance from the exo-C(4/7)H protons is shorter to the exo-C(5/6)H 
protons (2.30 Å) than to the endo-C(5/6)H protons (2.85 Å). In the ROESY spectrum, a strong 
NOE cross-peak from the exo-C(4/7)H multiplet to the most upfield multiplet at 3.02 ppm thus 
assigns the multiplet to the exo-C(5/6)H protons. Similarly, an NOE cross-peak from the endo-
C(4/7)H multiplet to the most downfield multiplet at 3.81 ppm assigns this multiplet to the endo-
C(5/6)H protons. The tosyl methyl singlet (2.53 ppm) of 6 has an NOE cross-peak to the tosyl 
doublet at 7.65 ppm, unambiguously assigning it to the tosyl H3/5 protons and the other tosyl 
doublet to H2/6. The latter is more downfield (8.05 ppm), consistent with the proximity of the 
H2/6 protons to the sulfonamide group, shown in previous work on the 
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[Re(CO)3(N(SO2tol)dpa)]PF6 analogue to have an electron-withdrawing inductive effect.35 A 
strong H2/6-to-endo-C(5/6)H NOE cross-peak and a very weak H2/6-to-exo-C(5/6)H cross-peak 
is consistent with the shorter H2/6-to-endo-C(5/6)H average distance (2.60 Å) compared to the 
H2/6-to-exo-C(5/6)H average distance (2.81 Å), thus confirming the assignment of the endo-
C(5/6)H and exo-C(5/6)H signals (Table 2.3).  
1H NMR Shift Interpretation. The exo-C(5/6)H signal is more upfield for 5 and 6 than 
for 4 in acetone-d6 (Figure 2.4). In 6 (Figure 2.2 and Chart 2.1), the relative average distance 
from the centroid of the tosyl ring to the exo-C(5/6)H protons (which point toward the center of 
the ring) is shorter (3.45 Å) than the distance (4.09 Å) to the endo-C(5/6)H protons (Chart 2.1). 
Thus, the anisotropic effect of the aromatic ring of the R group explains the unusually upfield 
shift of the exo-C(5/6)H multiplet at 3.02 ppm in acetone-d6 for 5 and 6. This explanation is 
supported by the fact that the exo-C(5/6)H signal is not so upfield for 4, a complex in which R 
lacks an aromatic ring. This same trend, with the methylene endo-CH signal downfield from the 
exo-CH signal and the latter signal appearing more upfield when R has an aromatic ring (tol) than 
when R = Me, was reported for the [Re(CO)3(N(SO2R)dpa)]X complexes.35 
Coordination of a ligand normally leads to downfield 1H NMR shift changes attributable 
to the metal inductive effect. Upon coordination to ReI of the free N(SO2R)dien ligands 1 and 3 
in acetonitrile-d3, the downfield shift for signals of the C4/7 protons is ~ 0.4 ppm. For example, 
the C(4/7)H2 triplet for 1 shifts from 2.76 ppm downfield to ~3.18 ppm for the overlapping 
C(4/7)H signals of [Re(CO)3(N(SO2Me)dien)]PF6 (4). A corollary of the relationships of the 
distance of the exo-C(5/6)H protons to the aromatic groups mentioned above for 6 is that the 
endo-C(5/6)H protons are farther from R, and the shift of the endo-C(5/6)H signal for 4 and 6 is 
not influenced by the R group. Hence, compared to the C(5/6)H2 triplets of 1 and 3, the endo-
C(5/6)H signals of 4 and 6 are shifted downfield (~0.4 ppm to ~3.5 ppm in acetonitrile-d3). 
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Remarkably, upon coordination of N(SO2Me)dien to form 4, the exo-C(5/6)H signal (expected to 
shift downfield by ~0.4 ppm owing to inductive effects) is shifted slightly upfield (0.14 ppm) 
compared to the free ligand triplet, even though R = Me is not anisotropic. Presently there are not 
enough other complexes with assigned signals for us to interpret the factors influencing shift, but 
the upfield shift may be caused by the SO2 group anisotropy. Also, although the reaction of free 
amines with acetone prevents comparison using acetone-d6, in DMSO-d6 (the other solvent rather 
different from acetonitrile-d3 that we used for the complexes) the same pattern of shift changes 
was observed upon coordination of 1 to form 4, including the slight upfield shift of the exo-
C(5/6)H signal (Supporting Information). Thus, solvent effects are probably not causing the 
unexpected upfield shift. 
The methyl 1H NMR signal of N(SO2Me)dien (1) shifted downfield upon coordination of 
1 to form [Re(CO)3(N(SO2Me)dien)]PF6 (4) in both acetonitrile-d3 (0.47 ppm) and DMSO-d6 
(0.66 ppm) (Experimental Section and Supporting Information). These downfield shifts can be 
attributed to the ReI inductive effect. We previously attributed a similar downfield shift (0.76 
ppm) observed for [Re(CO)3(N(SO2Me)dpa)]PF6 to the ReI inductive effect.35 A slightly greater 
downfield shift (1.03 ppm) relative to the free ligand reported for the [Re(CO)3(N(Me)dien)]PF6 
complex in DMSO-d646 can be explained by the transmission of the inductive effect through just 
two bonds (N–C and C–H) versus three bonds in 4 (N–S,  S–C, and C–H).   
13C NMR Shift Interpretation. Unlike 1H NMR signals, the shifts of 13C NMR signals 
are not very dependent on solvent effects (e.g., as discussed for the NH signals) or on aromatic 
ring anisotropic effects (e.g., as discussed for exo-C(5/6)H signals). Instead, 13C NMR signals are 
influenced more significantly by other factors, with signals of aliphatic carbons most frequently 
being shifted downfield by metal inductive effects. Analysis of 13C NMR shifts can often provide 
insight into the effect of a diamagnetic metal center on the ligand. Therefore, we undertook the 
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unambiguous assignment of the 13C NMR signals of selected ligands and complexes as described 
in Supporting Information. The 13C NMR signals of the chelate ring carbons shift downfield, as 
expected, by 4 to 5 ppm upon coordination of the tridentate ligands 1 and 3 to form complexes 4 
and 6, and the shifts for the C4/7 and C5/6 signals of 4 are very similar to the shifts for these 
signals of 6 (data for acetonitrile-d3 are reported in Supporting Information).  
The methyl group 13C NMR signal for the free N(SO2Me)dien ligand (1) appears at 37.87 
ppm, but it is shifted considerably upfield for [Re(CO)3(N(SO2Me)dien)]PF6 (4) (33.02 ppm, 
Supporting Information). The almost 5 ppm upfield change in shift when 1 forms 4 is unusual in 
that 13C NMR shifts are influenced mainly by through-bond effects, such as the metal inductive 
effect expected to produce a downfield shift. For example, a significant ~14 ppm downfield 13C 
NMR shift was observed for the methyl group of [Re(CO)3(N(Me)dien)]PF6 (56.48 ppm) 
compared to the methyl group in the free N(Me)dien ligand (42.72 ppm) in acetonitrile-d3.51 
Because of the unexpected upfield direction of the shift change of the methyl 13C NMR signal of 
4, we measured the 13C NMR shift of the methyl signal of [Re(CO)3(N(SO2Me)dpa)]PF6 in 
DMSO-d6 (32.88 ppm), a value ~6.5 ppm upfield compared to the methyl signal in the free 
N(SO2Me)dpa ligand (39.24 ppm).51 We attribute the observed unusual upfield shift for 4 to the 
fact that the sulfonamide N undergoes an sp2-to-sp3 rehybridization upon coordination to ReI in 
both 4 and [Re(CO)3(N(SO2Me)dpa)]PF6.  
Challenge Reactions of [Re(CO)3(N(SO2tol)dien)]PF6 (6) in DMSO-d6. No change was 
observed in the 1H NMR signals of 6 (5 mM), even after six months, indicating that 6 is robust. 
However, addition of diethylenetriamine to 5 mM solutions of 6 to create solutions that were 50 
mM or 10 mM in diethylenetriamine led to the elimination of all peaks for 6 by the next day and 
after about 6 days (t1/2 28 h), respectively. In both cases, the final 1H NMR spectrum exhibits 
peaks for the N(SO2tol)dien ligand (3) and for the known [Re(CO)3(N(H)dien)]PF6 complex.46 
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No signals indicating any intermediates were observed. The complete displacement of the 
coordinated N(SO2tol)dien ligand of 6 by 10 mM diethylenetriamine establishes that although the 
Re–N bonds involving the central donor of N(SO2R)dien ligands have normal lengths, the donor 
ability of the central sulfonamide nitrogen atom is lower than that of the central nitrogen atom of 
diethylenetriamine.  
A related study38 was reported for the neutral Re(CO)3(tmbSO2-dien) complex. The 
coordinated unsymmetrical monoanionic NNN donor ligand, tmbSO2-dien
- (Chart 2.2), 
employed in that study has a 2,4,6-trimethylbenzenesulfonyl (tmbSO2) group linked to one of the 
terminal N atoms of diethylenetriamine. The terminal donor of the free ligand prior to 
coordination is a secondary sulfonamide of the type (RSO2)R'NH. When 10 molar equiv of 
diethylenetriamine was added to a solution of Re(CO)3(tmbSO2-dien) (3 mM, DMSO-d6), no 
coordinated tmbSO2-dien
- ligand was displaced, even after the solution was heated at 60 oC.38 
Thus, the deprotonated monoanionic tmbSO2-dien
- ligand is clearly a better ligand than neutral 
N(SO2tol)dien. 
 
 
 
 
Chart 2.2.  The tmbSO2-dien
- monoanionic ligand.38 
If the central tertiary sulfonamide donor in N(SO2tol)dien were coordinated weakly 
enough to the Re in [Re(CO)3(N(SO2R)dien)]PF6 complexes, a good monodentate ligand might 
be able to substitute for the coordinated sulfonamide group. Therefore, we conducted a challenge 
experiment in which the strongly basic, potentially monodentate 4-Me2Npy ligand was added to 
- 
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[Re(CO)3(N(SO2tol)dien)]PF6 (6). No 1H NMR spectral changes were observed over many days, 
even with a tenfold excess of 4-Me2Npy. Such evidence indicates that the central sulfonamide 
bond is strong enough to stay coordinated to Re, even in the presence of an excess of a strong 
monodentate ligand. Also, the results show that the [Re(CO)3(N(SO2tol)dien)]PF6 complex is 
resistant to strong base, an advantage over [Re(CO)3(N(SO2Me)dpa)]PF6, which decomposes 
readily in the presence of base.35  
Solubility of [Re(CO)3(N(SO2tol)dien)]PF6 (6) in Water. A mixture of 5 mg of 
[Re(CO)3(N(SO2tol)dien)]PF6 (6) and 450 L of D2O gave a clear solution when heated in a 
boiling water bath for 30 min. The 1H NMR spectrum of this solution, which compares favorably 
with spectra of 6 in other solvents (Figure 2.4), has four methylene multiplets, whereas the 
N(SO2tol)dien ligand has two methylene triplets in D2O. These results established that 6 
dissolved unchanged to an extent much greater than is required for radiopharmaceuticals and that 
6 is robust even in a hot aqueous solution. Furthermore, another experiment conducted using 5 
mg of 6 also showed complete dissolution (observed visibly and by 1H NMR spectroscopy) of 6 
in a 450 L:20 L of D2O:DMSO mixture (95.7%:4.3%). In contrast, similar NMR experiments 
carried out using the previously reported [Re(CO)3(N(SO2Me)dpa)]PF6 complex35 show that even 
the [Re(CO)3(N(SO2R)dpa)]PF6 complex having the smallest R group is insoluble in D2O or in 
D2O:DMSO (95.7%:4.3%). 
2.4 Conclusions 
From the present results with [Re(CO)3(N(SO2R)dien)]PF6 complexes, in which the 
chelate rings are less rigid, we conclude that the M–N bond of normal length observed was not a 
result of the rigid tridentate framework in the [Re(CO)3(N(SO2R)dpa)]X35 complexes. In both 
series of complexes, the methyl 13C NMR signal of the R = Me member of the series exhibited a 
very unusual upfield shift for an aliphatic carbon signal upon coordination of the ligand. This 
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result, attributed to the similar sp2-to-sp3 rehybridization of the sulfonamide N upon coordination 
to ReI in both series of complexes, further establishes that coordination of the sulfonamide N is 
not influenced by the rigidity of the N(SO2R)dpa chelate rings. The decomposition of the 
[Re(CO)3(N(SO2R)dpa)]X complexes by base35 led us to hypothesize that base was attacking the 
coordinated N(SO2R)dpa ligand, most likely by deprotonating the CH2 group, and that the low 
electrophilicity of the Z = CH2NH2 group of the N(CH2CH2NH2)2 framework would confer 
stability toward base. The stability of the new [Re(CO)3(N(SO2R)dien)]PF6  complexes toward 
base supports these hypotheses and allowed us to conduct a challenge reaction study with the 
basic N(H)dien ligand. N(H)dien replaced the coordinated N(SO2tol)dien ligand in 
[Re(CO)3(N(SO2tol)dien)]PF6, indicating that the neutral sulfonamide N central donor in 
N(SO2tol)dien is a somewhat weaker donor than the central traditional sp3 N donor in N(H)dien. 
Nevertheless, the new [Re(CO)3(N(SO2R)dien)]PF6 complexes are long lived, even in the 
presence of base, and are relatively robust to heat treatment. As expected, the moderately 
hydrophilic character of the Z = CH2NH2 group of the N(CH2CH2NH2)2 framework also confers 
water solubility on the [Re(CO)3(N(SO2R)dien)]PF6 complexes. The aqueous solubility of the 
new ligands and complexes is much higher than necessary for radiopharmaceutical kit 
formulation. Also, there are perceived advantages in using small chelate ligands when 
constructing bioconjugates, and the N(CH2CH2NH2)2 framework is relatively small. Thus, the 
results obtained here suggest that N(SO2R)dien ligands should be explored in the development of 
radiopharmaceuticals, including bioconjugates. 
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CHAPTER 3 
NEW MONODENTATE AMIDINE SUPERBASIC LIGANDS WITH A SINGLE 
CONFIGURATION IN fac-[Re(CO)3(5,5- OR 6,6-Me2BIPYRIDINE)(AMIDINE)]BF4 
COMPLEXES 
3.1 Introduction 
Owing to the many ideal properties of the fac-[MI(CO)3] core in radiopharmaceuticals, 
fac-[MI(CO)3L]n (M = various isotopes of Tc and Re) complexes have recently been receiving 
much attention.1-7 Some fac-[99mTcI(CO)3L]n  imaging agents have undergone evaluation in 
humans,8-9 and fac-[186/188ReI(CO)3L]n  agents are emerging as being among the most promising 
radionuclides for therapeutic applications.2,10-11 At present, great interest surrounds the concept 
of combining 99mTc and 186/188Re with biomolecules in order to produce selective targeting 
agents.5-6,11-17 fac-[ReI(CO)3L]n  complexes prepared with natural-abundance rhenium are 
excellent models for the short-lived fac-[MI(CO)3L]n radiopharmaceuticals and are almost non-
radioactive. Thus, the investigation of fac-[ReI(CO)3L]n  complexes both aids in interpreting the 
chemistry of the radiopharmaceuticals and offers the potential for the discovery of new 
chemistry, some of which could be applied to radiopharmaceutical development.18-19 
Our objectives are aimed at expanding the known chemistry of complexes with the fac-
[ReI(CO)3] core.7,20-21 Syntheses in aqueous media carried out with the commonly used 
precursor, aqueous fac-[ReI(CO)3(H2O)3]+,22 have some limitations.23 Thus, we have recently 
investigated the suitability of fac-[Re(CO)3(CH3CN)3]X (X = PF6 or BF4) as a precursor for the 
synthesis of new complexes in organic solvents.23 Treatment of fac-[Re(CO)3(CH3CN)3]X with 
 
 
 
*Reproduced with permission from American Chemical Society: Abhayawardhana, P.; 
Marzilli, P. A.; Perera, T.; Fronczek, F. R.; Marzilli, L. G. “New Monodentate Amidine 
Superbasic Ligands with a Single Configuration in fac-[Re(CO)3(5,5′- or 6,6′-
Me2bipyridine)(amidine)]BF4 Complexes”. Inorg. Chem. 2012, 51, 7271−7283. Copyright 
2015 American Chemical Society. 
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bidentate aromatic sp2 N-donor bipyridine-type L in either acetonitrile or benzene as solvent 
produced the desired fac-[Re(CO)3(L)(CH3CN)]X complexes in excellent yield [e.g., when L = 
2,2-bipyridine (bipy) or a dimethyl-2,2-bipyridine (Me2bipy), Scheme 3.1].24 However, a recent 
study revealed that reactions to form these complexes in methanol instead led to addition of 
solvent to bound acetonitrile, forming iminoether complexes, fac-
[Re(CO)3(Me2bipy)(HNC(CH3)OCH3)]BF4.23 The original acetonitrile carbon with a triple bond 
to the rhenium-bound nitrogen (N3) is converted in the reaction to an iminoether carbon (Cie), 
and N3 adds a proton and rehybridizes from sp to sp2 (Scheme 3.1). The Cie–N3 bond has 
double-bond character, and the iminoether ligand potentially can have E and Z configurations. 
However, the Z isomer (Scheme 3.1) is favored exclusively because the axial iminoether ligand 
steric repulsions with the equatorial ligands (the two CO’s and the Me2bipy) are lower for the Z 
configuration than for the E configuration.23  
 
 
 
 
 
 
Scheme 3.1. General reaction scheme for the synthesis of [Re(CO)3(L)(CH3CN)]+ starting 
material24 and for the formation of [Re(CO)3(Me2bipy)(HNC(CH3)OCH3)]+ (iminoether) 
complexes.23  
 
The reactions of fac-[Re(CO)3(5,5-Me2bipy)(CH3CN)]+ (1) with alcohols to form 
iminoethers were slow.23 On the other hand, the related reactions of primary amines with 1 to 
form amidine complexes, fac-[Re(CO)3(5,5-Me2bipy)(HNC(CH3)NHR)]+, were more rapid.25 
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However, these amidine complexes exist as mixtures of isomers. In the HNC(CH3)NHR ligands, 
both C–N bonds involving the amidine carbon (Cam), Cam–N3 and Cam–N4, have double-bond 
character. This situation raises the possibility that four configurations (E, E, Z and Z) of the 
amidine ligands could exist (Figure 3.1). In fact, three configurations (E, E, and Z) were found.25 
The isomers are named using these configurations. As illustrated and discussed below, steric 
effects strongly influence the relative abundance of the isomers.  
 
 
 
 
 
 
 
 
 
 
Figure 3.1. The four conceivable [Re(CO)3(5,5-Me2bipy)HNC(CH3)NHR)]+ isomers, in which 
N–N denotes the 5,5-Me2bipy  ligand. The isomers with the E and Z configurations are typically 
abundant. The isomer with the Z configuration is unstable and not observed.25 The isomer with 
the E configuration is known, but its abundance is usually too low to allow detection. However, 
as illustrated here, the pathway between the E and Z configurations undoubtedly passes through 
the E configuration and not the Z configuration.   
The amidine group, such as that present in fac-[Re(CO)3(5,5-
Me2bipy)(HNC(CH3)NHR)]BF4 complexes,25 has the potential to serve as a linking group in the 
conjugation of the fac-[M(CO)3]+ core (M = 99mTc and 186/188Re radionuclides) with biomedical 
targeting moieties. The nitrogen donor group in amidine (and iminoether) ligands is 
superbasic.23,25 However, the finding of isomers of these complexes (Figure 3.1) complicates the 
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development of agents useful for biomedical imaging. Therefore, we now explore amidine 
ligands with a C2-symmetrical NR2 substituent in place of the NHR substituent. This change 
eliminates the possibility of two configurations about the Cam–N4 bond, restricting the number of 
conceivable isomers to two (with E or Z configurations about the Cam–N3 bond). Furthermore, 
we expected that a large difference in substituent bulk (NR2 vs. CH3) on Cam should favor the E 
isomer exclusively.  
We chose C2-symmetrical saturated heterocyclic secondary amines in our synthetic 
strategy because many related symmetric heterocyclic amine derivatives are present in 99mTc and 
186/188Re agents13,26-31 and in successful drugs.31-32 Because their use as ubiquitous building 
blocks in the synthesis of pharmaceuticals31 has provided information on the synthesis and 
properties of such amines, these amines are particularly desirable candidates for study. Indeed, a 
modified arylpiperazine was employed in one of the earliest examples of a fac-[99mTc(CO)3]+-
containing agent linked to a targeting biomolecule.13 All of the new complexes discussed below 
have the facial geometry, and thus from this point onward we omit the fac- designation when 
discussing specific compounds. 
3.2 Experimental Section 
Starting Materials. Re(CO)5Br was synthesized as described in the literature.33 
Re2(CO)10, 5,5-dimethyl-2,2-bipyridine (5,5-Me2bipy), 6,6-dimethyl-2,2-bipyridine (6,6-
Me2bipy), piperidine, homopiperidine, heptamethyleneimine, morpholine, piperazine, and AgBF4 
were obtained from Aldrich. [Re(CO)3(CH3CN)3]BF4 (prepared by a slight modification of a 
known procedure34) was used to prepare [Re(CO)3(5,5- or 6,6-Me2bipy)(CH3CN)]BF4.24  
NMR Measurements. 1H NMR spectra were recorded on a 400 MHz Bruker 
spectrometer. Peak positions are relative to TMS or to solvent residual peak, with TMS as 
reference. All NMR data were processed with TopSpin and Mestre-C software.  
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X-ray Data Collection and Structure Determination. Intensity data were collected at 
low temperature on a Nonius Kappa CCD diffractometer fitted with an Oxford Cryostream 
cooler with graphite-monochromated Mo K ( = 0.71073 Å) radiation. Data reduction included 
absorption corrections by the multi-scan method, with HKL SCALEPACK.35 All X-ray 
structures were determined by direct methods and difference Fourier techniques and refined by 
full-matrix least squares by using SHELXL-97.36 All non-hydrogen atoms were refined 
anisotropically. All H atoms were visible in difference maps, but were placed in idealized 
positions, except for N-H hydrogen atoms, for which coordinates were refined. A torsional 
parameter was refined for each methyl group. For compounds 4, 5, and 9, the BF4- site was 
shared by a few percent bromide, and the occupancies of the two anions were constrained to sum 
to unity in the refinement.In compound 10, the BF4- is disordered into two orientations and the 8-
membered ring is disordered into two conformations. The occupancies refined to 
0.891(5):0.109(5) for the anion and 0.521(6):0.479(6) for the 8-membered ring. Crystal data and 
details of refinements are listed in Tables 3.1 and 3.2. 
General Synthesis of Amidine Complexes. An acetonitrile solution (6 mL) of 
[Re(CO)3(5,5-Me2bipy)(CH3CN)]BF4 (1) or [Re(CO)3(6,6-Me2bipy)(CH3CN)]BF4 (2) (40 mg, 
0.06 mmol) was treated with an amine (0.60 mmol), and the reaction mixture was stirred at room 
temperature for 30 min or as specified. The volume was reduced to 1 mL by rotary evaporation. 
Addition of diethyl ether to the point of cloudiness (10-200 mL) produced a yellow crystalline 
material that was collected on a filter, washed with diethyl ether, and dried. All 1H NMR spectra 
recorded both immediately upon dissolution of the products (3 to 12) and subsequently showed 
signals for one isomer. 
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Table 3.1. Crystal Data and Structural Refinement for Complexes Having the General Formula, 
[Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 
 
Y = CH2 (CH2)2 (CH2)3 NH O 
Complex 3 4 5 6 7 
empirical  
formula 
C22H26N4O3Re
·BF4 
C23H28N4O3Re·  
0.95(BF4)·0.05(
Br) 
C24H30N4O3Re·       
0.96(BF4)·0.04(Br) 
C21H25N5O3Re
·BF4 
C21H24N4O4R
e·BF4 
Fw 667.48 681.16 695.50 668.47 669.45 
crystal system monoclinic monoclinic monoclinic monoclinic monoclinic 
space group P21/n P21/n P21/n P21/n P21/n 
a (Å) 11.4576(10) 13.3550(15) 13.7247 (14) 11.6155(10) 11.3847(9) 
b (Å) 13.4757(15) 13.2081(14) 11.1284 (10) 12.9640(14) 13.3112(10) 
c (Å) 15.9875(15) 14.7562(18) 18.141 (2) 15.8176(11) 15.7988(15) 
 (deg) 97.502(5) 105.347(6) 109.392 (3) 97.341(6) 97.843(6) 
V (Å3) 2447.3(4) 2510.1(5) 2613.6 (5) 2362.3(4) 2371.8(3) 
T (K) 200 150 95 95 90 
Z 4 4 4 4 4 
calc (Mg/m3) 1.812 1.802 1.768 1.880 1.875 
abs coeff (mm-1) 5.03 4.98 4.78 5.21 5.19 
2max () 60.2 61.0 72.6 68.4 70.0 
R [I> 2(I)]a 0.032 0.032 0.029 0.032 0.033 
wR2b 0.073 0.075 0.060 0.067 0.075 
w scheme d,e 0.0315, 2.4602 0.0343, 3.5449 0.0230, 1.6351 0.0252, 1.6969 0.0354, 0 
data/param 7180/323 7045/344 12259/345 9257/326 10062/323 
Res. dens (eÅ-3) 1.23, -1.23 1.08, -1.85 1.16, -1.54 1.37, -1.72 1.46, -1.70 
 
a R = (||F| - |Fc||)/|F|. b wR2 = [[w(F2 - Fc2)2]/[w(F2)2]]1/2,  in which w = 1/[2(F2) + 
(dP)2 + (eP)] and P = (F2 + 2Fc2)/3. 
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Table 3.2. Crystal Data and Structural Refinement for Complexes Having the General Formula, 
[Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 
 
Y = CH2 (CH2)2 (CH2)3 NH O 
Complex 8 9 10 11 12 
empirical 
formula 
C22H26N4O3Re·
BF4 
C23H28N4O3Re· 
0.97(BF4)· 
0.03(Br) 
C24H30N4O3Re· 
BF4 
C21H25N5O3Re· 
BF4 
C21H24N4O4Re· 
BF4 
Fw 667.48 681.31 695.53 668.47 669.45 
crystal system monoclinic monoclinic monoclinic monoclinic monoclinic 
space group P21/n P21/n P21/c P21/n P21/n 
a (Å) 8.9242(5) 11.4040(10) 12.5348(10) 12.401(2) 15.6441(15) 
b (Å) 21.862(2) 17.724(2) 10.8431(9) 14.221(3) 9.3838(10) 
c (Å) 12.3282(10) 12.3056(11) 19.692(2) 13.630(2) 16.1555(12) 
 (deg) 95.358(4) 98.914(5) 105.942(4) 100.750(9) 91.294(4) 
V (Å3) 2394.7(3) 2457.2(4) 2573.5(4) 2361.5(7) 2371.0(4) 
T (K) 90 100 90 95 90 
Z 4 4 4 4 4 
calc (Mg/m3) 1.851 1.842 1.795 1.880 1.875 
abs coeff (mm-1) 5.14 5.05 4.79 5.21 5.19 
2max () 72.0 69.8 68.0 65.2 71.4 
R [I> 2(I)]a 0.031 0.031 0.030 0.037 0.029 
wR2b 0.074 0.068 0.070 0.097 0.069 
w scheme d,e 0.0349, 0 0.0271, 2.2079 0.0307, 2.8985 0.0575,0.7244 0.0349, 1.1307 
Data/param 10749/323 10050/333 9861/388 8537/326 10909/323 
Res. dens (eÅ-3) 1.59, -2.07 1.35, -1.99 1.83, -1.58 4.45, -2.55 2.22, -1.69 
 
a R = (||F| - |Fc||)/|F|. b wR2 = [[w(F2 - Fc2)2]/[w(F2)2]]1/2,  in which w = 1/[2(F2) + 
(dP)2 + (eP)] and P = (F2 + 2Fc2)/3. 
 
 48 
The 1H NMR spectrum of all crystals described below was identical to that of the product 
obtained by this procedure. In order to study the progress of the amidine formation reactions, a 
10 mM solution of 1 or 2 was prepared in 600 L of acetonitrile-d3. We refer to such a solution 
as the 10 mM solution. An excess of amine (100 mM) was added to the 10 mM solution, and the 
reaction was monitored by NMR spectroscopy. In all cases, the only signals observed for 
products were those expected from the isolated products. 
Synthesis of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2CH2)]BF4 (3). The use 
of this general method in the reaction of 1 with piperidine (59 L, 0.60 mmol) afforded 30 mg 
(74% yield) of yellow crystalline material. 1H NMR signals (ppm) in acetonitrile-d3:  8.85 (s, 2H, 
H6/6), 8.26 (d, J = 8.4 Hz, 2H, H3/3), 8.04 (d, J = 8.4 Hz, 2H, H4/4), 4.78 (b, 1H, NH), 3.01 
(m, 4H, 2CH2), 2.48 (s, 6H, 5/5-2CH3), 2.10 (s, 3H, CCH3), 1.48 (m, 2H, CH2), 1.28 (m, 4H, 
2CH2).  
X-ray quality crystals of 3 (E isomer) were produced upon slow evaporation of a solution 
of the crystalline material (5 mg/6 mL) in a 1/5 (v/v) mixture of acetonitrile/diethyl ether. The 1H 
NMR spectrum of the crystals dissolved in acetonitrile-d3 was identical to that of the bulk 
product.   
Monitoring the progress of the reaction of 1 with piperidine (5.9 L) as described above 
indicated that no signals for 1 remained after 5 min, and signals for 3 were the only product 
signals present. 
Synthesis of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2(CH2)2)]BF4 (4). The 
use of the general method in the reaction of 1 with homopiperidine (60 L, 0.60 mmol) produced 
33 mg (80% yield) of yellow crystalline material. 1H NMR signals (ppm) in acetonitrile-d3: 8.87 
(s, 2H, H6/6), 8.27 (d, J = 8.6 Hz, 2H, H3/3), 8.05 (d, J = 8.1 Hz, 2H, H4/4), 4.52 (b, 1H, NH), 
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3.30 (b, m, 2H, CH2), 2.96 (b, m, 2H, CH2),  2.48 (s, 6H, 5/5-2CH3), 2.10 (s, 3H, CCH3), 1.46 
(b, m, 2H, CH2), 1.31 (b, m, 2H, CH2), 1.15 (b, m, 2H, CH2), 0.96 (b, m, 2H, CH2). 
X-ray quality crystals of 4 (E isomer) grew upon slow evaporation of a solution of the 
crystalline material (5 mg/4 mL) in a 1/3 (v/v) mixture of acetonitrile/diethyl ether. The 1H NMR 
spectrum of the crystals dissolved in acetonitrile-d3 was identical to that of the bulk product.   
Monitoring the progress of the reaction of 1 with homopiperidine (6 L) as described above 
indicated that no signals for 1 remained after 8 min. 
Synthesis of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2(CH2)3)]BF4 (5). The 
use of the general method in the reaction of 1 with heptamethyleneimine (76 L, 0.60 mmol), but 
stirring for 8 h, yielded 13 mg (32%) of yellow crystalline material. 1H NMR signals (ppm) in 
acetonitrile-d3: 8.87 (s, 2H, H6/6), 8.27 (d, J = 8.3 Hz, 2H, H3/3), 8.04 (d, J = 8.0 Hz, 2H, 
H4/4), 4.49 (b 1H, NH), 3.25 (b, 2H, CH2), 3.05 (b, 2H, CH2), 2.48 (s, 6H, 5/5-2CH3), 2.12 (s, 
3H, CCH3), 1.50 (b, m, 2H, CH2), 1.39 (b, m, 2H, CH2), 1.18 (b, m, 2H, CH2), 0.96 (b, m, 2H, 
CH2), 0.71 (b, m, 2H, CH2).  
X-ray quality crystals of 5 (E isomer) grew upon slow evaporation of a solution of the 
crystalline material (10 mg/~200 mL) in a 1/200 (v/v) mixture of acetonitrile/diethyl ether. The 
1H NMR spectrum of the crystals dissolved in acetonitrile-d3 was identical to that of the bulk 
product.   
Monitoring the progress of the reaction of 1 with heptamethyleneimine (7.6 L) as 
described above indicated that no signals for 1 remained after 6 h. 
Synthesis of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2NH)]BF4 (6). The 
general synthetic reaction of 1 with piperazine (52 mg, 0.60 mmol) yielded 34 mg (84%) of 
yellow crystalline material. 1H NMR signals (ppm) in acetonitrile-d3: 8.85 (s, 2H, H6/6), 8.26 (d, 
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J = 8.4 Hz, 2H, H3/3), 8.04 (d, J = 8.4 Hz, 2H, H4/4), 4.84 (b, 1H, NH), 2.95 (m, 4H, 2CH2), 
2.53 (m, 4H, 2CH2), 2.48 (s, 6H, 5/5-2CH3), 2.12 (s, 3H, CCH3).  
X-ray quality crystals of 6 (E isomer) formed upon slow evaporation of a 16 mL solution 
of the crystalline material (5 mg) in a 1/15 (v/v) mixture of acetonitrile/diethyl ether. The 1H 
NMR spectrum of the crystals dissolved in acetonitrile-d3 was identical to that of the bulk 
product.   
Monitoring the progress of the reaction of 1 with piperazine (5.2 mg) as described above 
indicated that no signals for 1 remained after 20 min. 
Synthesis of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2O)]BF4 (7). The general 
synthetic reaction of 1 with morpholine (53 L, 0.60 mmol) (stirring time, 6 h) yielded 33 mg 
(83%) of yellow crystalline material. 1H NMR signals (ppm) in acetonitrile-d3: 8.85 (s, 2H, 
H6/6), 8.26 (d, J = 8.4 Hz, 2H, H3/3), 8.05 (d, J = 8.1 Hz, 2H, H4/4), 4.94 (b, 1H, NH), 3.45 
(m, 2H, CH2), 3.00 (m, 2H, CH2),  2.48 (s, 6H, 5/5-2CH3), 2.14 (s, 3H, CCH3). 
X-ray quality crystals of 7 (E isomer) grew upon slow evaporation of a 4 mL solution of 
the crystalline material (5 mg) in a 1/3 (v/v) mixture of acetonitrile/diethyl ether. The 1H NMR 
spectrum of the crystals dissolved in acetonitrile-d3 was identical to that of the bulk product.   
Monitoring the progress of the reaction of 1 with morpholine (5.3 L) as described above 
indicated that no signals for 1 remained after 4 h. 
Synthesis of [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2CH2)]BF4 (8). The 
general treatment of 2 with piperidine (59 L, 0.60 mmol) yielded 35 mg (88%) of yellow 
crystalline material. 1H NMR signals (ppm) in acetonitrile-d3: 8.19 (d, J = 8.1 Hz, 2H, H3/3), 
8.06 (t, J = 7.9 Hz 2H, H4/4), 7.62 (d, J = 7.9 Hz, 2H, H5/5), 5.14 (b, 1H, NH), 3.06 (s, 6H, 
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6/6-2CH3), 3.03 (overlapped m, 4H, 2CH2), 1.60 (s, 3H, CCH3), 1.53 (m, 2H, CH2), 1.29 (m, 
4H, 2CH2).  
X-ray quality crystals of 8 (E isomer) formed upon slow evaporation of a 6 mL solution 
of the crystalline material (5 mg) in a 1/5 (v/v) mixture of acetonitrile/diethyl ether. The 1H NMR 
spectrum of the crystals dissolved in acetonitrile-d3 was identical to that of the bulk product.   
Monitoring the progress of the reaction of 2 with piperidine (5.9 L) as described above 
indicated that no signals for 2 remained after 3 min. 
Synthesis of [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2(CH2)2)]BF4 (9). The 
general treatment of 2 with homopiperidine (60 L, 0.60 mmol) yielded 32 mg (78%) of yellow 
crystalline material. 1H NMR signals (ppm) in acetonitrile-d3: 8.19 (d, J = 7.8 Hz, 2H, H3/3), 
8.06 (t, J = 7.9 Hz, 2H, H4/4), 7.61 (d, J = 7.8 Hz, 2H, H5/5), 4.90 (b, 1H, NH), 3.26 (b, m, 2H, 
CH2), 3.07 (s, 6H, 6/6-2CH3), 3.04 (overlapped m, 2H, CH2), 1.62 (s, 3H, CCH3), 1.44 (b, m, 
2H, CH2), 1.38 (b, m, 2H, CH2), 1.32 (b, m, 2H, CH2), 1.11 (b, m, 2H, CH2).  
X-ray quality crystals of 9 (E isomer) grew upon slow evaporation of a 5 mL solution of 
the crystalline material (5 mg) in a 1/4 (v/v) mixture of acetonitrile/diethyl ether. The 1H NMR 
spectrum of the crystals dissolved in acetonitrile-d3 was identical to that of the bulk product.   
Monitoring the progress of the reaction of 2 with homopiperidine (6 L) as described 
above indicated that no signals for 2 remained after 4.5 min.  
Synthesis of [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2(CH2)3)]BF4 (10). The 
general treatment of 2 with heptamethyleneimine (76 L, 0.60 mmol) afforded 15 mg (35%) of 
yellow crystalline material. 1H NMR signals (ppm) in acetonitrile-d3: 8.19 (d, J = 8.1 Hz, 2H, 
H3/3), 8.07 (t, J = 7.9 Hz, 2H, H4/4), 7.63 (d, J = 7.7 Hz, 2H, H5/5), 4.82 (b, 1H, NH), 3.23 (b, 
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m, 2H, CH2), 3.16 (b, m, 2H, CH2),  3.07 (s, 6H, 6/6-2CH3), 1.66 (s, 3H, CCH3), 1.49 (b, m, 2H, 
CH2), 1.42 (b, m, 2H, CH2), 1.32 (b, m, 2H, CH2), 1.21 (b, m, 2H, CH2), 0.92 (b, m, 2H, CH2).  
X-ray quality crystals of 10 (E isomer) formed upon slow evaporation of a solution of the 
crystalline material (5 mg/16 mL) in a 1/15 (v/v) mixture of acetonitrile/diethyl ether. The 1H 
NMR spectrum of the crystals dissolved in acetonitrile-d3 was identical to that of the bulk 
product.   
Monitoring the progress of the reaction of 2 with heptamethyleneimine (7.6 L) as 
described above indicated that no signals for 2 remained after 6 min. 
Synthesis of [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2NH)]BF4 (11). The 
general treatment of 2 with piperazine (52 mg, 0.60 mmol) yielded 33 mg (83%) of yellow 
crystalline material. 1H NMR signals (ppm) in acetonitrile-d3: 8.19 (d, J = 8.0 Hz, 2H, H3/3), 
8.07 (t, J = 7.9 Hz, 2H, H4/4), 7.62 (d, J = 7.7 Hz, 2H, H5/5), 5.18 (b, 1H, NH), 3.05 (s, 6H, 
6/6-2CH3), 2.96 (m, 4H, 2CH2), 2.53 (m, 4H, 2CH2), 1.63 (s, 3H, CCH3).  
X-ray quality crystals of 11 (E isomer) grew upon slow evaporation of a solution of the 
crystalline material (5 mg/5 mL) in a 1/4 (v/v) mixture of acetonitrile/diethyl ether. The 1H NMR 
spectrum of the crystals dissolved in acetonitrile-d3 was identical to that of the bulk product.   
Monitoring the progress of the reaction of 2 with piperazine (5.1 mg) as described above 
indicated that no signals for 2 remained after 3 min. 
Synthesis of [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2O)]BF4 (12). The 
general treatment of 2 with morpholine (53 L, 0.60 mmol) (stirring time, 1 h) afforded 36 mg 
(90%) of yellow crystalline material. 1H NMR signals (ppm) in acetonitrile-d3: 8.19 (d, J = 7.9 
Hz, 2H, H3/3), 8.07 (t, J = 7.9 Hz, 2H, H4/4), 7.62 (d, J = 7.7 Hz, 2H, H5/5), 5.30 (b, 1H, NH), 
3.45 (m, 4H, 2CH2), 3.05 (s, 6H, 6/6-2CH3), 3.01 (m, 4H, 2CH2), 1.66 (s, 3H, CCH3).   
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X-ray quality crystals of 12 (E isomer) grew upon slow evaporation of a solution of the 
crystalline material (5 mg/4 mL) in a 1/3 (v/v) mixture of acetonitrile/diethyl ether. The 1H NMR 
spectrum of the crystals dissolved in acetonitrile-d3 was identical to that of the bulk product.   
Monitoring the progress of the reaction of 2 with morpholine (5.3 L) as described above 
indicated that no signals for 2 remained after 30 min. 
Challenge Reactions. A 5 mM solution of [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2CH2)2CH2)]BF4 (3) in acetonitrile-d3 (600 L) was treated with a 
fivefold excess of 4-dimethylaminopyridine (2.0 mg, 25 mM), and the solution was monitored 
over time by 1H NMR spectroscopy. A similar experiment was conducted in CDCl3. 
3.3 Results and Discussion  
Synthesis. Treatment of [Re(CO)3(L)(CH3CN)]BF4 (L = 5,5-Me2bipy (1), and 6,6-
Me2bipy (2)) with heterocyclic amines in acetonitrile at room temperature afforded good yields 
(usually greater than 70%) of amidine complexes of the general formula, 
[Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4 (L = 5,5-Me2bipy or 6,6-Me2bipy; Y = CH2, 
(CH2)2, (CH2)3, NH, or O), as illustrated in Figure 3.2. 1H NMR spectroscopic studies and 
structural characterization by single-crystal X-ray crystallography (see below) show that the 
reactions with cyclic amines form only one isomer (E) of the new amidine complexes. Reactions 
are often rapid at ambient temperature (≤3 min for complete reaction). Because the greater 
reactivity of [Re(CO)3(6,6-Me2bipy)(CH3CN)]BF4 (2)  than of [Re(CO)3(5,5-
Me2bipy)(CH3CN)]BF4 (1) with a given amine is best understood after a discussion of structural 
and spectroscopic results, we shall return to the topic of reaction times later.  
Structural Results. Summarized in Tables 3.1 and 3.2 are the crystal data and details of 
the structural refinement for complexes 3-12, having the general formula,  
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Figure 3.2. Reactions forming [Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]+ complexes observed 
upon treatment of [Re(CO)3(L)(CH3CN)]+ complexes with heterocyclic amines 
(HN(CH2CH2)2Y) in acetonitrile at 25 C.  
 
[Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4 (L = 5,5-Me2bipy or 6,6-Me2bipy, Y = CH2, 
(CH2)2, (CH2)3, NH, or O). Figures 3.3 and 3.4 show the ORTEP plots of the cations in 
complexes 3-12, together with the numbering scheme used to describe the solid-state data. All 
complexes have a pseudo octahedral structure, in which the three carbonyl ligands are 
coordinated facially. The remaining three coordination sites are occupied by the two nitrogen 
atoms of L and by one nitrogen atom of the neutral monodentate amidine ligand having the E 
configuration. Ni(II) amidine complexes formed upon addition of secondary amines to 
coordinated acetonitrile have the E configuration in the solid state.38-39 
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Figure 3.3. ORTEP plots of the cations in [Re(CO)3(5,5-Me2bipy)(HNC(CH3) 
N(CH2CH2)2CH2)]BF4 (3), [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2(CH2)2)]BF4 (4),  
[Re(CO)3(5,5-Me2bipy)(HNC(CH3) N(CH2CH2)2(CH2)3)]BF4 (5), [Re(CO)3 
(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2NH)]BF4 (6), and [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2CH2)2O)]BF4 (7). Thermal ellipsoids are drawn with 50% 
probability. 
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Figure 3.4. ORTEP plots of the cations in [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2 
CH2)]BF4 (8), [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2(CH2)2)]BF4 (9), [Re(CO)3 
(6,6-Me2bipy)(HNC(CH3) N(CH2CH2)2(CH2)3)]BF4 (10), [Re(CO)3(6,6-Me2bipy) 
(HNC(CH3)N(CH2CH2)2NH)]BF4 (11), and [Re(CO)3(6,6-Me2bipy)(HNC(CH3) 
N(CH2CH2)2O)]BF4 (12). Thermal ellipsoids are drawn with 50% probability. For 10, both 
conformations of the disordered 8-membered ring are shown, and H atoms are not illustrated, 
except for N-H. 
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The Re−C bond distances (not shown) of the two CO groups cis to the amidine ligand are 
generally not significantly different from the one trans to it in all complexes (3-12). All of the 
[Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 complexes (3-7) show Re−N bond 
lengths (Table 3.3) comparable to the typical Re sp2 nitrogen bond length, typically ranging from 
2.14 to 2.18 Å.22 This result is consistent with the structural results for the recent monodentate 
amidine complexes of ReI with primary amines.25 As found for the iminoether complexes, in 
which the Re−N3 bond lengths found for [Re(CO)3(5,5-Me2bipy)(HNC(CH3)OCH3)]BF4 
(2.1860(18) Å) and [Re(CO)3(6,6-Me2bipy)(HNC(CH3)OCH3)]BF4 (2.175(3) Å) were not 
significantly different,23 the Re−N3 bond lengths are quite similar for complexes 3-12. These 
bond lengths appear to be very slightly longer for the 6,6-Me2bipy complexes (range 2.1848(18) 
- 2.193(2), mean 2.190 Å) than for the 5,5-Me2bipy complexes (range 2.178(3) - 2.1806(18), 
mean 2.179 Å). 
The recent study of fac-[Re(CO)3(L)(HNC(CH3)OCH3)]BF4 complexes revealed that the 
Re−N bond lengths in the equatorial plane were significantly longer for L = 6,6-Me2bipy than 
for L = 5,5-Me2bipy.23 These examples of a slight Re−N bond lengthening were attributed to the 
distorted nature of the 6,6-Me2bipy ligand as a result of the close proximity of the two methyl 
substituents to the equatorial carbonyl groups. A comparison of the equatorial Re−N bond 
lengths (Tables 3.3 and 3.4) of all five [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 
complexes (8-12) with those of the corresponding five [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 complexes (3-7)  reveals that only some bonds in the 
6,6-Me2bipy complexes are slightly longer by criteria of statistical significance. However, as for 
the Re–N3 axial distances, the equatorial Re–N(Me2bipy) distances appear to be on average very 
slightly longer for the 6,6-Me2bipy complexes (range 2.194(2) - 2.213(2), mean 2.206 Å) than 
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for the 5,5-Me2bipy complexes (range 2.168(3) - 2.194(2), mean 2.179 Å). Thus, the more 
extensive solid-state results for complexes 3-12 now available indicate that the 6,6-methyl 
groups in 8-12 affect the equatorial Re−N bond distances only slightly.   
In all but one of the new complexes, the amidine ligand has a similar orientation 
(specified by the projection onto the equatorial plane of the amidine plane defined by the N3, 
C16 and N4 atoms). In this orientation, the amidine plane bisects the two N–Re–C angles in the 
equatorial plane. In [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2(CH2)2)]BF4 (4), the 
amidine plane orientation is different: it is rotated by about 65°, with the methyl group almost 
directly above one carbonyl ligand. However, in solution there is no evidence for this difference 
in orientation, as the 1H NMR signals of 4 have chemical shifts similar to those of other 
[Re(CO)3(5,5-Me2bipy(HNC(CH3)N(CH2CH2)2Y)]BF4 complexes (3, 5, 6, 7). The different 
orientation in 4 is thus attributed to subtle packing effects. Furthermore, the structures of most of 
the complexes in this and previous studies lead us to conclude that the orientation of the amidine 
and iminoether ligands does not depend on the substitution pattern of the bipyridine ligands (L = 
5,5-Me2bipy or L = 6,6-Me2bipy) present in the equatorial plane.23,25 
Tables 3.3 and 3.4 show that for complexes 3-12 the bond lengths from Cam (C16) to the 
rhenium-bound nitrogen atom (N3), and to the remote nitrogen atom (N4), are all closer to an 
average sp2 C=N bond length (~1.28 Å), than to an average sp3 C–N bond length (~1.47 Å), as 
also reported for [Re(CO)3(5,5-Me2bipy)(HNC(CH3)NHR)]BF4 complexes25 and for Ni and Cu 
complexes.37-39 In addition to the C16–N3 and C16–N4 bond lengths, the values of the C16–N4–
C18, C16–N4–C(n) and N3–C16–N4 angles, which are all close to 120° (Tables 3.3 and 3,4), 
also provide evidence for electron delocalization within the amidine group, as discussed in 
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previous reports.23, 37-40 Furthermore, the N3 hydrogen atoms in these complexes are all located in 
positions consistent with sp2 rather than sp3 hybridization for N3. 
Table 3.3 Selected Bond Distances (Å) and Angles (deg) for Complexes Having the General 
Formula, [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 
 
Y = CH2 (CH2)2 (CH2)3 NH O 
complex 3 4 5 6 7 
bond distances 
Re–N1 2.168 (3) 2.172 (3) 2.1691 (18) 2.177 (2) 2.177 (2) 
Re–N2 2.186 (3) 2.173 (3) 2.1823 (18) 2.190 (2) 2.194 (2) 
Re–N3 2.178 (3) 2.179 (3) 2.1806 (18) 2.179 (2) 2.178 (2) 
N3–C16  1.306 (4) 1.310 (5) 1.308 (3) 1.300 (4) 1.304 (3) 
N4–C16 1.346 (5) 1.344 (5) 1.346 (3) 1.354 (4) 1.359 (3) 
bond angles 
N1–Re–N2 75.06 (11) 74.58 (11) 74.82 (6) 75.08 (8) 75.16 (8) 
N1–Re–N3 80.23 (11) 83.44 (11) 87.21 (6) 79.90 (9) 78.78 (8) 
N2–Re–N3 86.41 (11) 79.02 (11) 79.34 (6) 86.11 (9) 86.30 (8) 
Re–N3–H3N  113 (3) 111 (3) 106 (2) 110 (2) 110 (2) 
Re–N3–C16 137.4 (2) 135.6 (3) 136.82 (15) 136.5 (2) 137.03 (18) 
C16–N3–H3N 110 (3) 110 (3) 116 (2) 114 (2) 113 (2) 
N3–C16–N4 123.6 (3) 122.9 (3) 122.47 (19) 123.3 (3) 122.5 (2) 
N3–C16–C17 118.6 (3) 118.5 (3) 119.58 (19) 119.2 (3) 119.9 (2) 
N4–C16–C17 117.8 (3) 118.7 (3) 117.95 (19) 117.4 (2) 117.7 (2) 
C16–N4–C18 122.2 (3) 121.2 (3) 123.86 (18) 121.8 (2) 121.4 (2) 
C16–N4–C(n)a  120.3 (3)b   122.7 (3)c   120.44 (18)d   120.7 (2)e   120.1 (2)f 
 
a n varies in number according to the R group. b n = 22. c n = 23. d n = 24.  e n = 21.  f n = 21. 
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Table 3.4. Selected Bond Distances (Å) and Angles (deg) for Complexes Having the General 
Formula, [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 
 
Y = CH2 (CH2)2 (CH2)3 NH O 
complex 8 9 10 11 12 
bond distances 
Re–N1 2.213 (2) 2.203 (2) 2.211 (2) 2.212 (3) 2.2051 (19) 
Re–N2 2.1984 (18) 2.194 (2) 2.211 (2) 2.202 (3) 2.2086 (19) 
Re–N3 2.193 (2) 2.188 (2) 2.190 (2) 2.192 (3) 2.1848 (18) 
N3–C16  1.307 (3) 1.309 (3) 1.308 (3) 1.307 (4) 1.307 (3) 
N4–C16 1.356 (3) 1.350 (3) 1.347 (3) 1.350 (4) 1.356 (3) 
bond angles 
N1–Re–N2 74.29 (7) 74.60 (8) 74.40 (8) 75.29 (11) 74.90 (7) 
N1–Re–N3 80.26 (7) 82.12 (8) 83.41 (8) 79.19 (10) 79.35 (7) 
N2–Re–N3 82.97 (7) 80.44 (8) 79.26 (8) 83.85 (10) 82.00 (7) 
Re–N3–H3N  110 (2) 110 (2) 108 (2) 107 (3) 109 (2) 
Re–N3–C16 136.66 (16) 135.62 (19) 136.74 (19) 135.4 (2) 137.12 (15) 
C16–N3–H3N 113 (2) 115 (2) 115 (2) 115 (3) 114 (2) 
N3–C16–N4 123.2 (2) 122.9 (2) 123.0 (2) 124.2 (3) 122.84 (19) 
N3–C16–C17 119.5 (2) 119.8 (2) 119.2 (2) 118.4 (3) 119.85 (19) 
N4–C16–C17 117.3 (2) 117.3 (2) 117.8 (2) 117.3 (3) 117.28 (19) 
C16–N4–C18 122.62 (19) 122.4 (2) 123.2 (2) 124.2(3) 122.27(18) 
C16–N4–C(n) a 
 
122.93 (19)b 121.2 (2)c 121.0 (2)d 123.7 (3)e     121.29 (19)f 
a n varies in number according to the R group. b n = 22. c n = 23. d n = 24. e n = 21. f n = 21. 
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Distances that are slightly shorter for C16–N3 than for C16–N4 (Tables 3.3 and 3.4) 
indicate more double-bond character in the C16–N3 bond. For example, in [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2CH2)2CH2)]BF4 (3) the C16–N3 bond length is 1.306(4) Å and the 
C16–N4 bond length is 1.346(5) Å. Similar differences in the C16–N3 and C16–N4 bond 
distances reported previously for [Re(CO)3(5,5-Me2bipy)(HNC(CH3)NHR)]BF4 complexes were 
attributed to greater double-bond character for the C16–N3 bond than for the C16–N4 bond.25 
In the solid state, [Re(CO)3(5,5-Me2bipy)(HNC(CH3)NHR)]BF4 complexes exist as the 
E isomer.25 In solutions made with polar solvents such as acetonitrile, the E isomer equilibrated 
to a mixture of the E and Z isomers. This equilibration, involving sequential rotations around the 
C16–N4 bond (fast step forming the E isomer as an undetectable intermediate in polar solvents) 
and then around the C16–N3 bond (slow step), required several minutes.25 The solution results 
are consistent with the X-ray data that indicate more double-bond character in the C16–N3 bond 
than in the C16–N4 bond. In solvents with low polarity, such as chloroform, abundant amounts 
of E, E and Z isomers were found. Two-dimensional NMR data demonstrated that the E to E 
interconversion, involving rotation around the C16–N4 bond (Figure 3.1), was fast. The 
similarity in the C16–N3 and C16–N4 bond distances in new and old amidine complexes 
indicates that E to Z isomer interconversion should be slow for the new amidine complexes (3-
12) as well. Thus, the NMR evidence (see below) for the presence of only one isomer on 
dissolution of crystals containing only the E isomer indicates beyond doubt that this one isomer 
is the E isomer and that the Z isomer of the new [Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4 
complexes (3-12) is unstable. Preliminary data suggest that the rotation around the C16–N4 bond 
does occur and studies are planned to elucidate this process. 
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Steric Interaction of the Amidine Axial Ligand with the Equatorial Ligands. For 
amidine complexes 3-12, one of the bond angles from an equatorial N atom to the axial N3 atom 
(N1–Re–N3 or N2–Re–N3) is always significantly greater than the other such angle. For 
example, in complexes 3, 6, 7, 8, 11 and 12, the N2–Re–N3 angle is greater than the N1–Re–N3 
angle, whereas in complexes 4, 5, 9 and 10 the N1–Re–N3 angle is the larger (cf. Tables 3.3 and 
3.4). The smaller N–Re–N3 angle is always the one involving the equatorial N closest to the 
amidine N3H group. A similar relationship was also evident between the smaller equatorial N–
Re–N3 bond angle and the orientation of the N3H group of previously studied primary amidine25 
and iminoether23 complexes, when the axial ligand was oriented in the normal way. For the new 
complexes, this normal orientation is shown in Supporting Information. The reason that one N–
Re–N3 bond angle is significantly larger than the other N–Re–N3 bond angle in complexes 3-12 
is clearly because the larger angle leads to reduced repulsions between the amidine methyl group 
and the closest atoms of equatorial ligands.  
When we began our investigations into reactions of coordinated acetonitrile in complexes 
with the fac-[MI(CO)3] core, one initial goal was to explore the effect of increasing the steric 
bulk near the metal center by using the 6,6-Me2bipy ligand. In the first such study (involving 
iminoether complexes), we found that, when the iminoether was oriented in the same way, the 
value of the larger N–Re–N3 angle in [Re(CO)3(bipy)(HNC(CH3)OCH3)]BF4 was greater than 
the corresponding larger N–Re–N3 value in [Re(CO)3(6,6-Me2bipy)(HNC(CH3)OCH3)]BF4.23 
We hypothesized that the distortion in the 6,6-Me2bipy complex decreases those interactions of 
the axial iminoether ligand with the equatorial ligands that cause one of the two N–Re–N3 angles 
to be larger. 
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In the new complexes, the size of the larger of the two N–Re–N3 bond angles in the 5,5-
Me2bipy complexes is greater on average than the larger bond angles in the 6,6-Me2bipy 
complexes (Tables 3.3 and 3.4 and Supporting Information). This comparison supports the 
hypothesis that the distortion in the 6,6-Me2bipy complexes decreases those axial-equatorial 
ligand interactions that cause one of the two N–Re–N3 angles to be larger. This apparently 
counter-intuitive finding of smaller interactions in 6,6-Me2bipy complexes than in the related 
[Re(CO)3(bipy)(HNC(CH3)OCH3)]BF4 complexes can be understood by considering our 
structural results and those that have appeared during the course of our work.41 In the many 
structures now available, the clashes between the methyl groups of the 6,6-Me2bipy ligand and 
the two equatorial CO ligands distort the 6,6-Me2bipy ligand and force the 6,6-methyl groups 
out of the equatorial plane (defined by the C13–Re–C14 atoms) toward the axial CO. These 
distortions of the Re(CO)3(6,6-Me2bipy) moiety in [Re(CO)3(6,6-
Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 amidine complexes (8-12) (Figure 3.5 and Supporting 
Information are very similar to those of the other complexes.23,41  
As can be seen in Figure 3.5, the distortion results in a tilted plane of the 6,6-Me2bipy 
ligand. To appreciate the effect of the tilting, it is convenient to view the two Me2bipy ligands as 
having an interior or front side (atoms N1, C1, N2, C10) and an exterior or back side (atoms C3, 
C4, C7, C8), according to the numbering scheme in Figures 3.3 and 3.4. Although in the solid 
state the ligands are not fully symmetrical or fully planar, the front-side carbons 1 and 10 lie 
slightly below the equatorial plane in 6,6-Me2bipy complexes and lie in the equatorial plane in 
5,5-Me2bipy complexes. To assess the space near the axial coordination site (trans to the axial 
CO), we measured some non-bonded distances from N3 (Supporting Information). For 
[Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4 (Y = CH2 or NH), the non-bonded distances from 
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N3 to C1 and C10 average ~0.15 Å longer in 6,6-Me2bipy than in 5,5-Me2bipy complexes. 
Properties (such as N–Re–N bond angles) affected by the interior structure have values (Tables 
3.3 and 3.4) consistent with this additional space. On the other hand, for these same complexes 
the non-bonded distances from N3 to C4 and C7 average ~0.5 Å shorter in 6,6-Me2bipy than in 
5,5-Me2bipy complexes. Other properties, such as some NMR shifts, are affected more by the 
exterior or peripheral structure (see below).  
 
 
 
 
 
 
 
Figure 3.5. Views of piperidinylamidine complexes, [Re(CO)3(L)(HNC(CH3)N(CH2CH2)2 
CH2)]BF4, depicted with the C13–Re–C14 equatorial plane perpendicular to the plane of the 
paper. Shown at left and middle are front and side views, respectively, of complex 8 with L = 
6,6-Me2bipy. Pictured at right is a side view of complex 3 with L = 5,5-Me2bipy.  
 
 
Furthermore, for some properties, the net effects of the differences in the bidentate ligand 
orientations may cancel. Indeed, regardless of whether the complex has L = 6,6-Me2bipy or 5,5-
Me2bipy, the isomer distribution seems to be unaffected. Thus, for all the complexes in the 
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present study, the repulsions are large enough to favor the presence of only one isomer, namely 
the E isomer.  
Our ranking of the expected effects of steric interactions on isomer stability for 
[Re(CO)3(Me2bipy)(HNC(CH3)OCH3)]+, [Re(CO)3(L)HNC(CH3)NHR)]+, and 
[Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]+ complexes is shown in Figure 3.6. This ranking  
 
 
 
 
 
Figure 3.6. Ranking of increasingly unfavorable total steric repulsive interactions (each double-
headed arrow indicates an interaction) in [Re(CO)3(Me2bipy)(HNC(CH3)OCH3)]+,  
[Re(CO)3(L)HNC(CH3)NHR)]+, and  [Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]+  complexes [N–
N denotes the 5,5- or 6,6-Me2bipy ligands, and Y = CH2, (CH2)2, (CH2)3, NH, or O].  
 
summarizes our experimental observations of the relative isomer abundance of these complexes 
in this and previous studies.23,25 This ranking takes into account steric repulsions of the 
substituents on Cam or Cie in the axial with the equatorial Me2bipy and CO ligands and also the 
relative repulsions within the amidine ligand between the CH3 and the NH or NR groups in 
[Re(CO)3(L)HNC(CH3)NHR)]+ complexes. As indicated for the two structures sketched at the 
far right of Figure 3.6, the repulsive interactions of the NR substituent with the equatorial ligands 
depicted in the respective Z and Z sketches are expected to be the most severe. Thus, these 
interactions are shown with thicker double-headed arrows. The order of the Z and E isomers of 
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[Re(CO)3(L)HNC(CH3)NHR)]+ complexes (4th and 5th structures from left in Figure 3.6) reflects 
our suggestion that the N4H interaction with the equatorial ligands is less repulsive than the 
corresponding CamCH3 interaction with the equatorial ligands.  
Repulsion between the CH3 and NR groups is secondary and noticeably influences 
abundance mainly when the two isomers have the same interaction with the equatorial ligands, 
such as is the case with the E and E isomers of [Re(CO)3(L)HNC(CH3)NHR)]+ complexes (3rd 
and 5th structures from left in Figure 3.6). For [Re(CO)3(L)HNC(CH3)NHR)]+ complexes,25 
clashes between the NR and the CH3 amidine substituents destabilize the E isomer, which 
normally has low abundance. The abundance of the E isomer increased as the steric bulk of the 
R substituent on Cam increased. In turn, the Z isomer of fac-[Re(CO)3(5,5-
Me2bipy)(HNC(CH3)NH2)]BF4 with similarly sized substituents (NH2 and CH3) on Cam was 
highly favored (~ 90% abundant). We caution that the differences in electronic effects 
influencing the stability of the Z and E configurations are not known. Nevertheless, the ranking 
as illustrated in Figure 3.6 does provide a good guide for predicting the relative abundance of the 
isomers, especially in polar solvents. 
NMR Spectroscopy. All complexes were characterized by 1H NMR spectroscopy in 
acetonitrile-d3; selected complexes were also studied in CDCl3 and DMSO-d6. 1H NMR spectra 
were recorded within at least 6 min of dissolution. In contrast to the spectral data of the 
previously studied [Re(CO)3(5,5-Me2bipy)(HNC(CH3)NHR)]BF4 complexes, all of the 1H NMR 
spectra of the new [Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4 amidine complexes regardless of 
the solvent used consistently indicate the presence of only one isomer in solution. Moreover, the 
spectra of all of these complexes (3-12) showed no changes with time, even after several days.  
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The atom numbering system used in this NMR discussion is that shown in Figures 3.3 
and 3.4. 1H NMR signals of the bidentate ligand and of N3H were assigned by using the splitting 
pattern and integration, and by comparison to unambiguous assignments of spectra for previously 
reported analogous ReI amidines and iminoether complexes.23,25  
We illustrate our findings by detailing our studies of compound 3, [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2CH2)2CH2)]BF4. When crystals of 3 were dissolved in three different 
solvents (acetonitrile-d3, CDCl3 and DMSO-d6), 1H NMR spectra showed no evidence for more 
than one isomer: All peaks in all three solvents remained constant when solutions were 
monitored from 3 min after dissolution until two weeks. As indicated in our analysis of the C16–
N3 bond lengths above, we believe that if the Z isomer were present, the interconversion rate 
would be slow and we would have detected signals for the Z isomer. Thus, we are absolutely 
confident that the Z isomer is unstable. 
The N3H signal in the new complexes is easily assigned because the peak is a broad 
singlet integrating to one proton and because it disappeared gradually after the addition of D2O. 
For 3, this N3H signal has a more downfield shift in DMSO-d6 (5.77 ppm) than in acetonitrile-d3 
(4.78 ppm) or CDCl3 (4.60 ppm). The related values for 4 were 5.32, 4.52, and 4.32 ppm, 
respectively. A similar NMR dependence of the N3H shift on solvent was observed for 
[Re(CO)3(5,5-Me2bipy)(HNC(CH3)OCH3)]BF4; in a standard chloride titration experiment, the 
downfield shift in DMSO-d6 was demonstrated to be caused by hydrogen bonding of N3H to 
DMSO-d6.23 In this iminoether complex, as for complexes 3 and 4, N3H projects out toward the 
solvent, making this proton available for hydrogen bonding to DMSO-d6. Such hydrogen 
bonding explains the solvent dependence found for 3 and 4. 
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Dependence on Y of the N3H NMR Signals of 
[Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4, for L = 5,5-Me2bipy and 6,6-Me2bipy. 
Selected 1H NMR signals of the new amidine complexes (3-12) in acetonitrile-d3 are compared in 
Table 3.5. For complexes with the amidines having six-membered N(CH2CH2)2Y rings, 
Table 3.5. 1H NMR Shifts (ppm) for L, N3H, and CamCH3 in 
[Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4 Complexes (Acetonitrile-d3, 25 C)  
 
 
 
 
 
 
 
 
 
 
 [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 (3, 6, and 7) and [Re(CO)3(6,6-
Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 (8, 11, and 12), the most downfield shift observed for 
the N3H signal is for the morpholine derivative (Y = O) in each series (4.94 ppm for 7 and 5.30 
ppm for 12). The N3H signal is slightly upfield for piperazine derivatives (Y = NH) (4.84 ppm 
for 6 and 5.18 ppm for 11) and farther upfield for piperidine derivatives (Y = CH2) (4.78 ppm for 
3 and 5.14 ppm for 8). These data indicate that the remote O and N atoms of the morpholine and 
piperazine derivatives, respectively, exert electron-withdrawing effects on the amidine group, 
with the more electronegative O atom of the morpholine derivative having the greater downfield-
Y  H3/3 H4/4 H5/5 H6/6 L-CH3 N3H CamCH3 
  L = 5,5-Me2bipy     
CH2           (3) 8.26 8.04  8.85 2.48 4.78 2.10 
(CH2)2   (4) 8.27 8.05  8.87 2.48 4.52 2.10 
(CH2)3   (5) 8.27 8.04  8.87 2.48 4.49 2.12 
NH        (6) 8.26 8.04  8.85 2.47 4.84 2.12 
O           (7) 8.26 8.04  8.85 2.48 4.94 2.14 
  L = 6,6-Me2bipy 
    
CH2          (8) 8.19 8.06 7.62  3.06 5.14 1.60 
(CH2)2   (9) 8.19 8.06 7.61  3.07 4.90 1.62 
(CH2)3  (10) 8.19 8.07 7.63  3.07 4.82 1.66 
NH       (11) 8.19 8.07 7.62  3.05 5.18 1.63 
O          (12) 8.19 8.07 7.62  3.05 5.30 1.66 
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shifting effect on the N3H signal. In the two series, the N3H signal systematically shifted upfield 
as the size of the ring increased from six to seven to eight members. The most upfield N3H shift 
observed was for the heptamethyleneimine derivatives (Y = (CH2)3) with the eight-membered 
ring. The variations in NH shift as the ring size changes can be attributed to a combination of 
ring-strain, inductive, and solvation effects.  
Dependence on L of the CamCH3 NMR Signals of 
[Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4, for L = 5,5-Me2bipy and 6,6-Me2bipy. We 
can readily explain the differences in 1H NMR shifts of the CamCH3 signal between the two 
series, [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 (2.1 ppm, 3-7) and 
[Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 (1.6 ppm, 8-12). The shifts are very 
similar within each of the two series (Table 3.5). The more upfield shift (by ~0.5 ppm) of the 
CamCH3 signal for the 6,6-Me2bipy complexes (8-12) than for the 5,5-Me2bipy complexes (3-7) 
is clearly attributable to the anisotropic effect of the 6,6-Me2bipy aromatic ring system. 
Compared to the [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 complexes (3-7), all of 
the Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 complexes (8-12) have a shorter 
distance from the methyl carbon of the amidine ligand (C17) to the centroid of the closest 
bipyridine ring. This shorter distance results from the tilting in the 6,6-Me2bipy ligand, moving 
the back side of the ring up toward the amidine as discussed above. For example, these distances 
in [Re(CO)3(5,5-Me2bipy)(HNC(CH3)NC5H10)]BF4 (3) and [Re(CO)3(6,6-
Me2bipy)(HNC(CH3)NC5H10)]BF4 (8) are 4.2 Å and 3.4 Å, respectively. Therefore, the 
anisotropic upfield-shifting effect of the bipyridine rings is greater on the CamCH3 methyl signal 
of  [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 complexes 8-12 than on the CamCH3 
1H NMR signal for [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 complexes 3-7.  
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The N3H shifts of [Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4 complexes for L = 6,6-
Me2bipy are downfield from the corresponding shifts of the L = 5,5-Me2bipy analogues (Table 
3.5). At this time, we cannot identify the reasons for this difference because as mentioned above, 
N3H shifts are influenced by a multiplicity of possible factors. In addition, as L is changed, any 
changes in the heavy-atom anisotropic or inductive effects of the Re will affect the shift. 
 Dependence of Reaction Times on the Me2bipy Ligand and the Amine. For a given 
amine, reactions were relatively faster with [Re(CO)3(6,6-Me2bipy)(CH3CN)]BF4 (2) than with 
[Re(CO)3(5,5-Me2bipy)(CH3CN)]BF4 (1) (Table 3.6). For 1 and 2, the time required for 
reaction, assessed by checking for reaction completion from time to time by NMR spectroscopy 
 
Table 3.6. Times for Complete Reaction of [Re(CO)3(L)(CH3CN)]BF4 Complexes with 
Heterocyclic Amines (HN(CH2CH2)2Y) to Form [Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4 
Complexesa 
 
HN(CH2CH2)2Y (Y) pKa L = 6,6-Me2bipy L = 5,5-Me2bipy 
piperidine (CH2) 11.1 ≤3 min <5 min 
homopiperidine ((CH2)2) 10.9 4.5 min 8 min 
heptamethyleneimine ((CH2)3) 10.8 6 min 6 h 
piperazine (NH) 10.2 ≤3 min 20 min 
morpholine (O) 8.5 30 min 4  h 
a Reaction monitored by NMR spectroscopy in acetonitrile-d3 at 25 C.  
 
 (Figure 3.7), varied with basicity and the ring size of the heterocyclic amine. The pKa values of 
the heterocyclic amines42 (Table 3.6) decrease in the order, piperidine (with the highest pKa, 
11.1) > homopiperidine > heptamethyleneimine > piperazine > morpholine.42 The reactions of 
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Figure 3.7. Aromatic region of the 1H NMR spectra in acetonitrile at 25 C of the reaction of 
[Re(CO)3(5,5-Me2bipy)(CH3CN)]BF4 (1) with morpholine to form [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2CH2)2O)]BF4 (7). 
 
[Re(CO)3(6,6-Me2bipy)(CH3CN)]BF4 (2) with piperidine and piperazine were essentially 
complete before the first spectrum could be recorded (≤ 3 min). Morpholine, the other six-
membered-ring amine, required a much longer reaction time (30 min) owing to its lower basicity 
(pKa = 8.5). This same pattern as found for 2 was observed with these heterocyclic amines for 1. 
For example, morpholine had the longest reaction completion time (4 h) for the six-membered 
ring amines with 1 (Figure 3.7). These results indicate that greater heterocyclic amine basicity is 
associated with faster reactions, as would be expected. Piperazine has the second lowest pKa 
(10.2) compared to the other heterocyclic amines used here; however, the reactions of piperazine 
with 1 and 2 were relatively fast (≤ 3 min and 20 min, respectively). This relative reactivity can 
be attributed to the statistical reaction probability for each piperazine molecule (with two amine 
groups) being twice that of other amines used. 
A comparison of reaction completion times for amines with no other heteroatoms in the 
ring (Table 3.6) is instructive. For both the [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 and the [Re(CO)3(6,6-
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Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 series, the reaction times increase in the order, 
piperidine < homopiperidine < heptamethyleneimine (Table 3.6). This finding of longer reaction 
completion times as the number of amine methylene groups increases makes it clear that steric 
effects decrease amine reactivity. However, the effect of amine bulk on reaction time is highly 
pronounced only for heptamethyleneimine with the 5,5-Me2bipy complex 1. The effect is much 
less pronounced for the 6,6-Me2bipy complex 2 because of the greater interior space near the 
axial coordination site caused by the tilting of the 6,6-Me2bipy ligand (as described above). 
Reactions of most cyclic secondary amines with [Re(CO)3(5,5-Me2bipy)(CH3CN)]BF4 
(1) reached completion in less than 1 h (Table 3.6). In contrast, more time was required for 
reactions of 1 with primary aliphatic amines, even though most of these previously studied 
amines have a basicity lying within the pKa range in Table 3.6. For example, the reaction of 
[Re(CO)3(5,5-Me2bipy)(CH3CN)]BF4 (1) required ~6 h for methylamine (pKa43 = 10.6) and ~4 
days for tert-butylamine (pKa43 = 10.5).25 Reaction times of [Re(CO)3(5,5-
Me2bipy)(CH3CN)]BF4 (1) and [Re(CO)3(6,6-Me2bipy)(CH3CN)]BF4 (2) with isopropylamine 
(pKa43 = 10.6) are 28 h and 14 h, respectively.24 These results are consistent with the expected 
lower nucleophilicity of primary amines as compared with that of the cyclic secondary amines 
studied here. 
Robustness of the Piperidinylamidine Ligation. A fivefold excess of the relatively 
basic, strongly coordinating 4-dimethylaminopyridine ligand was added to [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2CH2)2CH2)]BF4 (3) in acetonitrile-d3 or in CDCl3. No changes in 
spectral features of 3 were observed for up to two months, indicating that the piperidinylamidine 
ligand is not readily replaced. The NMR signals for [Re(CO)3(5,5-Me2bipy)(4-
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dimethylaminopyridine)]BF4,25 synthesized as a control, did not change with time in either 
acetonitrile-d3 or CDCl3. 
3.4 Conclusions 
Unlike previously studied analogous amidine complexes derived from primary amines, all 
ten of the [Re(CO)3(5,5- or 6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 complexes formed 
from cyclic secondary amines studied here exist as only one isomer (the E isomer) in both the 
solid state and in solution. These findings are attributable to the combination of the high steric 
bulk and the C2 symmetry of the amidine substituents. After dissolution and sufficient time for 
equilibrium to be established in solution, only the initial E isomer was detectable. Thus, the 
equilibrium between the Z and E isomers must lie far to the side of the E isomer. We conclude 
that steric repulsions between the N(CH2CH2)2Y groups of the axial amidine ligands and the 
equatorial ligands preclude formation of any isomer other than E (Figures 2.2 and 2.6). 
Nevertheless, these repulsive interactions do not lead to a weakened Re–N3 bond, as indicated by 
the length of this bond. 
The 6,6-methyl groups in [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2CH2)2Y)]BF4 
complexes (8-12) cause the 6,6-Me2bipy ligand to distort and tilt. Although the “front side” of 
the 6,6-Me2bipy ligand with the 6,6-methyl groups projects down toward the axial CO group, 
the “back side” of the 6,6-Me2bipy ligand projects up. Thus the 6,6-Me2bipy ligand has a net 
steric footprint comparable to that of the untilted 5,5-Me2bipy ligand. 
The [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2CH2)]BF4 complex (3) in 
acetonitrile-d3 or in CDCl3 was robust when challenged with 4-dimethylaminopyridine, 
indicating that amidine ligands are strong donors. The heterocyclic amines employed here have a 
relatively high reactivity and form only amidines with the E configuration, indicating that 
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amidine complexes can be formed quickly and isomerically pure. All of these favorable 
properties cited here suggest that the strategy of using heterocyclic amines to create amidine links 
to the fac-[M(CO)3]+ core (M = 99mTc and 186/188Re radionuclides) may be a useful conjugation 
method for the development of targeted radiopharmaceuticals.  
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CHAPTER 4 
fac-[Re(CO)3(5,5- OR 6,6-Me2BIPYRIDINE)(HNC(R)N(CH2)x)]BF4 COMPLEXES (R = 
CH3 OR C6H5; X = 3 TO 5). FACILE SYNTHESIS OF fac-[Re(CO)3(L)(AMIDINE)]+ 
COMPLEXES BY USING SMALL CYCLIC AMINES 
 
4.1 Introduction 
The design of ligands for radiopharmaceuticals with the fac-MI(CO)3+ core (M = 99mTc, 
186/188Re) core having diagnostic and therapeutic properties continues to be an important 
endeavor.1-6 Nonradioactive Re analogues are useful for understanding the chemistry of the 
radioactive 99mTc agents as well as for improving ligand design and for designing new linking 
chemistry for bioconjugation.7,8 The recently developed straightforward preparations of aqueous 
solutions of the nonradioactive fac-[Re(CO)3(H2O)3]+ precursor7,9-12 have made possible the 
preparation of fac-[Re(CO)3(L)] complexes under aqueous conditions simulating preparations of 
the clinically useful fac-[99mTc(CO)3(L)] analogues from the fac-[99mTc(CO)3(H2O)3]+ precursor; 
this clinically relevant precursor is produced in aqueous solutions by employing commercially 
available “kits”.2,13,14 
Whereas the use of aqueous conditions is necessary for medical applications, aqueous 
conditions limit full exploration of the synthetic chemistry of fac-[Re(CO)3(L)] complexes 
because some ligands are not water soluble. Also, aqueous conditions can complicate the 
monitoring of reactions by NMR spectroscopy, TLC, etc. Finally, high pH conditions allowing 
basic ligands to coordinate can lead to oligomerization of fac-[Re(CO)3(H2O)3]+ complexes.15 
We have thus been exploring methods of synthesizing fac-[M(CO)3L] complexes in organic 
solvents.16 Once the new chemistry is developed in organic solvents, modifications can be made 
to adapt the chemistry for radiopharmaceutical applications. For example, mixed aqueous-
organic solvent conditions suitable for the use of the fac-[99mTc(CO)3(H2O)3]+ precursor can be 
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employed. In addition, ligands not soluble in water can be modified to increase their 
hydrophilicity.  
One approach for using organic solvents that we have recently explored employs the fac-
[Re(CO)3(CH3CN)3]X precursor (X = PF6- or BF4-).16-19We have investigated the use of this 
precursor for synthesizing fac-[Re(CO)3(Me2bipy)(CH3CN)]+ complexes (Me2bipy = dimethyl-
2,2-bipyridine) in organic solvents.17-19 In the present report, we refer to this reaction as step 1 of 
Method A. Step 2 of Method A is the reaction of fac-[Re(CO)3(Me2bipy)(CH3CN)]+ in 
acetonitrile with an amine to form amidine complexes. 
fac-[Re(CO)3(CH3CN)3]+  + Me2bipy ––>   fac-[Re(CO)3(Me2bipy)(CH3CN)]+                 (step 1) 
fac-[Re(CO)3(Me2bipy)(CH3CN)]+  + amine  ––>   fac-[Re(CO)3(Me2bipy)(amidine)]+     (step 2) 
 The first use of Method A involved the step 2 reaction of fac-[Re(CO)3(5,5-
Me2bipy)(CH3CN)]+ with primary amines to form fac-[Re(CO)3(5,5-
Me2bipy)(HNC(CH3)NHR)]+ amidine complexes (Figure 4.1).18 The sp carbon and sp nitrogen 
atoms of the acetonitrile nitrile group have been converted to an amidine sp2 carbon (Cam) and a 
rhenium-bound sp2 nitrogen (N3) (Figure 4.1).18,19 The partial double-bond character of the 
Cam−N3 and Cam−N4 bonds of these fac-[Re(CO)3(5,5-Me2bipy)(HNC(CH3)NHR)]+ complexes 
can lead to four configurations of the amidine ligand and hence four isomers in solution (Figure 
4.1). The fac-[Re(CO)3(5,5-Me2bipy)(HNC(CH3)NHR)]+ complexes were found to exist as the 
E isomer in the solid state; however, they equilibrated to mixtures of two isomers (E and Z) in 
polar solvents such as CD3CN and to three isomers (E, E, and Z) in less polar solvents such as 
CDCl3.18 The E to Z equilibration upon crystal dissolution required ~15 min, indicating that 
rotation around the Cam−N3 bond is relatively slow, a finding consistent with the shorter distance 
reported for the Cam−N3 bond than for the Cam−N4 bond.18 In less polar solvents, in which the E 
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isomer exists in detectable abundance, the E and E 1H NMR signals were somewhat broad and 
connected by EXSY cross-peaks. Thus, although rotation around the Cam−N4 bond is faster than 
rotation around the Cam−N3 bond, rotation around the Cam−N4 bond is slow enough to allow 
detection of separate E and E 1H NMR signals.18 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Four conceivable isomers of fac-[Re(CO)3(5,5-Me2bipy)(HNC(CH3)NHR)]+ N–N 
denotes a C2-symmetrical bidentate N-donor ligand. Note that the Z isomer was not detected.18  
We were encouraged by the finding that the monodentate axial amidine ligand is robustly 
attached to the metal and thus could be used as a means for bioconjugation of the fac-MI(CO)3+ 
core (M = 99mTc, Re) core.18-20 Our main goal became to identify a method of preparing 
exclusively a single isomer of amidine complexes because the presence of multiple isomers 
complicates the development of ideal agents for medical applications.19 The symmetry of C2-
symmetrical secondary amines restricts the number of possible isomers to two, the E and Z 
isomers. By employing large 6-, 7-, and 8-membered ring C2-symmetrical, heterocyclic 
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secondary amines (HN(CH2)2Y, see Figure 4.2) instead of linear primary amines, we were able to 
synthesize isomerically pure and robust E isomers of fac- 
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)2Y)]BF4 complexes.19 In these complexes, steric 
repulsions between the N-heterocyclic ring substituents, –N(CH2)2Y, of the axial amidine ligand 
and the ligands in the equatorial coordination plane (defined as the Me2bipy and two trans CO 
ligands) greatly destabilize the only other possible isomer (Z) (Figure 4.3). Recently we utilized 
this concept to prepare a single isomer of analogues with a large 6-membered-ring cyclic amine 
moiety linking the fac-ReI(CO)3+ core to a B12 model.20  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Synthetic scheme for fac-[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)2Y)]BF4 
complexes,19 showing numbering system for discussion of NMR data (N–N denotes the Me2bipy 
ligand). 
Y 
Y 
Y 
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Figure 4.3. Conceivable isomers of fac-[Re(CO)3(Me2bipy)(HNC(R)N(CH2)2Y)]BF4 complexes; 
R =  CH3 or C6H5. See Figures 4.2 and 4.4 for definition of Y. N–N = 5,5-Me2bipy or 6,6-
Me2bipy ligand; double-headed arrows indicate steric interactions between groups, and arrow 
thickness reflects predicted qualitative severity of the steric repulsions. 
Heterocyclic amines provide the added advantage of requiring less time than primary 
amines to form amidines.19 The smallest and most basic heterocyclic amines were most reactive. 
Greater reactivity is advantageous because smaller quantities of amines can be used. 
Consequently, in the present study we focus on the goal of further reducing reaction times for 
amidine formation by exploring the use of 4- and 5-membered cyclic amines in place of larger 
amines and of benzonitrile instead of acetonitrile. One important goal was to determine if smaller 
heterocyclic amines form amidine complexes having only a single isomer. 
We determined in the present study that the use of 4- and 5-membered cyclic amines in 
step 2 of Method A quickly afforded amidine complexes having only the E isomer from either 
the fac-[Re(CO)3(Me2bipy)(CH3CN)]BF4 (Figures 4.2 and 4.4) or fac-
[Re(CO)3(Me2bipy)(C6H5CN)]BF4 (Figure 4.5) intermediates. However, synthesis of these fac-
[Re(CO)3(Me2bipy)(RCN)]BF4 intermediates starting from the fac-[Re(CO)3(CH3CN)3]+ 
Y 
Y 
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precursor in organic solvents required many hours (cf. Figure 4.4).17 A faster method is needed to 
make the amidine bioconjugation process more applicable to clinical studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Comparisons of Methods A and B used to synthesize fac-[Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)3)]BF4, illustrated for azetidine. 
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In the present study we describe the use of the fac-[ReI(CO)3(H2O)3]+ precursor to 
synthesize fac-[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)x)]+ complexes in partially aqueous 
conditions. The new method, Method B (Figure 4.4), requires much less time for step 1 and thus 
is superior to previous preparations in purely organic solvents.  In addition, the conditions are 
consistent with employing the fac-[99mTc(CO)3(H2O)3]+ precursor.  
From this point onward, when discussing specific complexes, we omit the fac-designation 
because all of the new complexes and other similar complexes discussed below have the facial 
geometry. Whereas [Re(CO)3(Me2bipy)(HNC(R)N(CH2)2Y)]BF4 is used to define more general 
cases in which Y may contain a heteroatom in addition to CH2 groups (Figures 4.2, 4.3 and 4.5), 
numerical subscripts are used, as in [Re(CO)3(Me2bipy)(HNC(R)N(CH2)5-7)]BF4 (R = CH3 or 
C6H5), to designate complexes in which the heterocyclic ring substituent on the amidine carbon 
(Cam) contains a given number of methylene groups (5 to 7 in this case). (Note that in the present 
report, the atom-numbering scheme for crystallographic data uses C16 for Cam.) 
 
 
 
 
 
 
 
 
 
Figure 4.5. Synthesis of fac-[Re(CO)3(Me2bipy)(HNC(C5H6)N(CH2)2Y)]BF4 complexes, 
showing the numbering system for discussing the phenyl ring NMR signals. N–N denotes the 
Me2bipy ligand.  
Y 
Y 
Y 
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4.2 Experimental Section 
Starting Materials. Re(CO)5Br and previously reported 
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)5-7)]BF4 complexes were synthesized as described in the 
literature.19,21 Re2(CO)10, 5,5-dimethyl-2,2-bipyridine (5,5-Me2bipy), 6,6-dimethyl-2,2-
bipyridine (6,6-Me2bipy), benzonitrile, piperidine, piperazine, pyrrolidine, azetidine, and AgBF4 
were obtained from Aldrich. [Re(CO)3(CH3CN)3]BF4 (prepared by a slight modification of a 
known procedure22) was used to prepare [Re(CO)3(5,5- or 6,6-Me2bipy)(CH3CN)]BF4.17 An 
aqueous stock solution (0.1 M) of [Re(CO)3(H2O)3]OTf (prepared as previously reported)9 was 
prepared and used as needed. 
NMR Measurements. 1H and 13C NMR spectra were recorded on 400 MHz or 500 MHz 
Bruker spectrometers. Peak positions are relative to TMS or to solvent residual peak, with TMS 
as reference. All NMR data were processed with TopSpin and MestReNova software.   
X-ray Data Collection and Structure Determination. Intensity data were collected at 
low temperature on a Bruker Kappa Apex-II DUO CCD diffractometer fitted with an Oxford 
Cryostream cooler and graphite-monochromated Mo K (λ = 0.71073 Å) radiation. Data 
reduction included absorption corrections by the multiscan method, with SADABS.23 All X-ray 
structures were determined by direct methods and difference Fourier techniques and refined by 
full-matrix least-squares methods by using SHELXL97.24  
Synthesis of [Re(CO)3(Me2bipy)(C6H5CN)]BF4 Complexes (Me2bipy  = 5,5-Me2bipy 
and 6,6-Me2bipy). A CHCl3 solution (10 mL) of [Re(CO)3(Me2bipy)(CH3CN)]BF4  (29 mg, 
0.05 mmol) (Me2bipy  = 5,5-Me2bipy or 6,6-Me2bipy) was treated with benzonitrile (0.15 mL, 
1.50 mmol), and the reaction mixture was stirred and heated at reflux. The volume was reduced 
to ~1 mL by rotary evaporation. Addition of diethyl ether to the point of cloudiness (~10−20 
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mL) produced a yellow crystalline material that was collected on a filter, washed with diethyl 
ether, and dried in air. 1H NMR signals (ppm) in CDCl3 for [Re(CO)3(5,5-
Me2bipy)(C6H5CN)]BF4: 8.73 (s, 2H, H6/6), 8.70 (d, J = 8.6 Hz, 2H, H3/3), 8.13 (d, J = 7.8 Hz, 
2H, H4/4), 7.66 (t, J = 10.0 Hz, 1H, H4), 7.58 (d, J = 7.5 Hz, 2H, H2/6), 7.49 (t, J = 7.7 Hz, 1H, 
H3/5), 2.54 (s, 6H, 5/5-2CH3). MALDI-TOF m/z: [M+] calcd for C22H17O3N3Re, 558.08; found, 
558.139. 1H NMR signals (ppm) in CDCl3 for [Re(CO)3(6,6-Me2bipy)(C6H5CN)]BF4: 8.80 (d, J 
= 7.0 Hz, 2H, H3/3), 8.21 (t, J = 7.6 Hz, 2H, H4/4), 7.62 (d, J = 7.3 Hz, 2H, H5/5), 7.56 (t, J = 
7.8 Hz, 1H, H4), 7.55 (d, J = 8.6 Hz, 2H, H2/6), 7.48 (t, J = 7.8 Hz, 2H, H3/4), 3.09 (s, 6H, 6/6- 
2CH3). MALDI-TOF m/z: [M+] calcd for C22H17O3N3Re, 558.08; found, 558.142. 
General Procedure for the Synthesis and Isolation of 
[Re(CO)3(Me2bipy)(HNC(R)N(CH2)x)]BF4 Complexes (1–10). A reaction mixture consisting 
of 0.06 mmol [Re(CO)3(Me2bipy)(RCN)]BF4 (Me2bipy = 5,5- or 6,6-Me2bipy; R = CH3 or 
C6H5) and 0.60 mmol of azetidine, pyrrolidine, or piperidine in CH3CN (R = CH3) or  CHCl3 (R 
= C6H5) solution (6 mL) was stirred at room temperature for ~30 to 60 min. The volume was 
reduced to 1 mL by rotary evaporation. Addition of diethyl ether to the point of cloudiness (10 
mL) produced a yellow crystalline material that was collected on a filter, washed with diethyl 
ether, and dried in air. Ten new [Re(CO)3(Me2bipy)(HNC(R)N(CH2)x)]BF4 complexes (1–10) 
were prepared. For a given x, the five new 5,5-Me2bipy complexes are assigned an odd number 
(1, 3, 5, 7, and 9) and the five new 6,6-Me2bipy complexes are assigned an even number (2, 4, 6, 
8, and 10).   
All 1H NMR spectra, recorded both immediately upon dissolution of the products (1–10) 
in CDCl3 or CD3CN and subsequently, showed signals for only one isomer (established to be the 
E isomer, Figure 4.3, by both solution and solid-state characterization). Also, when the progress 
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of the amidine formation reactions was monitored over time by 1H NMR spectroscopy on a small 
scale in NMR tubes, the only signals observed for products were identical to those of the isolated 
products. 1H and 13C NMR data for 1–10 in CDCl3 appear in Tables 4.1–4.4. 1H NMR data for 
1–4 in CD3CN are given in Supporting Information. 
Table 4.1. 1H NMR Shifts (ppm) for [Re(CO)3(L)(HNC(CH3)N(CH2)x)]BF4 Complexes (CDCl3, 
27 °C) 
 
 
signal / x 3 4 519 619 719 3 4 519 619 
 L  = 5,5-Me2bipy L  = 6,6-Me2bipy 
H6/6  8.61 8.63 8.63 8.63 8.64     
H5/5       7.48 7.50 7.51 7.53 
H4/4  7.97 8.01 8.02 8.05 8.04 8.04 8.08 8.07 8.10 
H3/3   8.36 8.47 8.48 8.55 8.57 8.37 8.44 8.40 8.44 
L-CH3  2.50 2.50 2.50 2.50 2.50 3.03 3.05 3.04 3.06 
N3H  4.27 4.10 4.58 4.25 4.21 4.31 4.26 4.92 4.60 
Cam-CH3  2.08 2.30 2.32 2.33 2.34 1.66 1.83 1.88 1.87 
N–CH2 endo 4.05 3.37 3.06 br 3.35 3.30 4.03 3.31 3.08 br 3.31 
N–CH2 exo 3.68 2.78 3.06 br 2.88 3.03 3.67 2.80 3.08 br 2.96 
CH2 signals 2.13 1.83 1.49 1.58 1.60 2.20 1.84 1.52 1.54 
    1.43 1.43 1.52   1.43 1.43 
    1.31 1.33    1.37 
    1.25 1.10    1.37 
     0.95     
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Table 4.2. 1H NMR Shifts (ppm) for [Re(CO)3(L)(HNC(C6H5)N(CH2)x)]BF4 Complexes in 
CDCl3 at 27 C 
 
signal /x  3  4  5    3  4  5 
       L  = 5,5-Me2bipy        L  = 6,6-Me2bipy 
H6/6   8.37 8.38 8.42    
H5/5    7.39 7.44 7.46 
H4/4 7.95 7.99 8.00 8.05 8.09 8.09 
H3/3 8.38 8.44 8.44 8.45 8.51 8.44 
Ph ring H2/6 7.18 7.14 7.18 6.93 6.88 6.95 
Ph ring H3/5 7.44 7.45 7.48 7.35 7.36 7.40 
Ph ring H4 7.51 7.51 7.54 7.46 7.47 7.50 
L-CH3  2.45 2.47 2.49 2.75 2.75 2.81 
N3H  4.68 4.69 5.17 4.49 4.49 5.22 
N–CH2  endo 3.63 2.88 br 2.87 3.63 2.87 br 2.84  
N–CH2  exo 3.81 2.97 br 2.96  3.74 2.93 br 3.01 
CH2  signals 2.13 1.92 (exo) ~1.56 2.18 1.96 (exo) ~1.57 
   1.69 (endo) 1.52  1.71 (endo) 1.50 
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Table 4.3. 13C NMR Shifts (ppm) for [Re(CO)3(L)(HNC(CH3)N(CH2)x)]BF4 Complexes in 
CDCl3 at 27 C 
 
signal /x  3  4  519   619   719    3  4  519 619 
 L  = 5,5 -Me2bipy                      L  = 6,6-Me2bipy 
C6/6   152.22 152.28 152.35 152.24 152.25 162.52 162.33 162.68 162.64 
C5/5 138.21 138.39 138.47 138.50 138.54 127.00 127.12 127.36 127.36 
C4/4 141.09 141.44 141.51 141.67 141.69 140.44 140.87 140.86 141.02 
C3/3 124.74 125.13 125.08 125.36 125.39 123.06 123.59 123.03 123.27 
C2/2 153.88 153.53 153.48 153.41 153.98 157.69 157.73 157.67 157.63 
L-CH3  18.77 18.74 18.72 18.74 18.72 29.68 30.03 29.90 30.02 
Cam  167.23 166.14 167.13 167.52 167.03 166.89 165.79 166.48 166.04 
Cam-CH3  18.77 22.63 22.52 21.96 22.07 16.81 21.03 20.91 20.40 
N–CH2 endo 52.25 50.04 br 46.87 50.99 53.30 51.98 49.88 br 47.26 51.18 
N–CH2 exo 49.37 46.27 br 46.87 48.02 47.96 48.72 46.22 br 47.26 48.14 
CH2  signals 14.27 25.83 25.29 29.64 27.69 13.98 25.71 25.54 29.45 
   24.77 23.55 26.77 27.37  24.74 23.63 26.78 
    26.65 24.42    26.37 
    25.03 24.25    25.38 
     21.14     
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Table 4.4. 13C NMR Shifts (ppm) for [Re(CO)3(Me2bipy)(HNC(C6H5)N(CH2)x)]BF4 Complexes 
in CDCl3 at 27 C   
 
signal /x  3  4  5 3 4 5 
         L  = 5,5-Me2bipy                      L  = 6,6-Me2bipy 
C6/6   152.26 152.21 152.23 162.53 162.553 162.75 
C5/5 138.13 138.22 138.26 127.07 127.12 127.36 
C4/4 140.96 141.18 141.21 140.45 140.64 140.66 
C3/3 124.63 124.78 124.90 123.63 123.79 123.30 
C2/2 153.66 153.53 153.68 157.91 157.91 157.82 
L–CH3  18.76 18.75 18.79 29.93 29.93 29.93 
Cam  169.20 167.86 170.05 169.09 167.77 169.71 
Ph ring C1 131.90 135.27 134.95 131.09 134.69 134.22 
Ph ring C2/6 127.81 127.45 128.25 127.59 127.22 127.86 
Ph ring C3/5 129.12 129.24 129.34 129.13 129.28 129.38 
Ph ring C4 130.59 130.23 130.63 130.81 130.39 130.81 
N–CH2 endo 52.79 51.56 br 51.01 52.90 51.48 br 51.12 
N–CH2 exo 49.34 46.20 br 45.73 49.15 46.17 br 45.68 
CH2  signals 14.44 25.73 (endo) 
24.78 (exo) 
br 29.96 
br 27.72 
23.76 
 
14.38 25.69 
(endo) 
24.77 (exo) 
br 30.15 
br 25.96 
23.80 
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[Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)3)]BF4 (1). The use of the general procedure 
for the reaction of [Re(CO)3(5,5-Me2bipy)(CH3CN)]BF4 (34.9 mg, 0.06 mmol) with azetidine 
(40.7 L, 0.60 mmol) in acetonitrile afforded 20 mg (62% yield) of yellow crystalline material. 
Adding diethyl ether (19 mL) to a solution of this material in CH3CN (5 mg/1 mL) and allowing 
the solvent mixture to evaporate slowly afforded X-ray quality crystals of the E isomer. Crystals 
of the E isomer of complexes 2–10 were obtained in a similar manner, as described below. 
[Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2)3)]BF4 (2). In the treatment of 
[Re(CO)3(6,6-Me2bipy)(CH3CN)]BF4 (34.9 mg, 0.06 mmol) with azetidine (40.7 L, 0.60 
mmol) in CH3CN, the general procedure afforded 29 mg (76% yield) of yellow crystalline 
material. X-ray quality crystals of 2 were obtained as described for 1 by the addition of 25 mL of 
diethyl ether.  
[Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)4)]BF4 (3). The use of the general procedure 
for the reaction of [Re(CO)3(5,5-Me2bipy)(CH3CN)]BF4 (34.9 mg, 0.06 mmol) with pyrrolidine 
(49.6 L, 0.60 mmol) in CH3CN afforded 30 mg (77% yield) of yellow crystalline material. X-
ray quality crystals of 3 were obtained as described for 1 by adding diethyl ether (9 mL). 
[Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2)4)]BF4 (4). For the reaction of 
[Re(CO)3(6,6-Me2bipy)(CH3CN)]BF4 (34.9 mg, 0.06 mmol) with pyrrolidine (49.6 L, 0.60 
mmol) in CH3CN, the general procedure afforded 28 mg (71% yield) of yellow crystalline 
material. X-ray quality crystals of 4 were obtained as described for 1 by adding diethyl ether (15 
mL). 
[Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)3)]BF4 (5). The use of the general 
procedure in treating [Re(CO)3(5,5-Me2bipy)(C6H5CN)]BF4 (38.7 mg, 0.06 mmol) with 
azetidine (40.7 L, 0.60 mmol) in CHCl3 afforded 28 mg (67% yield) of yellow crystalline 
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material. X-ray quality crystals of 5 were obtained from a solution of this material in CHCl3 (3.87 
mg/600 L) by adding diethyl ether (3 mL) and allowing the solvent mixture to evaporate slowly.  
[Re(CO)3(6,6-Me2bipy)(HNC(C6H5)N(CH2)3)]BF4 (6). For the reaction of 
[Re(CO)3(6,6-Me2bipy)(C6H5CN)]BF4 (38.7 mg, 0.06 mmol) with azetidine (40.7 L, 0.60 
mmol) in CHCl3, the general procedure afforded 26 mg (62% yield) of yellow crystalline 
material. X-ray quality crystals of 6 were obtained as described for 5 by adding diethyl ether (5 
mL). 
[Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)4)]BF4 (7). The use of the general 
procedure in the reaction of [Re(CO)3(5,5-Me2bipy)(C6H5CN)]BF4 (38.7 mg, 0.06 mmol) with 
pyrrolidine (49.6 L, 0.60 mmol) in CHCl3 afforded 30 mg (70% yield) of yellow crystalline 
material. X-ray quality crystals of 7 were obtained by recrystallization from CHCl3 (15 mg/1 mL) 
after adding diethyl ether (~7 mL). 
[Re(CO)3(6,6-Me2bipy)(HNC(C6H5)N(CH2)4)]BF4 (8). The use of the general 
procedure in the reaction of [Re(CO)3(6,6-Me2bipy)(C6H5CN)]BF4 (38.7 mg, 0.06 mmol) with 
pyrrolidine (49.6 L, 0.60 mmol) in CHCl3 afforded 32 mg (75% yield) of yellow crystalline 
material. X-ray quality crystals of 8 were obtained by recrystallization from CHCl3 (21 mg/1 mL) 
after adding diethyl ether (~10 mL). 
[Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)5)]BF4 (9). Reaction of [Re(CO)3(5,5-
Me2bipy)(C6H5CN)]BF4 (38.7 mg, 0.06 mmol) with piperidine (59.2 L, 0.60 mmol) in CHCl3 
by the general procedure afforded 38 mg (87% yield) of yellow crystalline material. X-ray quality 
crystals of 9 were obtained by recrystallization from CHCl3 (5 mg/2 mL) after adding diethyl 
ether (7 mL).  
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[Re(CO)3(6,6-Me2bipy)(HNC(C6H5)N(CH2)5)]BF4 (10). Using the general procedure 
to treat [Re(CO)3(6,6-Me2bipy)(C6H5CN)]BF4 (38.7 mg, 0.06 mmol) with piperidine (59.2 L, 
0.60 mmol) in CHCl3 afforded 36 mg (82% yield) of yellow crystalline material. X-ray quality 
crystals of 10 were obtained by recrystallization from CHCl3 (18 mg/1 mL) after adding diethyl 
ether (~10 mL).  
New Method of Synthesizing Amidine Complexes Starting with the fac-
[Re(CO)3(H2O)3]+ Precursor (Method B). Aqueous solutions of fac-[Re(CO)3(H2O)3]+ (0.5 mL 
from the 0.1M stock solution, 0.05 mmol), (pH = 2.57) were treated with 5,5-Me2bipy (9.21 mg, 
0.05 mmol), 0.5 mL of CH3CN, and NaBF4 (5.49 mg, 0.05 mmol). The reaction mixture (1:1 
H2O:CH3CN), (pH = 5.87) was heated at reflux, and the reaction was monitored by 1H NMR 
spectroscopy (Figure 4.6). The 5,5-Me2bipy ligand dissolved within 2–3 min in step 1 of the 
preparation. Aliquots (10 L) of the reaction mixture were transferred to a vial and reduced to 
dryness by rotary evaporation. The residue was dissolved in CDCl3 for 1H NMR assessment. In 
the NaBF4 preparations (recorded at 10 min, Figure 4.6), the first spectrum showed peaks arising 
from the [Re(CO)3(5,5-Me2bipy)(CH3CN)]+ product17 that were more intense than peaks from 
the reactant (5,5-Me2bipy). Product peaks continued to increase until no reactant peaks remained 
(~30 min, Figure 4.6). After 5 additional minutes, the solution was allowed to cool to room 
temperature to complete step 1 of the process.  
In step 2, a 10:1 molar excess of piperidine (49.4 L, 0.5 mmol) was added to the reaction 
mixture at room temperature, and the aliquot method described above was used to monitor the 
reaction by 1H NMR spectroscopy (Figure 4.6). 1H NMR spectra indicated complex formation of 
the expected amidine 30 min after the addition of piperidine. The reaction mixture was filtered 
and the dark yellow residue left in the vial after the solvent was removed by rotary evaporation 
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Figure 4.6. Stack plot of 1H NMR spectra (CDCl3, 27 C) obtained to monitor steps 1 and 2 of 
Method B. Spectra chosen for the figure to illustrate the NMR data for Method B are from 
reaction of piperidine to form [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)5)]BF42  because slow 
enough to obtain intermediate spectra for step 2. Also, the salt is NaBF4 because crystals could be 
obtained. Signals of starting 5,5-Me2bipy are labeled with •. Signals for [Re(CO)3(5,5-
Me2bipy)(CH3CN)]BF4 are labeled with * in the 10-min step 1 and step 2 traces and with 
assignments in the step 1 30-min trace. Signals for the final [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)5)]BF4 product are labeled with  in the step 2 10-min trace and 
with assignments in the step 2 30-min trace. 
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was collected on a filter, washed well with water, and air dried. This residue was then washed 
well with diethyl ether (~20 mL) and dissolved in CHCl3 (5 mL). After filtration, the filtrate was 
taken to dryness (rotary evaporation), yielding 37 mg of product (91%); all yields in this section 
are based on the fac-[Re(CO)3(H2O)3]+ precursor. The residue from this NaBF4 preparation was 
dissolved in 0.5 mL of CH3CN, and diethyl ether (7 mL) was added to the point of cloudiness. 
Yellow crystals were obtained after 24 h. The 1H NMR spectra in CD3CN of the residue and of 
the crystals identically matched the 1H NMR spectrum reported for [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)5)]BF4.19  
Furthermore, in step 2 the addition of azetidine (40.7 L, 0.5 mmol) or pyrrolidine (49.6 
L, 0.5 mmol) to [Re(CO)3(5,5-Me2bipy)(CH3CN)]+  (generated in solution by Method B, 30 
min) formed the expected products within 3 and 6 min, respectively. The 1H NMR spectra in 
CDCl3 of the crystalline precipitates, 1 (29 mg, 92% yield) and 3 (28 mg, 88% yield), were 
identical to those recorded for complexes 1 and 3 prepared by using Method A (Table 4.1). 
Virtually identical results were obtained when NaCl (2.92 mg, 0.05 mol) was used in step 
1 in place of the NaBF4 in order to simulate the 0.1 M NaCl solution typically used in 99mTc 
radiolabeling. In step 2, with a 10:1 molar excess of either piperidine (49.4 L, 0.5 mmol) or 
azetidine (40.7 L, 0.5 mmol), 1H NMR spectra indicated formation of the expected amidine 
complex within 20 min (piperidine) or 4 min (azetidine) in yields of 25 mg (85%) and 24 mg 
(80%), respectively.  
Challenge Reactions. A 5 mM solution of [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)3)]BF4  (1), [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)4)]BF4 (3), 
[Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)3)]BF4  (5), and [Re(CO)3(5,5-
Me2bipy)(HNC(C6H5)N(CH2)4)]BF4  (7)  in CDCl3 (600 L) was treated with a 1:5 molar ratio of 
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4-dimethylaminopyridine (2.0 mg, 25 mM), and the solution was monitored over time by 1H 
NMR spectroscopy. 
4.3 Results and Discussion  
Synthesis. Use of 100% Organic Solvents (Method A). 
[Re(CO)3(Me2bipy)(CH3CN)]BF4 (Me2bipy = 5,5- or 6,6-Me2bipy) complexes prepared in 
organic solvents from the [Re(CO)3(CH3CN)3]BF4 precursor as described previously17 were used 
to prepare the new [Re(CO)3(Me2bipy)(C6H5CN)]BF4 (Me2bipy = 5,5- or 6,6-Me2bipy) 
complexes in CHCl3 (Experimental Section). Addition of heterocyclic secondary amines 
(HN(CH2)x) (x = 3 to 5) to [Re(CO)3(Me2bipy)(RCN)]BF4 (Me2bipy = 5,5- or 6,6-Me2bipy; R = 
CH3 or C6H5) in CH3CN (R = CH3) or CHCl3 (R = C6H5) in a 10:1 ratio produced good-to-high 
yields (~60% to 90%) of ten new [Re(CO)3(Me2bipy)(HNC(R)N(CH2)x)]BF4 complexes (1–10). 
For a given x, all new 5,5-Me2bipy complexes are assigned an odd number: [R = CH3, x = 3 (1); 
R = CH3, x = 4 (3); R = C6H5, x = 3 (5); R = C6H5, x = 4  (7); R = C6H5, x = 5  (9)) and all new 
6,6-Me2bipy complexes are assigned an even number (R = CH3, x = 3 (2); R = CH3, x = 4 (4); R 
= C6H5, x = 3 (6); R = C6H5, x = 4 (8); R = C6H5, x = 5 (10)].  Both solution and solid-state 
characterizations establish that 1–10 exist only as the E isomer (Figure 4.3), as was found 
previously for the [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)5)]BF4 complexes (Me2bipy = 5,5- or 
6,6-Me2bipy).19 
In a previous report,19  we found that the reactions of the same cyclic amine to form 
amidine complexes from [Re(CO)3(Me2bipy)(CH3CN)]BF4 complexes in CD3CN were complete 
in less time for 6,6-Me2bipy than for 5,5-Me2bipy complexes and that, for a given basicity of 
the amine, reactions of smaller-ring cyclic amines were faster than for the large-ring cyclic 
amines or for primary amines. Table 4.5 shows the time required for complete reaction, evaluated  
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Table 4.5. Times (min) for Complete Reaction of [Re(CO)3(5,5-Me2bipy)(RCN)]BF4 Complexes 
with Amines to Form [Re(CO)3(5,5-Me2bipy)(amidine)]BF4  Complexes  
 
by monitoring a 10 mM solution of [Re(CO)3(5,5-Me2bipy)(RCN)]BF4 in CDCl3 or CD3CN 
(600 L) by 1H  NMR spectroscopy after the addition of a 1:10 molar excess of various amines 
(100 mM). All reactions of [Re(CO)3(5,5-Me2bipy)(CH3CN)]BF4 with 4-, 5-, or 6-membered 
ring heterocyclic amines in CD3CN were significantly faster than the reactions of [Re(CO)3(5,5-
Me2bipy)(CH3CN)]BF4 with primary amines.18 Reactions of azetidine or pyrrolidine with 
[Re(CO)3(5,5- or 6,6-Me2bipy)(CH3CN)]BF4 in 100% CD3CN reached completion in under 3 
min, even before the first spectrum could be recorded. The short reaction times of these amines 
with [Re(CO)3(Me2bipy)(CH3CN)]BF4 in CD3CN preclude comparison of the reactivity of 
azetidine or pyrrolidine with that of the larger cyclic secondary amines studied previously in 
CD3CN.19 Therefore, the amidine formation reaction was monitored in CDCl3, in which slower 
R amine       CD3CN CDCl3 
CH3  azetidine < 3  < 4  
CH3  pyrrolidine < 3  ~ 32  
CH3  piperidine < 5  ~ 200  
CH3 piperazine ~20  ~ 1320  
C6H5  azetidine  < 4  
C6H5  pyrrolidine  < 7  
C6H5  piperidine  ~ 60  
C6H5  piperazine  ~ 180  
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reaction times of [Re(CO)3(5,5-Me2bipy)(CH3CN)]BF4 with azetidine or pyrrolidine allowed us 
to estimate by 1H NMR spectroscopy the time required for complete reaction. As shown in Table 
4.5, the completion time in CDCl3 with azetidine (<4 min) was significantly faster than the 
completion times with pyrrolidine (~32 min) or piperidine (~200 min). Decreasing the size of the 
heterocyclic amine to 4- and 5-membered rings decreased the completion time, a trend found 
earlier for 6-, 7-, and 8-membered cyclic amines.19  
Moreover, although the times for the azetidine reactions were too short to assess by our 
method, the reactions with [Re(CO)3(5,5-Me2bipy)(RCN)]BF4 in CDCl3 for a given amine 
(pyrrolidine, piperidine, and piperazine) were relatively faster when R = C6H5 than when R = 
CH3. This favorable reactivity in forming the [Re(CO)3(5,5-
Me2bipy)(HNC(C6H5)N(CH2)2Y)]BF4 complexes can be attributed to the electron-withdrawing 
ability of the phenyl ring, which facilitates addition of the amine to the coordinated nitrile group.  
Use of 50% Water and 50% Acetonitrile Solvent Mixture (Method B). Formation of 
the [Re(CO)3(5,5-Me2bipy)(CH3CN)]+ complex from the organic solvent soluble 
[Re(CO)3(CH3CN)3]BF4 precursor needed for Method A requires 2-3 days in acetonitrile and 16 
h in benzene.17 The time required to form the [Re(CO)3(5,5-Me2bipy)(CH3CN)]+ complex in the 
50% water/50% acetonitrile solvent mixture is only 30 min (Figure 4.6). The final yields 
obtained from Method B are also higher (89%-92%, Experimental Section).19 Most importantly, 
the utilization of the aqueous solution of the fac-[Re(CO)3(H2O)3]+ precursor provides guidance 
for the use of the fac-[99mTc(CO)3(H2O)3]+ precursor. Knowledge of relevant amidine chemistry 
gained in earlier work17-20 and in the present work can now potentially be adapted in utilizing this 
fac-[99mTc(CO)3(H2O)3]+ precursor for biomedical studies. 
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Structural Results. Recrystallization of the crystalline products isolated afforded X-ray 
quality crystals for the ten new complexes (1–10). Tables 4.6 and 4.7 summarize the crystal data 
Table 4.6. Crystal Data and Structural Refinement for [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)3)]BF4 (1), [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2)3)]BF4 (2),  
[Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)4)]BF4 (3), and [Re(CO)3(6,6-
Me2bipy)(HNC(CH3)N(CH2)4)]BF4 (4) 
 
complex 1 2 3 4 
empirical formula C20H22N4O3Re•0.8
4 (BF4)•0.16(Br) 
C20H22N4O3Re•BF4 C21H24N4O3Re•0.97(BF4
)•0.03(Br) 
C21H24N4O3Re•
BF4 
fw 638.29 639.42 653.24 653.45 
crystal system triclinic monoclinic monoclinic monoclinic 
space group P1̅  P21/n P21/n P21/n 
a (Å) 8.2743(4)  10.4580(2) 11.233(2) 8.9664(4) 
b (Å) 10.3582(5) 11.7078(2) 13.582(2) 12.1161(4) 
c (Å) 13.9310(7) 17.9573(4) 15.495(3) 21.9930(8) 
 (deg) 78.234(2) 99.815(1) 100.307(17) 98.127(2) 
V (Å3) 1124.24(10) 2166.51(7) 2325.9 (7) 2365.28(16) 
T (K) 100 90 90 180 
Z 2 4 4 4 
calc (Mg/m3) 1.886 1.960 1.866 1.835 
abs coeff (mm-1) 5.75 5.67 5.34 5.20 
2max () 61.0 84.2 80.4 64.0 
R [I> 2(I)]a 0.026 0.026 0.017 0.026 
wR2 b 0.073 0.054 0.042 0.059 
data/param 6737/309 15173/305 14590/317 8186/323 
aR = (||F| - |Fc||)/|F|. bwR2 = [[w(F2 - Fc2)2]/[w(F2)2]]1/2,  in which w = 1/[2(F2) + 
(dP)2 + (eP)] and P = (F2 + 2Fc2)/3. 
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Table 4.7. Crystal Data and Structural Refinement for [Re(CO)3(5,5-
Me2bipy)(HNC(C6H5)N(CH2)3)]BF4 (5), [Re(CO)3(6,6-Me2bipy)(HNC(C6H5)N(CH2)3)]BF4 (6), 
[Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)4)]BF4 (7), [Re(CO)3(6,6-
Me2bipy)(HNC(C6H5)N(CH2)4)]BF4 (8), [Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)5)]BF4 (9), 
and [Re(CO)3(6,6-Me2bipy)(HNC(C6H5)N(CH2)5)]BF4 (10) 
 
 
complex 5 6 7 8 9 10 
empirical 
formula 
C25H24N4O3 
Re•0.09(Br) 
•0.91(BF4) 
C25H24N4O3 
Re•BF4 
C26H26N4O3Re
•0.911(BF4)• 
0.089(Br) 
 
C26H26N4O3R
e•BF4 
 
C27H28N4O3Re
•BF4 
 
5(C27H28N4O3
Re•BF4) 
 
fw 699.86 701.49 714.82 715.52 729.54 3647.71 
crystal system monoclinic monoclinic monoclinic monoclinic triclinic trigonal 
space group P21/c Ia P21/c P21/c P1̅  R3̅:R 
a (Å) 16.6697(12) 10.9466(4) 16.730(3) 10.6300(16) 9.0850(5) 27.6668(9) 
b (Å) 11.1504(8) 16.3982(5) 11.0485(19) 47.473(7) 10.3191(6) 90 
c (Å) 14.7196(10) 15.1842(6) 15.439(3) 15.928(2) 14.8996(8) 27.6668(9) 
α (deg) 90 90 90 90 89.884(3) 83.540(1) 
 (deg) 110.827(4) 109.033(1) 112.223(8) 102.985(7) 81.639(3) 90 
γ (deg) 90 90 90 90 74.276(3) 90 
V (Å3) 2557.2(3) 2576.62(16) 2641.9(8) 7832(2) 1333.10(13) 20802(2) 
T (K) 90 90 90 100 90 90 
Z 4 4 4 12 2 6 
calc (Mg/m3) 1.818 1.808 1.797 1.820 1.817 1.747 
abs coeff 
(mm-1) 
4.95 4.78 4.79 4.72 4.62 4.44 
2max () 84.2 75.4 91.2 67.2 61.2 63.0 
R [I> 2(I)]a 0.030 0.020 0.030 0.0037 0.023 0.033 
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(Table 4.7 continued) 
complex 5 6 7 8 9 10 
wR2 b 0.070 0.053 0.072 0.062 0.048 0.075 
data/param 17947/346 8475/349 22180/367 26084/1116 8041/367 46238/1826 
aR = (||F| - |Fc||)/|F|. bwR2 = [[w(F2 - Fc2)2]/[w(F2)2]]1/2,  in which w = 1/[2(F2) + 
(dP)2 + (eP)] and P = (F2 + 2Fc2)/3. 
 
and details of the structural refinement for complexes 1–4 and 5–10, respectively. ORTEP plots 
of the molecular structures showing the atom-numbering scheme used to describe the solid-state 
data are shown in Figure 4.7 for the cations of [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)3 or 4)]BF4 
(1–4), and in Figures 4.8 and 4.9 for the cations of [Re(CO)3(Me2bipy)(HNC(C6H5)N(CH2)3-
5)]BF4 (5–10). Selected bond distances and angles for the 
[Re(CO)3(Me2bipy)(HNC(R)N(CH2)x)]BF4 complexes are listed in Tables 4.8 and 4.9.  
Complexes 1–10 have a pseudo octahedral structure; three carbonyl groups occupy one face 
and the N1 and N2 atoms of the Me2bipy ligand and the N3 atom of the amidine ligand having 
the E configuration (Figures 4.2 to 4.4) occupy the opposite face. The two carbonyl ligands trans 
to the N1 and N2 atoms and the bidentate Me2bipy ligand are considered to define the equatorial 
coordination plane. The carbonyl trans to N3 and the monodentate amidine ligand are referred to 
as axial ligands. Unfavorable repulsive interactions between the 6-, 7-, or 8-membered 
heterocyclic ring moiety attached to C16 and the equatorial ligands believed to destabilize the Z 
isomer (Figure 4.3) were invoked to explain why the E isomer is favored for 
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)2Y)]BF4 complexes with Y = (CH2)3, (CH2)4, (CH2)5, 
(CH2)2NH, and (CH2)2O.19  
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Figure 4.7. ORTEP plots of the cations of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)3)]BF4 (1), 
[Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2)3)]BF4 (2),  [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)4)]BF4 (3), and [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2)4)]BF4 
(4). Thermal ellipsoids are drawn with 50% probability. 
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Figure 4.8. ORTEP plots of the cations of [Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)3)]BF4 
(5), [Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)4)]BF4 (7), and [Re(CO)3(5,5-
Me2bipy)(HNC(C6H5)N(CH2)5)]BF4 (9). Thermal ellipsoids are drawn with 50% probability. 
5) 
 
7) 9) 
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Figure 4.9. ORTEP plots of the cations of [Re(CO)3(6,6-Me2bipy)(HNC(C6H5)N(CH2)3)]BF4 
(6), [Re(CO)3(6,6-Me2bipy)(HNC(C6H5)N(CH2)4)]BF4 (8), and [Re(CO)3(6,6-
Me2bipy)(HNC(C6H5)N(CH2)5)]BF4 (10). Thermal ellipsoids are drawn with 50% probability. 
6) 
8) 10 
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Table 4.8. Selected Bond Distances (Å) and Angles (deg) for [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)3)]BF4 (1), [Re(CO)3(6,6-Me2bipy)(HNC(CH3)N(CH2)3)]BF4 (2),  
[Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)4)]BF4 (3), and [Re(CO)3(6,6-
Me2bipy)(HNC(CH3)N(CH2)4)]BF4 (4)  
 
complex 1 2 3 4 
Re–N1 2.178(2) 2.2050(12) 2.176(1) 2.198(2) 
Re–N2 2.172(2) 2.1990(12) 2.186(1) 2.200(2) 
Re–N3 2.184(3) 2.1704(11) 2.186(1) 2.181(2) 
N3–C16  1.305(4) 1.3068(18) 1.311(1) 1.303(3) 
N4–C16 1.331(4) 1.3313(17) 1.338(2) 1.334(3) 
N4–C(n) 1.468(4)b 1.4667(18)b 1.471(2)c 1.460(4)c 
N4–C18 1.477(4) 1.4708(18) 1.474(2) 1.480(3) 
N1–Re–N2 75.28(9) 75.10(5) 74.85(3) 74.90(9) 
N1–Re–N3 80.13(9) 80.15(5) 80.57(4) 80.14(8) 
N2–Re–N3 82.84(9) 83.84(5) 85.19(4) 85.19(8) 
Re–N3–H3  108(3) 111.3(16) 111(1) 111(2) 
Re–N3–C16 133.6(2) 135.47(10) 135.44(8) 135.5(2) 
C16–N3–H3 116(3) 113.2(17) 114(1) 113(2) 
N3–C16–N4 121.4(3) 121.82(13) 122.8(1) 123.0(2) 
N3–C16–C17 123.2(3) 122.88(12) 120.3(1) 120.1(2) 
N4–C16–C17 115.4(3) 115.31(12) 116.9(1) 116.9(2) 
C16–N4–C18 131.5(3) 131.78(12) 125.1(1) 124. 6(2) 
C16–N4–C(n)a 129.8(3)b 131.58(12)b  122. 9(1)c 123.4(2)c 
C18–N4–C(n)a 94.4(2)b 95.39(10)b  111.6(1)c 112.0(2)c 
a n varies in number according to the R group.  b n = 20.  c n = 21. 
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Table 4.9. Selected Bond Distances (Å) and Angles (deg) for [Re(CO)3(5,5-
Me2bipy)(HNC(C6H5)N(CH2)3)]BF4 (5), [Re(CO)3(6,6-Me2bipy)(HNC(C6H5)N(CH2)3)]BF4 (6), 
[Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)4)]BF4 (7), [Re(CO)3(6,6-
Me2bipy)(HNC(C6H5)N(CH2)4)]BF4 (8), [Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)5)]BF4 (9), 
and [Re(CO)3(6,6-Me2bipy)(HNC(C6H5)N(CH2)5)]BF4 (10) 
 
complex 5 6 7 8 9 10 
Re–N1 2.1797(14) 2.214(3) 2.1819(12) 2.211(2) 2.1726(19) 2.193(2) 
Re–N2 2.1774(14) 2.201(4) 2.1773(11) 2.205(2) 2.1745(19) 2.218(3) 
Re–N3 2.1785(13) 2.173(3) 2.1851(11) 2.183(2) 2.206(2) 2.178(2) 
N3–C16  1.313(2) 1.307(5) 1.3121(16) 1.311(4) 1.301(3) 1.296(4) 
N4–C16 1.327(2) 1.322(5) 1.3345(16) 1.339(4) 1.352(3) 1.362(4) 
N4–C(n)a 1.469(2)d 1.467(5)d 1.4780(17) e 1.472(4) e 1.477(3) f 1.477(4)f 
N4–C23 1.474(2) 1.479(5) 1.4680(17) 1.474(4) 1.480(3) 1.472(4) 
N1–Re–N2 74.56(5) 75.74(12) 74.59(4) 75.01(9) 75.05(7) 75.48(9) 
N1–Re–N3 81.10(5) 84.26(12) 84.10 (4) 77.61(10) 82.63(7) 78.71(9) 
N2–Re–N3 85.07(5) 80.85(13) 81.88 (4) 87.15(9) 89.23(7) 82.36(10) 
Re–N3–H3N  109.1(14) 115(2) 113.7(15) 111.233(4) 109.0(2) 107.0(3) 
Re–N3–C16 134.03(11) 136.4(3) 133.16(9) 134.5(2) 137.04(17) 137.0(2) 
C16–N3–H3N 115.2(14) 108(2) 112.7(15) 110.468(7) 111.0(2) 116.0(3) 
N3–C16–N4 121.91(15) 123.5(4) 124.11(12) 122.4(3) 124.1(2) 123.1(3) 
N3–C16–C17 122.27(14) 122.2(3) 120.68(11) 118.8(3) 119.1(2) 118.9(3) 
N4–C16–C17 115.75(14) 114.3(3) 115.18(11) 118.7(3)  116.8(2) 117.9(3) 
C16–N4–C23 134.71(15) 131.6(3) 124.41(11) 125.2(3) 121.7(2) 120.4(3) 
C16–N4–C(n)a 130.72(14)d 132.6(4)d 123.92(11)e 122.1(3)e 120.6(2) f 121.1(3)f 
C23–N4–C(n)a 94.57(12)d 94.6(3)d 111.62(10)e 111.41(2)e 115.3(2) f 113.4(3)f 
a n varies in number according to the R group.  d n = 25. e n = 26. f n = 27. 
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Both crystallographic solid-state data and NMR solution data (see below) establish that 
[Re(CO)3(Me2bipy)(HNC(R)N(CH2)3, 4, or 5)]BF4 complexes 1–10 exist only as the E isomer. 
This finding strongly indicates that steric repulsions between the equatorial ligands and a 
substituent on the amidine carbon (C16) as small as a 4-membered ring can destabilize the Z 
isomer (Figure 4.3).   
The characteristics of structures 1–10 (Tables 4.8 and 4.9) are similar to those typically 
found in structures reported for primary ([Re(CO)3(Me2bipy)(HNC(CH3)NHR)]BF4)18 and 
secondary  ([Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)2Y)]BF4) amidine19 complexes and even of 
iminoether ([Re(CO)3(Me2bipy)(HNC(CH3)OCH3)]BF4) complexes.17 We attribute the similarity 
in structure of these complexes to the fact that the NHR (E isomer) or N(CH2)2Y) (E isomer) 
substituent on the amidine carbon (C16) projects away from the equatorial plane, and thus the 
nature of the substituent has little influence on the structural features of the Re(CO)3(Me2bipy), 
HNC(CH3)N, and HNC(C6H5)N moieties of the amidine complexes. 
Structures 1–10 (Tables 4.8 and 4.9) all have Re−N bond lengths that are at the upper end 
or slightly longer than the typical ReI–N(sp2) bond length (usually stated as ranging from 2.14–
2.18 Å).9 The axial amidine ligand C17, C16, and N4 atoms usually are close to a pseudo "axial" 
plane which includes the axial CO, Re and N3 and which is equidistant from the two bound N 
atoms and the two bound C atoms of the equatorial ligands (Figure 4.10). In structures 1–10, the 
two Nequatorial−Re−N3 bond angles differ significantly from each other (Tables 4.8 and 4.9), a 
finding similar to those reported for related complexes.17-19 The larger of these two 
Nequatorial−Re−N3 angles involved the equatorial N closer to the amidine or imino ether methyl 
group, a finding consistent with a minimization of repulsions between the methyl group and the 
closest atoms of the equatorial plane.19 This explanation applies to 1–4 (Table 4.8) and to 
[Re(CO)3(Me2bipy)(HNC(C6H5)N(CH2)3-5)]BF4 complexes 5–10  in which the Nequatorial−Re−N3 
 107 
angle involving the equatorial N closer to the amidine phenyl group is significantly larger than 
the other Nequatorial−Re−N3 (Table 4.9). This relationship holds true even for three of the 
[Re(CO)3(Me2bipy)(HNC(C6H5)N(CH2)3-4)]BF4 complexes (5, 7, and 10) in which the C6H5 
group of complexes 5, 7, and 10 lie almost directly above one of the equatorial carbonyl groups 
and is thus not oriented close to the axial plane. As discussed in the next section, NMR 
spectroscopic evidence indicates this difference in orientation does not occur in solution. 
 
 
 
 
 
 
 
 
Figure 4.10. View from top of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)5)]BF42 (left) and 
[Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)5)]BF4 (right) complexes with the mean plane of the 
5,5-Me2bipy rings oriented parallel to the plane of the paper. The heterocyclic CH2 groups were 
deleted for clarity. 
The N3–C16 and N4–C16 bond lengths for complexes 1–10, ranging from 1.296 (3) Å to 
1.362(4) Å (Tables 4.8 and 4.9), are closer to an average sp2 C=N bond length (~1.28 Å) than to 
an average sp3 C–N bond length (~1.47 Å).25 All bond angles around C16 (close to 120°) 
indicate the presence of some electron delocalization. The N4–C16 bond distances in complexes 
1–4, with a 4- and a 5-membered ring, reported here are not statistically different from those of 
other [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)5-7)]BF4 complexes having 6-, 7-, or 8-membered 
rings19 (Supporting Information) or from the N4–C16 bond distances in the 
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[Re(CO)3(Me2bipy)(HNC(C6H5)N(CH2)3-5)]BF4 complexes (5-10) with the exception that this 
bond is very slightly but significantly longer in 9 and 10 (Table 4.9). The barrier to rotation 
around the N4–C16 bond created by its partial double-bond character gives rise to some 
interesting observations in the NMR studies, as discussed in the next section. 
NMR Spectroscopy. General Considerations. The new 
[Re(CO)3(Me2bipy)(HNC(CH3)(CH)2)3,4)]BF4 complexes with 4- or 5-membered heterocyclic 
rings (1–4), the previously reported [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)5-7)]BF4 complexes 
with larger 6-, 7-, and 8-membered heterocyclic rings,19 and the new 
[Re(CO)3(Me2bipy)(HNC(C6H5)(CH)2)3-5)]BF4 complexes with 4-, 5-, and 6-membered 
heterocyclic rings (5–10) were all characterized by 1H and 13C NMR spectroscopy in CDCl3 or 
CD3CN (Tables 4.1–4.4 and Supporting Information). NMR signals were assigned by using 2D 
NMR data and by analyzing the splitting pattern and integration of signals in comparison to 
unambiguous assignments reported for [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)2Y)]BF419 and 
[Re(CO)3(5,5-Me2bipy)(HNC(CH3)NHR)]BF4 complexes.18 
The atom-numbering systems used for NMR signals are shown in Figures 4.2 and 4.5. 
Also, in order to distinguish between types of methyl signals, the Me2bipy signals are labeled as 
L-CH3 and amidine methyl signals are labeled as Cam-CH3. Furthermore, when rotation about the 
Cam–N4 bond is slow, the two N–CH2 signals observed are designated as endo and exo (Figure 
4.11). 
All amidine complexes with heterocyclic ring substituents of the general class, 
[Re(CO)3(Me2bipy)(HNC(R)N(CH2)2Y)]BF4, in the present study (R =  CH3 and C6H5) and a 
previous study (R =  CH3)19 show only one NMR signal for each type of proton. The 1H NMR 
spectra of new complexes recorded within 5 min of dissolution in CDCl3 or CD3CN showed only 
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one signal for each type of proton (For examples, see spectra for 1 and 3 in Figure 4.12 and for 5, 
7, and 9 in Figure 4.13). The 1H NMR spectra in both solvents did not change with time. The 
finding of only one signal for each type of proton has two possible explanations: all complexes 
exist either as only one isomer, or else they exist as a mixture of isomers in rapid exchange. 
Complexes 1–10 all undoubtedly exist as only the E isomer in solution because this is the isomer 
found in the solid state, and isomerization between the E and Z isomers is slow enough for 
isomers to be detected easily by 1D NMR spectra.18,19  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Designation of the N–CH2 endo and N–CH2 exo groups, illustrated for the structure 
of fac-[Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)4)]BF4 (3).  
Sufficient precedent exists to permit assignment of the NMR signals by analysis of the 
shift, integral, and splitting patterns of the signals. Nevertheless, ROESY and HSQC data in 
CDCl3 (for examples, see spectra in Figures 4.14–4.16 and Supporting Information) were used to 
Cam  
N–CH2 exo 
 N–CH2 endo 
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assign the 1H NMR signals of all of the new [Re(CO)3(5,5-Me2bipy)(HNC(R)N(CH2)x)]BF4 
complexes (1, 3, 5, 7, and 9). The 1H NMR signals of the [Re(CO)3(6,6-
Me2bipy)(HNC(R)N(CH2)x)]BF4 complexes were assigned by inspection because of the close 
parallels between the two series. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Stack plot of a selected region of the 1H NMR spectra (CD3CN, 27 C) of  
[Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes.19 
 
For all [Re(CO)3(Me2bipy)(HNC(R)N(CH2)x)]BF4 complexes studied, the two protons in 
each methylene group of the C2-symmetrical heterocyclic ring moiety are magnetically equivalent 
because the puckered rings undergo rapid fluxional motion, creating a time-averaged planar 
amidine ligand. Because rotation about both Cam–N bonds is slow (except for the special case of 
6-membered rings; see end of the NMR discussion of amidine ligand signals), each ring 
methylene group of the amidine ligands is unique and gives rise to one signal. 
Analysis of 1H and 13C NMR Data for Me2bipy Ligands in Complexes 1–10. The 
presence of only one 1H NMR signal per type of Me2bipy proton (e.g., H4/4) for all of the 
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[Re(CO)3(Me2bipy)(HNC(R)N(CH2)x)]BF4 complexes studied here (Tables 4.1, 4.2, and 
Supporting Information, Figures 4.12 and 4.13) indicates, as expected, that rotation about the 
Re–N3 bond is fast. If rotation about the Re–N3 bond were slow, two 1H NMR signals for each 
type of Me2bipy proton would be observed when the amidine ligand is oriented as found in the 
molecular structures (Figures 4.7–4.9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Stack plot of a selected region of the 1H NMR spectra (CDCl3, 27 C) of  
[Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)x)]BF4 complexes. Diethyl ether signals are marked 
with an asterisk. 
 
For all [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes studied here, the 
5,5-Me2bipy H6/6 1H NMR signals have shifts falling in narrow ranges of ~8.63 ppm in CDCl3 
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(Table 4.1 and ~8.85 in CD3CN (Figure 4.12 and Supporting Information). These shifts agree 
well with the values reported for the E and E isomers (Figure 4.1) of all [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)NHR]BF4 complexes studied in these solvents.18 In contrast, the values 
reported for the Z isomer of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)NHR]BF4 complexes are 
consistently farther upfield. These results strongly indicate that the shift of the H6/6 signal is 
influenced by a through-space effect from the closest amidine substituent. Because for both 
[Re(CO)3(5,5-Me2bipy)(HNC(CH3)NHR]BF4 and  [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes the Cam-CH3 methyl group is closest to H6/6 
protons in the E or E isomers, the similarity in H6/6 shifts noted above is consistent with the 
conclusion reached here and in our previous study19 that the E isomer is greatly favored when the 
amidine substituent is a heterocyclic ring.   
For both series of [Re(CO)3(Me2bipy)(HNC(CH3)(CH2)x)]BF4 complexes, the Me2bipy 
H4/4 1H NMR signals are independent of the differences in heterocyclic substituent (Table 4.1 
and Supporting Information). Because the H4/4 protons are in the para position and remote from 
the axial amidine ligand, the H4/4 signal is subject to inductive effects but not to through-space 
effects from the axial ligand. Thus, the H4/4 shift is a good indicator of the relative electron-
donor ability of the axial amidine ligand. The similarity in the H4/4 shifts and the independence 
of the H4/4 shifts on the axial ligand found in the present study both indicate that changes in the 
heterocyclic substituent do not signficantly affect the donor ability of the axial ligand. 
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Figure 4.14. Selected region of the ROESY spectrum (CDCl3, 27 C) of Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)3)]BF4 (1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15. Selected region of the ROESY spectrum (CDCl3, 27 C) of Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)4)]BF4 (3). 
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Figure 4.16. ROESY spectrum (CDCl3, 27 C) of [Re(CO)3(5,5-
Me2bipy)(HNC(C6H5)N(CH2)4)]BF4 (7). Diethyl ether signals are marked with an asterisk. 
13C NMR data for complexes 1–4 in CDCl3 are presented in Table 4.3 (along with new 
13C NMR data for related previously reported complexes).19 13C NMR signals for the free 5,5'-
Me2bipy and 6,6'-Me2bipy ligands in CDCl317 are listed in Supporting Information. Although the 
shifts differ for the [Re(CO)3(Me2bipy)(HNC(CH3)(CH2)x)]BF4 complexes between the 5,5-
Me2bipy and the 6,6-Me2bipy series of complexes, within each series the shifts of the L–CH3 13C 
NMR signals do not vary much (Table 4.3), confirming the conclusion from the analysis of 1H 
NMR signals that the nature of the heterocyclic ring moiety does not significantly change the 
amidine ligand's electron-donating ability. The same conclusion is reached from the 13C NMR 
shifts of the Me2bipy endocyclic carbons in the two series; shifts of signals for each type of 
endocyclic carbon fall into narrow ranges independent of changes in the amidine ligand.  
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For both series of [Re(CO)3(Me2bipy)(HNC(C6H5)N(CH2)x)]BF4 complexes (5–10) the 
Me2bipy H4/4 1H NMR signals are independent of the heterocyclic substituent (Table 4.2 and 
Figure 4.13). Furthermore, these H4/4 shifts for the two R = C6H5 series are very similar to those 
for the two R = CH3 series. Thus, the donor ability of the axial amidine ligand is not significantly 
dependent on either the heterocyclic substituent or the R substituent in 
[Re(CO)3(Me2bipy)(HNC(R)N(CH2)x)]BF4 complexes. Consequently, differences in through-
space effects between the two types of amidine R substituents, R = CH3 and R = C6H5, will be 
the main factor affecting shifts of 1H NMR signals of the Me2bipy protons close to the axial 
amidine ligand. 
In our previous studies, the majority of the molecular structures of 
[Re(CO)3(Me2bipy)(axial ligand)]X complexes with amidine (HNC(CH3)NHR or 
HNC(CH3)N(CH2)2Y) or iminoether (HNC(CH3)OCH3) axial ligands had the same orientation of 
the axial ligand in the solid state.17-19 The common orientation is shown in Figure 4.10. Those 
few complexes with a differently oriented axial ligand, nevertheless, had very similar shifts for 
signals of protons of identical types, a result indicating that the axial ligands in these complexes 
had the same net orientation in solution regardless of the orientation in the solid state. However, 
the NMR data when R in the axial ligand is CH3 did not provide clear evidence that the amidine 
orientation in solution was indeed the same as the common orientation in the solid. The 
analogues with R = C6H5 do provide such evidence. 1H NMR signals of the 5,5-Me2bipy H6/6 
protons for all [Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)x)]BF4 complexes (5, 7, and 9) fall in 
a narrow range of ~8.4 ppm in CDCl3 (Table 4.2 and Figure 4.13). The shifts of the H6/6 
signals, when R = C6H5, are ~0.2 ppm upfield compared to when R = CH3 (Tables 4.1, 4.2, and 
Figure 4.17), a finding consistent with an axial amidine net orientation in solution very similar to 
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that in the solid (Figure 4.10). Likewise, whereas the signals of the relatively remote 5,5-methyl 
groups have shifts that are independent of both the heterocyclic substituent or the R substituent in 
[Re(CO)3(Me2bipy)(HNC(R)N(CH2)x)]BF4 complexes, the close-in 6,6-methyl groups have 
signals with shifts that are  ~0.25 ppm more upfield for R = C6H5 than for R = CH3 (Tables 4.1 
and 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17. 1H NMR stack plot of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)3)]BF4 (bottom) 
and  [Re(CO)3(5,5-Me2bipy)(HNC(C6H5)N(CH2)3)]BF4 (top) in CDCl3 at 27 C.  
 
The narrow range observed for the 13C NMR signals of the 5,5-Me2bipy carbons for all 
[Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes studied in CDCl3 (Table 4.4) was 
also observed for the 13C NMR signals of the 5,5-Me2bipy carbons for all of the [Re(CO)3(5,5-
Me2bipy)(HNC(C6H5)N(CH2)x)]BF4 complexes (5, 7, and 9) in CDCl3. In addition, the shifts of 
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the 5,5-Me2bipy signals are very similar for R = C6H5 and R = CH3 (Tables 4.3 and 4.4). Thus, 
for [Re(CO)3(5,5-Me2bipy)(HNC(R)N(CH2)x)]BF4 complexes in this study, the net electron-
donating ability of the axial amidine ligands appears to be virtually independent of the identity of 
both R and N(CH2)x.  
Analysis of 1H and 13C NMR Data for Amidine Ligands in Complexes 1–10. In this 
section we will discuss the 1H and 13C NMR data of the axial HNC(R)N(CH2)x ligands and relate 
the NMR information to the properties of the complexes. The section is arranged in the following 
order of NMR data: 1H and 13C of R groups (CH3 and C6H5); 1H and 13C of N–CH2 endo and N–
CH2 exo groups; 1H of N3H; and finally the special properties of 6-membered heterocyclic rings. 
Within the discussion of each of these NMR features, we will treat R = CH3 before R = C6H5 
complexes and 1H NMR data before 13C NMR data, when possible. It should be noted that in 
addition to the new complexes, 1–10, for the present study we conducted additional NMR studies 
on previously reported compounds in CDCl3, and the new NMR results for both new and 
reported complexes19 can be found in Tables 4.1–4.4 and Figures 4.12–4.16. 
1H and 13C NMR Signals of the R Groups of 
[Re(CO)3(Me2bipy)(HNC(R)N(CH2)x)]BF4 Complexes. Comparing 
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes, the 6,6-Me2bipy complexes 2 and 4 
show a ~0.45 ppm upfield shifting of the Cam-CH3 1H NMR signal relative to 5,5-Me2bipy 
complexes 1 and 3. In our previous work with [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)2Y)]BF4 
complexes, we observed a similar upfield shift of the Cam-CH3 1H NMR signal for the 6,6-
Me2bipy complexes vs 5,5-Me2bipy complexes.19 We attributed such upfield shifts of the Cam-
CH3 1H NMR signal when the amidine ligand is in the E configuration in 6,6-Me2bipy 
complexes to the anisotropic effect of the aromatic rings of the tilted 6,6'-Me2bipy ligand.19  In 
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these complexes, the E configuration of the amidine ligand places it close to the Me2bipy ligands 
and the 6,6-Me2bipy tilting increases the shielding resulting from the anisotropic rings.  
The previously studied [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)2Y)]BF4 complexes had 
very similar 1H NMR shifts for the Cam-CH3 methyl group within each Me2bipy series.19 The 
shifts of the Cam-CH3 1H NMR signal of the complexes with 5-membered rings (3 and 4) are 
similar in range to those of other [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)5-7)] complexes for each 
Me2bipy series (Table 4.1 and Supporting Information). In contrast, complexes with 4-membered 
rings (1 and 2) have very different Cam-CH3 1H NMR chemical shifts as compared to complexes 
with larger rings within each Me2bipy series. Complexes 1 and 2 have the most upfield Cam-CH3 
1H NMR signals in each Me2bipy series. Moreover, in each of the two series of amidine 
complexes presented in Table 4.3, the Cam-CH3 methyl 13C NMR signal is significantly more 
upfield in complexes 1 and 2 (with a 4-membered heterocyclic ring moiety), whereas the signal 
for complexes 3 and 4 (with a 5-membered heterocyclic ring moiety) has a shift that is similar to 
the shifts observed for complexes with larger-ring substituents in each series (Table 4.3). We 
attribute these effects to differences in the relative amounts of s and p character in the bonds of 
the heterocyclic ring moiety as the size of the ring changes from 4- to 5-membered. These 
changes in bond character of the rings in turn are transmitted through the N4–Cam–C(R group) 
bonds, and thus the changes affect the shifts of the R group NMR signals. Recall that the C18–
N4–C(n) bond angles for complexes 1 and 2 (Table 4.8 and Supporting Information) are 
significantly more acute than in all of the other [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)4-7)]BF4 
complexes studied here or previously.19 
Comparing [Re(CO)3(Me2bipy)(HNC(C6H5)N(CH2)x)]BF4 complexes, the 6,6-Me2bipy 
complexes (6, 8 and 10) show an ~0.25, ~0.1, and ~0.05 ppm upfield shifting of the phenyl H2/6, 
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H3/5, and H4 NMR signals, respectively, relative to 5,5-Me2bipy complexes 5, 7 and 9 (Table 
4.2). The trend in decreasing size of the upfield shifts reflects the relative distance to the phenyl 
ring protons from the Me2bipy rings. The upfield shifts can be attributed to the shorter distance 
from the phenyl protons to the 6,6-Me2bipy ligand resulting from the tilting of the anisotropic 
6,6-Me2bipy ligand. 
For each of the two series of [Re(CO)3(Me2bipy)(HNC(C6H5)N(CH2)x)]BF4 complexes in 
Table 4.4, the phenyl C1 13C NMR signal has a significant ~ 3 ppm upfield shift in complexes 5 
and 6 (with the 4-membered heterocyclic ring moiety) as compared to the C1 13C NMR signal for 
complexes 7, 8, 9, and 10 (with a 5- or 6-membered heterocyclic ring moiety). The relationship 
of these shifts to heterocyclic ring size can be attributed to differences in hybridization of the 
heterocyclic ring atoms as explained above.  
1H and 13C NMR Signals of the N–CH2 Groups of 
[Re(CO)3(Me2bipy)(HNC(R)N(CH2)x)]BF4 Complexes. For all complexes, because of 
relatively fast change in the ring pucker, each CH2 group has only one 1H NMR signal and one 
13C NMR signal (Tables 4.1–4.4). Except for the four complexes with the 6-membered N(CH2)5 
ring substituent studied by NMR methods in the present work, which are discussed below, the 
heterocyclic ring moiety of all other complexes undergoes relatively slow rotation around the 
Cam–N4 bond.  
The [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)3,4)]BF4 complexes (1–4) show two sharp N–
CH2 1H NMR signals in both CD3CN and CDCl3 (Figure 4.12), indicating slow rotation around 
the N4–C16 bond for the 4- and 5-membered heterocyclic ring moieties. Relative sizes of NOE 
cross-peaks allow the unambiguous assignment of the two heterocyclic ring N–CH2 signals, as 
the N–CH2 endo protons are closer to the Cam-CH3 methyl group and the N–CH2 exo protons are 
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closer to the N3H proton (Figure 4.11). As shown in ROESY spectra for complexes 1 and 3 
(Figures 4.14 and 4.15), the downfield N–CH2 signal of both 1 and 3 has a strong NOE cross-
peak to the Cam-CH3 methyl signal, thus assigning it to N–CH2 endo. Similarly, the upfield N–
CH2 signal, which has a strong NOE cross-peak with the N3H signal, is assigned to the N–CH2 
exo protons. The similarity in the 1D NMR spectra of 2 and 4 to the spectra of 1 and 3 allowed us 
to assign the N–CH2 endo and N–CH2 exo signals for these [Re(CO)3(6,6-
Me2bipy)(HNC(CH3)N(CH2)3,4)]BF4 analogues (2 and 4). Furthermore, the close similarity in 
these shifts for the 5,5-Me2bipy and 6,6-Me2bipy analogues establishes that even for the N–CH2 
exo protons, the closest ring protons to the equatorial ligand (Figure 4.11), the distance is too 
long (Figure 4.7) for detecting a shielding effect from the tilted 6,6-Me2bipy ligand.  For all 
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes (both in CDCl3 and CD3CN) with 
resolved N–CH2 endo and N–CH2 exo 1H NMR signals, the N–CH2 endo signal is downfield from 
the  N–CH2 exo signal regardless of the size of the heterocyclic ring (Figure 4.12, Table 4.1 and 
Supporting Information). 
In 1H NMR spectra of [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes 1–4, the 
N–CH2 endo triplets are downfield of the N–CH2 exo triplets by 0.45 to 0.65 ppm (Table 4.1). 
These differences in shift for the two N–CH2 triplets cannot be attributed to the greater distance 
of the N–CH2 endo group from the anisotropic bipyridine rings in the equatorial plane because 
even the closer-in N–CH2 exo group is too distant to be affected by bipyridine anisotropy. Rather, 
as we discuss next, we believe that the difference in geometric relationship of the N–CH2 endo 
and exo groups to the N3H and the Cam-CH3 groups of 
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes (Figure 4.11) can account for the 
difference in chemical shift between the N–CH2 endo and the N–CH2 exo signals.  
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For [Re(CO)3(Me2bipy)(HNC(CH3)NHR)]BF4 complexes,18 the CH signals of the R 
group of the E isomer (having the same relationship to the N3H and the Cam-CH3 groups as the 
N–CH2 endo group) are typically downfield by ~0.4 ppm to the corresponding CH signals of the 
R groups of the E isomer (having the same relationship to the N3H and the Cam-CH3 groups as 
the N–CH2 exo group). Thus, the relative downfield and upfield chemical shifts of the N–CH2 
endo and exo 1H NMR signals result from differences in the environment of the N4–CH2 protons 
with respect to the amidine ligand N3H and the Cam-CH3 groups. The difference in relative 
chemical shifts is not a consequence of the different location of these methylene groups within 
the heterocyclic ring because the [Re(CO)3(Me2bipy)(HNC(CH3)NHR)]BF4 complexes do not 
have any such ring. However, as discussed in the next paragraph, the size of the ring can have a 
significant effect on the chemical shifts of both types of N–CH2 signals. 
Both N–CH2 1H NMR triplets (average shift ~ 3.85 ppm) for complexes 1 and 2, with a 
4-membered heterocyclic ring, have significantly downfield chemical shifts in both CD3CN and 
CDCl3 compared to the N–CH2 signals (average shift ~ 3.1 ppm) for all other 
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes studied, including the N–CH2 triplets of 
complexes 3 and 4 (Figure 4.12, Table 4.1 and Supporting Information). The 13C NMR signals of 
the two N–CH2 carbon atoms of the heterocyclic ring moiety are well separated for complexes 1–
4 and for complexes with a 7- or 8-membered heterocyclic ring, 
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)6,7)]BF4 (Table 4.3). The N–CH2 13C NMR signals for 1 
and 2 are more downfield (average shift > 50 ppm) than for complexes with larger rings (average 
shift < 50 ppm). This finding of downfield 1H and 13C NMR shifts of N–CH2 signals for 
complexes 1 and 2 compared to the complexes with larger heterocyclic rings is again attributed 
to differences in hybridization of atoms in the 4-membered heterocyclic ring as compared to the 
larger rings.  
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The same strategy used for assigning the 1H and 13C NMR N–CH2 endo and N–CH2 exo 
signals of [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes was employed to assign 
these signals for the [Re(CO)3(Me2bipy)(HNC(C6H5)N(CH2)x)]BF4 complexes (Tables 4.2 and 
4.4). In ROESY spectra for these R = C6H5 complexes 5 (not shown) and 7 (Figure 4.16) used in 
the assignments of the N–CH2 signals, strong NOE cross-peaks are present between the 
downfield N–CH2 signal and the N3H signal and between the upfield N–CH2 signal and the 
phenyl ring H2/6 signal, thus assigning these to N–CH2 exo and N–CH2 endo signals, 
respectively. Both the N–CH2 exo signals and the N3H signals are ~0.1 to ~0.2 ppm downfield 
from the corresponding signals in the [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)x)]BF4 analogues, 
as might be expected from the electron-withdrawing nature of the phenyl group. In contrast, the 
N–CH2 endo 1H NMR signal for [Re(CO)3(Me2bipy)(HNC(C6H5)N(CH2)3,4)]BF4 complexes has 
been shifted ~0.4 ppm upfield by the anisotropic effect of the phenyl ring, relative to this signal 
for the [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)x)]BF4 analogues (Tables 4.1 and 4.2). This 
notable upfield shift has the result that the N–CH2 endo signal is now slightly upfield (~0.1 ppm) 
to the N–CH2 exo signal (Figures 4.12 and 4.17).  
Relation of the Size of the Heterocyclic Ring Moiety to the Ease of its Rotation about 
the Cam–N4 Bond of [Re(CO)3(Me2bipy)(HNC(R)N(CH2)x)]BF4 Complexes. As mentioned 
above, restricted rotation of the N(CH2)2Y ring moiety around the amidine Cam–N4 bond occurs 
in [Re(CO)3(Me2bipy)(HNC(R)N(CH2)x)]BF4 complexes. [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes with x = 3, 4, 6, and 7 exhibit NMR spectral 
features indicating restricted rotation around the Cam–N4 bond (Tables 4.1 and 4.3 and Figures 
4.14, 15, and 16), and each heterocyclic ring CH2 group has one 13C NMR signal, one 1H NMR 
signal, and one HSQC cross-peak in CDCl3 (for examples, see spectra in Supporting Information 
when x = 3 and 4). This rotation around the Cam–N4 bond in these [Re(CO)3(5,5-
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Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes can be qualitatively assessed from the ROESY 
spectra. As can be seen in Figures 4.14 and 4.15, the ROESY spectra for both complexes 1 and 3 
in CDCl3 show EXSY cross-peaks between the two well-separated N–CH2 endo and N–CH2 exo 
signals, providing unambiguous evidence for rotation around the Cam–N4 bond.  
In order to use the intensities of these EXSY cross-peaks to estimate roughly the relative 
ease of rotation around the Cam–N4 bond for complexes 1 and 3 as compared to [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)6,7)]BF4 complexes, we acquired ROESY spectra for these two 
previously reported complexes,19 under identical conditions in CDCl3 as those used for 1 and 3. 
Next we compared the size of the EXSY cross-peaks for the four complexes. The ratios for N–
CH2 endo and N–CH2 exo cross-peaks to N–CH2 endo and N–CH2 exo diagonal signals were 
computed by summing the intensities of the cross-peaks on both sides of the diagonal and 
dividing this sum by the sum of the diagonal peaks. The ratios obtained are as follows: 0.31 for x 
= 3 (1); 0.29 for x = 4 (3); 0.97 for x = 6; and 0.82 for x = 7.  These ratios clearly indicate that 
rotation around the Cam–N4 bond is slower for complexes 1 and 3 than for the [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)6,7)]BF4 complexes with larger rings.  
In addition to the EXSY cross-peaks, the NOE cross-peaks in the ROESY spectra of 
complexes 1 and 3 (Figures 4.14 and 4.15) also provide information on the relative ease of 
rotation in 1 and 3 versus the complexes with the larger rings. For both 1 and 3, the downfield 
N–CH2 endo signal has a strong NOE cross-peak with the Cam-CH3 methyl signal, and the upfield 
N–CH2 exo has a strong NOE cross-peak with the N3H signal. In [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)6,7)]BF4 complexes (ROESY spectra not shown), however, both 
endo and exo N–CH2 signals have NOE cross-peaks of equal intensity with the Cam-CH3 methyl 
signal as well as with the N3H signal. The comparable NOE cross-peak intensity exhibited by the 
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complexes with larger rings arises from rotation fast enough to allow a phenomenon we have 
called "exchange-NOE peaks".26 This observation also indicates that rotation around the Cam–N4 
bond in these two complexes with larger rings is faster than in complexes 1 and 3. 
In contrast to complexes with both smaller and larger heterocyclic rings, when x = 5 
([Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)5)]BF4), instead of two N–CH2 signals, only one 
broad 1H NMR signal integrating to four protons can be seen in CD3CN or CDCl3 (at ~3.0 ppm 
in CD3CN and ~3.1 ppm in CDCl3, Figures 4.12 and 4.18). The rest of the CH2 protons in the 
piperidine-derived ring moiety give rise to two multiplets integrating to two and four protons in 
CD3CN or CDCl3. The larger C–CH2 multiplet arises from time-averaging of the signals of the 
two  CH2 groups. 
For [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)5)]BF4 complexes with a 6-membered 
heterocyclic ring (x = 5), the two N–CH2 13C NMR signals are undetectably broad in the 
corresponding 1D 13C NMR spectrum at 27 C (Supporting Information). The chemical shifts of 
the broad N–CH2 signals in [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)5)]BF4 complexes were 
determined by using 2D HSQC experiments (for L = 5,5-Me2bipy, Figure in Supporting 
Information). A very weak HSQC 1H-13C cross-peak between a broad 1H NMR signal and very 
broad 13C NMR signal [at ~3.0 ppm to ~47 ppm for both 5,5-Me2bipy, (Supporting Information) 
and 6,6-Me2bipy complexes] allowed us to assign the ~47 ppm 13C NMR peak of the 
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)5)]BF4 complexes to the N–CH2 carbon atoms. At -13 C, 
a solution of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)5)]BF4 in CDCl3 showed two 1H NMR 
signals (at 3.21 ppm and 2.80 ppm, Figure 4.18) and two 13C NMR signals (at 49.41 and 44.45 
ppm, Supporting Information) for the endo and exo N–CH2 groups, respectively, consistent with 
slower rotation around the Cam–N4 bond at lower temperature. 
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Figure 4.18. 1H NMR stack plot of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)5)]BF42  in CDCl3 
at -13 C (blue) and 27 C (red). Diethyl ether signals are marked with an asterisk. 
 
The structure of the 6-membered heterocyclic ring is most probably responsible for the 
shallowness of the barrier to rotation around the Cam–N4 bond in the [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)5)]BF4 complex compared to this barrier in analogues with 3-, 4-, 6-, 
and 7-membered rings. As the rings rotate around the Cam–N4 bond, this bond's character 
changes from partial double bond to single bond near the top of the rotation barrier. The 
hybridization of N4 changes from sp2 to sp3. In a 6-membered ring, all ring atoms can readily be 
pseudo tetrahedral because a 6-membered ring accommodates best to nearly ideal 109.5° bond 
angles at the ring atoms. Thus, the change in hybridization from sp2 to sp3 hybridization of the N 
ring atom is energetically more favorable than for the other rings, especially the smaller 4- and 5-
membered rings. 
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4.4 Conclusions 
The smaller heterocyclic amines employed here have a relatively high reactivity and form 
only [Re(CO)3(5,5-Me2bipy)(HNC(R)N(CH2)3,4)]BF4 amidine complexes with the E 
configuration, indicating that amidine complexes can be formed quickly and isomerically pure. 
We conclude that the bulk of the 4- and 5-membered rings is small enough to enhance the ease of 
attack of the amine onto the bound nitrile group but large enough to destabilize the Z isomer. The 
[Re(CO)3(5,5-Me2bipy)(HNC(R)N(CH2)3,4)]BF4 complexes were robust when challenged with 
4-dimethylaminopyridine, indicating that amidine ligands are strong donors. The 13C NMR shifts 
also indicate that amidine ligands with the smaller heterocyclic ring substituents have electron-
donor ability to the Re similar to that of amidine ligands with larger rings. All of these favorable 
properties cited here suggest that the strategy of using heterocyclic amines to create amidine links 
to the fac-M(CO)3+ core (M = 99mTc and 186/188Re radionuclides) may be a useful conjugation 
method for the development of targeted radiopharmaceuticals. The feasibility of such an 
approach is further demonstrated by the new, convenient method of preparation of 
[Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)x)]BF4 complexes in a 1:1 water:acetonitrile mixture 
utilizing the fac-[Re(CO)3(H2O)3]+ precursor. The present study has shown that rotation of the 
heterocyclic ring moiety around the Cam–N4 bond is facile. Thus, heterocyclic amines based on 
the azetidine ring and bearing a targeting substituent at the 3-position would readily form 
amidine ligands without generating an asymmetric center; consequently, a conjugated targeting 
derivative could be designed by using this approach. Furthermore, although further studies are 
needed to find a solvent system compatible with preparing radiopharmaceuticals, our work has 
shown that the somewhat weaker donor benzonitrile can form complexes and that treatment of 
the resulting complex with heterocyclic amines preferentially creates amidine links instead of 
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replacing the weak benzonitrile donor ligand from the complex. The approach used is applicable 
to other nitriles, thus expanding the number of possible R substituents that could be used to 
develop targeting agents. 
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CHAPTER 5 
CONCLUSIONS 
In general, this dissertation research contributes toward the understanding of conjugation 
of the fac-[Re(CO)3]+ core to make complexes of potential radiopharmaceutical utility. New fac-
[Re(CO)3L]+ complexes demonstrating two new approaches of possible bioconjugation of the 
fac-[Re(CO)3]+ core via a tridentate sulfonamide ligand and a monodendate amidine ligand are 
studied in detail by 1H NMR spectroscopy. The new complexes assist in exploring the chemistry 
of linking the fac-[Re(CO)3]+ core.  
The new conjugation approach presented through the synthesis of novel N(SO2R)dien 
ligands and their Re complexes aids in achieving the goal of identify a robust, hydrophilic, and 
flexible chelate framework. Moreover, these N(SO2R)dien ligands possess the ability of 
anchoring the fac-[Re(CO)3]+ core with one sulfonamide nitrogen-to-metal bond having a normal 
length. 
The chemistry related to the fac-[Re(CO)3(L)(amidine)]+ complexes discovered in this 
work holds promise as providing suitable guidelines for preparing isomerically pure conjugates 
of fac-[M(CO)3L]+ (M = 99mTc, 186/188Re) radiopharmaceutical agents. In contrast to the 
formation of multiple isomers by previously reported fac-[Re(CO)3(5,5-
Me2bipy)(HNC(CH3)NHR)]+ amidine complexes, formation of a single isomer of the fac- 
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)2Y)]BF4 complexes was achieved by utilizing C2-
symmetrical, saturated, heterocyclic secondary amines. The reason for the instability of other 
isomers is undoubtedly attributable to the unfavorable steric clashes between the equatorial 
ligands and the bulky the axial amidine ligand. The amidine formation reaction in organic 
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solvents could be made faster by replacing the methyl group of the amidine ligand with a phenyl 
group or by using a smaller heterocyclic amine. 
The new method introduced in this work to synthesize fac-[Re(CO)3(L)(amidine)]+ 
complexes utilizes a fewer number of steps making it faster and employs the fac-
[Re(CO)3(H2O)3]+ precursor in partially aqueous solvent conditions. This faster method and use 
of the fac-[Re(CO)3(H2O)3]+ precursor, which more closely resembles the 99mTc precursor 
needed for the biomedical usage of radiopharmaceutical complexes, make the new amidine 
synthetic approach more applicable than the previous method to clinical studies. Utilization of 
this new synthetic strategy with smaller heterocyclic amines further reduced reaction times 
needed for amidine ligand formation, increasing the likely utility for the biomedical use of the 
new approach. 
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APPENDIX A 
 
SUPPLEMENTARY MATERIAL FOR CHAPTER 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1. Overlay of Re, C1, C2, and C3 atoms (C atoms of the carbonyl groups) of 
[Re(CO)3(N(SO2tol)dien)]PF6 (6) (blue) and [Re(CO)3(N(Me)dien)]PF6 49 (yellow).  
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Figure A.1. Overlay of Re, C1, C2, and C3 atoms (C atoms of the carbonyl groups) of 
[Re(CO)3(N(SO2tol)dien)]PF6 (6) (blue) and [Re(CO)3(N(Me)dien)]PF6 49 (yellow).  
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Figure A.2.  Aliphatic region of the 1H NMR spectra of N(SO2R)dien  ligands (1–3) in CDCl3 at 
25 ºC.  
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Figure A.4. 1H NMR spectra of [Re(CO)3(N(SO2R)dien)]PF6 complexes (4–6) in acetonitrile-d3 
at 25 ºC. 
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Figure A.5. COSY spectrum of [Re(CO)3(N(SO2tol)dien)]PF6 (6) in acetone-d6 at 25 ºC. The NH 
signals have weak COSY cross-peaks to multiplets at 3.55 ppm and 3.52 ppm, indicating that 
these are the two C(4/7)H2 multiplets (C4/7 is the carbon attached to the terminal amines). The 
CH signals are connected by a strong COSY cross-peak, further confirming that the protons are 
attached to the same methylene carbon atom. The other two multiplets (for C(5/6)H2) are 
connected by a COSY cross-peak, as expected. In the aromatic region, the tosyl H2/6 doublet at 
8.05 ppm has a COSY cross-peak to the doublet at 7.65 ppm, unambiguously assigning it as the 
tosyl H3/5 signal.  
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Figure A.6. 1H-1H ROESY spectrum of [Re(CO)3(N(SO2tol)dien)]PF6 (6) in acetone-d6 at 25 ºC. 
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Figure A.7. 13C NMR spectrum of [Re(CO)3(N(SO2tol)dien)]PF6  (6) in acetone-d6 at 25 ºC. 
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the methyl carbon of the tosyl ring. The HSQC spectrum of 6 also has two intense cross-peaks in 
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7.65/131.59 ppm). These two cross-peaks thus arise from H2/6–C2/6 (aromatic ring) and H3/5–
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ppm lack HSQC cross-peaks, but do have HMBC cross-peaks (Figure S8) to the H2/6 and H3/5 
doublets, respectively. The most downfield 13C NMR signal (148.88 ppm) also shows an HMBC 
cross-peak to the tosyl CH3 singlet at 2.53 ppm, allowing the assignment of the carbon signal to 
C4 in the tosyl ring. The remaining 13C NMR signal at 127.05 ppm, which has an HMBC cross-
peak to only the H3/5 doublet, is thus attributable to the tosyl ring quaternary C1 atom. Both 
multiplets of each methylene group have a strong HSQC cross-peak, allowing us to assign the 
13C NMR signal at 46.00 ppm to C4/7 and the signal at 56.94 ppm to C5/6. 
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Figure A.8. Aromatic region of the HMBC spectrum of [Re(CO)3(N(SO2tol)dien)]PF6 (6) in 
acetone-d6 at 25 ºC. 
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Figure A.9. HSQC spectrum of [Re(CO)3(N(SO2tol)dien)]PF6  (6) in acetone-d6 at 25 ºC.  
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Table A.1. Comparison of 13C NMR Shifts (ppm) of N(SO2R)dien Ligands and 
[Re(CO)3(N(SO2R)dien)]PF6 Complexes in Acetonitrile-d3 at 25 C   
signal 
 
(N(SO2Me)dien) 
(1) 
 
[Re(CO)3(N(SO2Me)dien)] 
PF6 (4) 
 
(N(SO2tol)dien) 
(3) 
 
[Re(CO)3(N(SO2tol)
dien)]PF6                                 
(6) 
C4   145.04 149.40 
ring C3/5   128.64 131.62 
ring C2/6   130.71 132.67 
C1   136.79 126.60 
     
C5/6 52.65 56.29 51.50 56.76 
C4/7 41.91 45.61 41.10 45.56 
CH3 37.87 33.02 21.03 21.87 
 
The 1H NMR signal assignments for the two triplets of the free ligands were confirmed by 
using values predicted by ChemBioDraw Ultra 12.0. 13C NMR signals of the free N(SO2tol)dien 
and  N(SO2Me)dien ligands (1 and 3, in acetonitrile-d3) were assigned unambiguously 
(Experimental Section) by using 1H-13C HSQC and HMBC cross peaks and were used for the 
shift comparison with the 13C NMR signals of [Re(CO)3(N(SO2Me)dien)]PF6 (4) and 
[Re(CO)3(N(SO2tol)dien)]PF6 (6), for which the signals were also completely assigned by 1H-13C 
HSQC and HMBC spectral data (in acetonitrile-d3).  
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APPENDIX B 
 
SUPPLEMENTARY MATERIAL FOR CHAPTER 3 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.1. Overlay of Re, O1, O2 and O3 atoms of carbonyl ligands of [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2CH2)2O)]BF4 (7) (gold) and [Re(CO)3(6,6-
Me2bipy)(HNC(CH3)N(CH2CH2)2O)]BF4 (12) (purple) depicted with the C13–Re–C14 
equatorial plane perpendicular to the plane of the paper.  
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Table B.1. Selected Non-Bonded Distances (Å) for Complexes Having the General Formula, 
[Re(CO)3(L)(HNC(CH3)N(CH2CH2)2Y)]BF4 
bond distances 
L = 5,5-Me2bipy 
Y = CH2 
L = 6,6-Me2bipy 
Y = CH2 
L = 5,5-Me2bipy 
Y = NH 
L = 6,6-Me2bipy 
Y = NH 
N3 -N1 2.800 (4) 2.840 (3) 2.797 (3) 2.807 (4) 
N3 -N2 2.987 (4) 2.909 (3) 2.983 (3) 2.935 (4) 
N3- C1 3.517 (5) 3.867 (3) 3.528 (3) 3.748 (4) 
N3-C10 3.859 (5) 3.913 (3) 3.871 (4) 3.938 (4) 
N3- C4 4.541 (5) 4.146 (3) 4.452 (4) 4.057 (5) 
N3-C7 4.689 (5) 3.848 (3) 4.667 (4) 4.171 (4) 
N3-C3 5.030 (5) 4.935 (3) 4.954 (4) 4.764 (5) 
N3-C8 5.288 (5) 4.606 (3) 5.293 (4) 4.935 (4) 
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Figure B.2. Structures of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2(CH2)2)]BF4 (4) and 
[Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2CH2)2(CH2)3)]BF4 (5) showing the orientation of the 
amidine ligand with the aromatic rings in the plane of the paper and amidine ligand projected 
toward the viewer. In the bottom two structures, selected atoms have been omitted in order to 
show the amidine group more clearly. All complexes in this work, except for 4, have the plane of 
the amidine group bisecting the N–Re–C angles in the equatorial plane as shown at the bottom 
right. 
(4) 
(4) (5) 
(5) 
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APPENDIX C 
 
SUPPLEMENTARY MATERIAL FOR CHAPTER 4 
Table C.1. 1H NMR Shifts (ppm) for [Re(CO)3(L)(HNC(CH3)N(CH2)x)]BF4 (CD3CN, 25 C)   
   
signal / x 3 4 51 61 71 3 4 51 61 71 
 L  = 5,5-Me2bipy L  = 6,6-Me2bipy 
H6/6  8.82 8.83 8.85 8.87 8.87      
H5/5       7.61 7.61 7.62 7.61 7.63 
H4/4 8.04 8.04 8.04 8.05 8.04 8.06 8.07 8.06 8.06 8.07 
H3/3 8.26 8.28 8.26 8.26 8.27 8.19 8.19 8.19 8.19 8.19 
L-CH3  2.48 2.48 2.48 2.48 2.48 3.03 3.05 3.06 3.07 3.07 
N3H  4.15 4.21 4.78 4.52 4.49 4.59 4.62 5.14 4.90 4.82 
Cam-CH3  1.90 2.13 2.10 2.10 2.12 1.49 1.71 1.60 1.62 1.66 
N–CH2 endo 3.99 3.30 3.01 br 3.30 3.25 3.95 3.25 3.03 br 3.26 3.23 
N–CH2 exo 3.45 2.65 3.01 br 2.96 3.05 3.50 2.71 3.03 br 3.04 3.16 
CH2 signals 2.07 1.75 1.48 1.46 1.50 2.08 1.77 1.53 1.44 1.49 
    1.28 1.31 1.39   1.29 1.38 1.42 
    1.15 1.18    1.32 1.32 
    0.96 0.96    1.11 1.21 
     0.71     0.91 
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Table C.2. Selected Bond Distances and Angles for [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)2Y)]BF4 Complexes 
 
Y = CH2 (CH2)2 (CH2)31 (CH2)41 (CH2)51 (CH2)2NH1  (CH2)2O1 
complex 1 3      
bond distances (Å) 
Re–N1 2.178(2) 2.176(1) 2.168(3) 2.172(3) 2.1691(18) 2.177(2) 2.177(2) 
Re–N2 2.172(2) 2.186(1) 2.186(3) 2.173(3) 2.1823(18) 2.190(2) 2.194(2) 
Re–N3 2.184(3) 2.186(1) 2.178(3) 2.179(3) 2.1806(18) 2.179(2) 2.178(2) 
N3–C16  1.305(4) 1.311(1) 1.306(4) 1.310(5) 1.308(3) 1.300(4) 1.304(3) 
N4–C16 1.331(4) 1.338(2) 1.346(5) 1.344(5) 1.346(3) 1.354(4) 1.359(3) 
bond angles (deg) 
N1–Re–N2 75.28(9) 74.85(3) 75.06(11) 74.58(11) 74.82(6) 75.08(8) 75.16(8) 
N1–Re–N3 80.13(9) 80.57(4) 80.23(11) 83.44(11) 87.21(6) 79.90(9) 78.78(8) 
N2–Re–N3 82.84(9) 85.19(4) 86.41(11) 79.02(11) 79.34(6) 86.11(9) 86.30(8) 
Re–N3–H3N  108(3) 111(1) 113(3) 111(3) 106(2) 110(2) 110(2) 
Re–N3–C16 133.6(2) 135.44(8) 137.4(2) 135.6(3) 136.82(15) 136.5(2) 137.03(18) 
C16–N3–H3N 116(3) 114(1) 110(3) 110(3) 116(2) 114(2) 113(2) 
N3–C16–N4 121.4(3) 122.8(1) 123.6(3) 122.9(3) 122.47(19) 123.3(3) 122.5(2) 
N3–C16–C17 123.2(3) 120.3(1) 118.6(3) 118.5(3) 119.58(19) 119.2(3) 119.9(2) 
N4–C16–C17 115.4(3) 116.9(1) 117.8(3) 118.7(3) 117.95(19) 117.4(2) 117.7(2) 
C16–N4–C18 131.5(3) 125.1(1) 122.2(3) 121.2(3) 123.86(18) 121.8(2) 121.4(2) 
C16–N4–C(n)a 129.8(3) b 122.9(1) c  120.3(3)d 122.7(3)e 120.44(18)f 120.7(2)c 120.1(2)c 
C18–N4–C(n)a 94.4(2) b 111.6(1) c  113.3(3)d 114.3(3)e 115.7(2)f 112.6(2)c 112.3(2)c 
  
an varies in number according to the R group. bn = 20. cn = 21. dn = 22. en = 23. fn = 24.  
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Table C.3. Selected Bond Distances and Angles for [Re(CO)3(6,6-
Me2bipy)(HNC(CH3)N(CH2)2Y)]BF4 Complexes 
 
Y = CH2 (CH2)2 (CH2)31 (CH2)41   (CH2)51 (CH2)2NH1  (CH2)2O1 
complex 2 4          
bond distances (Å) 
Re–N1 2.2050(12) 2.198(2) 2.213(2) 2.203(2) 2.211(2) 2.212(3) 2.2051(19) 
Re–N2 2.1990(12) 2.200(2) 2.1984(18) 2.194(2) 2.211(2) 2.202(3) 2.2086(19) 
Re–N3 2.1704(11) 2.181(2) 2.193(2) 2.188(2) 2.190(2) 2.192(3) 2.1848(18) 
N3–C16  1.3068(18) 1.303(3) 1.307(3) 1.309(3) 1.308(3) 1.307(4) 1.307(3) 
N4–C16 1.3313(17) 1.334(3) 1.356(3) 1.350(3) 1.347(3) 1.350(4) 1.356(3) 
bond angles (deg) 
N1–Re–N2 75.10(5) 74.90(9) 74.29(7) 74.60(8) 74.40(8) 75.29(11) 74.90(7) 
N1–Re–N3 80.15(5) 80.14(8) 80.26(7) 82.12(8) 83.41(8) 79.19(10) 79.35(7) 
N2–Re–N3 83.84(5) 85.19(8) 82.97(7) 80.44(8) 79.26(8) 83.85(10) 82.00(7) 
Re–N3–H3N  111.3(16) 111(2) 110(2) 110(2) 108(2) 107(3) 109(2) 
Re–N3–C16 135.47(10) 135.5(2) 136.66(16) 135.62(19) 136.74(19) 135.4(2) 137.12(15) 
C16–N3–H3N 113.2(17) 113(2) 113(2) 115(2) 115(2) 115(3) 114(2) 
N3–C16–N4 121.82(13) 123.0(2) 123.2(2) 122.9(2) 123.0(2) 124.2(3) 122.84(19) 
N3–C16–C17 122.88(12) 120.1(2) 119.5(2) 119.8(2) 119.2(2) 118.4(3) 119.85(19) 
N4–C16–C17 115.31(12) 116.9(2) 117.3(2) 117.3(2) 117.8(2) 117.3(3) 117.28(19) 
C16–N4–C18 131.58(12) 124.6(2) 122.62(19) 122.4(2) 123.2(2) 124.2(3) 122.27(18) 
C16–N4–C(n)a 131.78(12)b 123.4(2)c 122.93(19)d 121.2(2)e 121.0(2)f 123.7(3)c 121.29(19)c 
C18–N4–C(n)a 95.4(1)b 112.0(2) 111.3(2)d 114.8(2)e 115.8(2)f 111.8(3)c 112.5(2)c 
 
an varies in number according to the R group. bn = 20. cn = 21. dn = 22. en = 23. fn = 24. 
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Table C.4. 13C NMR Shifts (ppm, 25 C) of the Me2bipy Ligands in CDCl32 
 
signal  5,5-Me2bipy 6,6-Me2bipy 
C6/6 149.40  157.80  
C5/5  132.90  122.90  
C4/4  137.30  136.80  
C3/3  120.10  118.00  
C2/2  153.70  155.80  
L-CH3  18.20  24.80  
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Table C.5. N3H 1H NMR Shifts (ppm, 25 C) of [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)x)]BF4 
Complexes vs Non-bonded Distance (d) from the N3H Atom to the Closest CH Atom of the 
Heterocyclic Ring Moiety    
 
x d (Å) 5,5-Me2bipy complexes d (Å) 6,6-Me2bipy complexes 
  CD3CN CDCl3  CD3CN CDCl3 
3 2.55 4.15 4.27 2.54 4.59 4.31 
4 2.15 4.21 4.10 2.21 4.62 4.26 
51 1.82 4.78 4.58 1.89 5.14 4.92 
61 1.88 4.52 4.23 1.96 4.90 4.60 
71 2.14 4.49 4.21 2.09 4.82  
 
As stated in a previous report,1,3 factors influencing  the N3H NMR signal shift are complex 
and difficult to explain. Within each Me2bipy series of [Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)3-
7)]BF4 for new complexes and for previously reported complexes,1 the N3H NMR signal has a 
more downfield shift when the non-bonded distance from N3H to the closest H atom of the 
heterocyclic ring moiety is relatively short (Table S5). The most upfield N3H signals in each 
series were observed for complexes with the smaller heterocyclic ring moiety (3- or 4-membered 
rings). The general trend suggests that through-space environmental effects of spatially close ring 
protons may be one of the factors influencing the shift of the N3H signal. 
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Figure C.1. As is evident from the molecular structures of 
[Re(CO)3(Me2bipy)(HNC(CH3)N(CH2)3-7)]BF4 complexes,1 the flexibility of the larger ring 
moieties appears in some cases to have allowed the large rings to lie over the equatorial Me2bipy 
ligands in the solid. However, there is no evidence to support this relation of the heterocyclic 
rings to the Me2bipy ligands in solution because the 1H or 13C NMR signals of the methylene 
groups of the ring moieties are not shifted significantly upfield in the bulkier rings in the 6,6-
Me2bipy vs. 5,5-Me2bipy analogue. 
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Figure C.2. HSQC spectrum (CDCl3, 27 C) of [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)5)]BF41.  
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Figure C.3. HSQC spectrum (CDCl3, 27 C) of [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)3)]BF4 (1). 
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Figure C.4. HSQC spectrum (CDCl3, 27 C) of [Re(CO)3(5,5-
Me2bipy)(HNC(CH3)N(CH2)4)]BF4 (3). 
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Figure C.5.  13C NMR stack plots of [Re(CO)3(5,5-Me2bipy)(HNC(CH3)N(CH2)5)]BF41 in 
CDCl3 at -13 C (blue) and 27 C (red). 
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